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Chapce' l 
General introduction and aim 
The emerging fungal threat 
Invasive fungal infections have continued to increase in incidence during the last 
20 years and are now significant causes of morbidity and mortality. This is particu-
larly true in patients with haematological malignanc"les undergoing induction or 
consolidation chemotherapy (especially during the nadir of their granulocytopenia), 
in immunosuppressed organ transplant recipients, and in patients with acquired 
immunodeficiency secondary to infection by human immunodeficiency viruses. 
The increase in number of patients with invasive fungal disease is a result of several 
factors, including (1) the development of new chemotherapy regimens for solid 
tumours, lymphoma, myeloma and leukemia; (2) an increase in the number of 
transplant recipients; (3) increased use of immunosuppressive regimens for autoim-
munediseases and (4) the advent ofthe AIDS pandemic. Autopsy data indicate that 
more than half of patients who die with malignancies are infected with Candida 
spp., approximately one-third with Aspergillus spp., and increas·mg numbers with 
Cryptococcus spp. or other fungi such as Fusarium spp. [5,6,24,54,94,99, 105]. 
Factors that predispose patients to invasive fungal infections are generally based 
on an impaired defence mechanism. These factors include: prolonged neutropenia 
(chemotherapy induced); defective T-lymphocyte function (associated with organ 
transplantation and HIV infection); impaired macrophage function, particularly of 
pulmonary macrophages (associated with high doses and prolonged administra-
tion of corticosteroids; and barrier defects (associated with invasive medical pro-
cedures, Vascular catheters, parenteral nutrition and haemodialysis and peritoneal 
dialysis) in compromised patients [4,5,23,29,80,101]. 
Invasive Pulmonary Aspergillosis 
Invasive aspergillosis is the most severe and life-threatening disease caused by the 
fungus Aspergillus. In most cases, invasive infections with Aspergillus spp. present 
as invasive pulmonary aspergillosis in which Aspergillus fumigatus is the main 
causative agent. This ubiquitous and usually saprophytic fungus grows and sponulates 
in humid environments on decaying organic matter. On inhalation of its airborne 
conidia, A. fumigatus can cause a wide spectrum of diseases [10,27]. Invasive 
pulmonary aspergillosis occurs in severely immunocompromised patients who usually 
develop rapid and often fatal infections. The incidence of invasive pulmonary 
aspergillosis can differ per centre and also within centres in time. Notorious are the 
nosocomial outbreaks of asperg.lllosis as a complicaf1on of construction work in or 
-:-able l. Incidence of aspergillosis according to underlying condition 
Condition 
Heart-lung or lung transplantation 
Chronic granu:omatous disease 
Acute leukemia 
Allogeneic BMT 
Autologous BMT without growth factors 
AIDS 
Liver transplantation 
Heart and kidney transplantation 
Severe combined immunodeficiency 
Burns 
Systemic lupus erythematosus 
Autologous BMT with growth factors 
Data are from [27] 
Range(%) 
19-26' 
25-40' 
5-24 
4-9 
0.5-6 
0-12 
1.5-10 
0.5-10 
3.5 
1-7 
1 
<1 
'Distinguishing colonisation from infection is particularly difficult in these patients. 
2 Ufetime incidenc;:. 
near hospital units in which neutropenic cancer and transplant recipients were housed 
[27]. Approximate incidence figures for different patient groups are shown in Table l. 
The portal entries for Aspergillus include the respiratory tract, damaged skin or opera-
tion wounds, the cornea and the ear. The majority of patients (80-90%) has pulmonary 
disease. Approximately 30% of patients initially has no symptoms attributable to inva-
sive pulmonary aspergillosis. As the disease progresses, symptoms appear. Early symp-
toms are cough and fever. At autopsy, many patients who die with invasive aspergillosis 
have disseminated disease [10,20,41,60,102,110,114]. Mortality associated with 
invasive pulmonary aspergillosis is nearly 100% if left untreated [25]. Treaiment with 
appropriate antifungal agents is still correlated with a mortality of 25-40% [27,63]. 
Survival depends largely on neutrophil recovery, status of malignancy and early 
diagnosis followed by early treatment ofthe infection [2,103]. 
Diagnosis of invasive pulmonary aspergillosis is problematic and infection is often 
confirmed at autopsy only [11]. Fever unresponsive to broad-spectrum antibiotics 
is regarded as an early and common clinical sign of an invasive fungal infection. 
Definitive diagnosis requires both histopathological evidence and cultures of 
Aspergillus in biopsy, respiratory tract secretions or broncho-alveolar lavage fluid. 
However, the detection of Aspergillus in tissue or fluids is insensitive [25]. As early 
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diagnosis and early start of treatment of invasive aspergillosis are correlated with 
favourable treatment outcome, the improvement of diagnostic techniques is war-
ranted [2,103]. Improvements in the diagnosis of invasive pulmonary aspergillosis 
include the use of high-resolution CT [18], polymerase chain reaction (PCR) for 
the detection offungal RNA or DNA [31,46] and enzyme-linked immunosorbent 
assay (ELISA) testing of serum or broncho-alveolar lavage fluid for galactomannan, 
a component of the fungal cell wall of Aspergillus [17,67]. None of the tests has 
been proven to identify definitively patients with invasive disease, but positive 
results are generally highly predictive of invasive disease [59]. 
Antifungal agents 
At present, only two agents are available for the routine clinical treatment of inva-
sive pulmonary aspergillosis, the fungicidal polyene amphotericin B (AMB) and 
the fungistatic triazole itraconazole. AMB is available as the desoxycholate salt 
(AMB-DOC), and as three different lipid formulations. In addition, several new 
drugs for invasive aspergillosis are in the developmental stage. 
Amphotericin B 
AMB has been the treatment of choice for most invasive fungal infections since its 
introduction in the 1950s. AMB is a macrolide polyene antibiotic derived from 
Streptomyces nodosus. It acts by binding to ergosterol, the principal sterol in the 
membrane of susceptible fungal cells, causing increased cell membrane perme-
ability, loss of cell components, metabolic disruption and eventually cell death. In 
addition to its membrane effects, the drug can cause damage to fungal cells possi-
bly by formation of reactive free oxygen rad·lcals after auto-ox·ldation of AMB bound 
to membrane components [13,16]. 
OH 0 OH OH 
HOOC 
HO 
'\o\o 
H~OH 
NH2 
Figure 1. Chemical structure of AMB 
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AMB has a broad spectrum of activity including Aspergillus fumigatus, Candida 
albicans, Cryptococcus neoformans. AMB is usually administered as the desoxy-
cholate salt (AMB-DOC, Fungizone"). The antifungal activity of AMB is fungicidal 
and dose-dependent. AMB is poorly absorbed in the gastro-intestinal tract ( <5%) 
[35], and has to be administered intravenously in the treatment of systemic fungal 
infections. Toxicity associated with intravenous AMB use can be severe and 
include acute effects during administration (fever, chills), and more delayed effects 
like thrombopr.lebitis, nephrotoxicity, hypokalaemia, hypomagnesaemia, anaemia 
and thrombocytopenia. This toxicity often limits adequate dosing, which reduces 
the potential clinical efficacy [34,35,45,50,65,66]. 
1traconazoie 
ltraconazole (Trisporal', Sporanox~) is the only registered azole agent with activity 
against Aspergillus spp. ltraconazole has fungistatic activity against Aspergillus 
spp., in contrast to the polyenes, which have fungkidal activity. ltraconazole 
inhibits fungal cytochrome P450 14cx-demethylase, which results in a depletion of 
ergosterol and a loss of membrane integrity and activity [48]. ltraconazole is sys-
temically absorbed after oral administration and has a good tissue distribution in 
organs that are frequent sites for invasive fungal infections (such as the spleen and 
lungs), and can therefore be used for prevention and treatment of a variety of inva-
sive fungal infections [15,48]. The recent development of an itraconazole oral 
solution and an intravenous itraconazole formulation has increased the oral 
bioavailability and improved the possibilities for the use of this drug [8]. 
ltraconazole has few side-effects and is generally well-tolerated. 
Lipid based formulations of AMB 
Lipid formulations of AMB have been developed to overcome the nephrotoxicity of 
AMB-DOC [5,42,49]. The reduction of toxicity of lipid formulations of AMB proba-
bly results from differences in affinity of AMB to cholesterol in the human cell 
membrane (lowest affinity) as opposed to the lipids of the liposomal carrier (inter-
mediate affinity) and to the ergosterol in the fungal membrane (highest affinity) 
[56,57]. Three lipid formulations are currently available for clinical use, liposomal 
AMB (L-AMB), AMB lipid-complex (ABLC), and AMB colloidal dispersion (ABCD) 
(Table 2). 
L-AMB (AmBisome") consists of small unilamellar liposomes of about 80 nm in 
diameter, made up of a bilayer membrane of hydrogenated soy phosphatidyl-
"' 
0 0 
"' 
0 
"" 
0 
9!. ~ 5' 
a ~ 
~ 
c g 
0 
0 
• 0 
~ 
• 3 
Table 2. Formulations of amphotericin B 
Formulation Brand name Manufacturer Carrier Colloidal type Size(J.lm) 
AMB-DOC Fungizone-R Bristol Myers- Desoxycholate Micelle 0.035 
Squibb 
L-AMB AmBisome Gilead Sciences HSPC/DSPG/Chol Liposome 0.08 
ABLC Abelcet» The Liposome DMPC/DMPG Lipid ribbon 1.6-11 
Company 
ABCD Amphocil', Alza Corporation Cholesteryl Lipid disk 0.11-0.12 
Amphotec" sulphate 
AMB, amphotericin B; HSPC, Hydrogenated Soy Phosphatldy!choline; DSPG, distearoylphosphatidylglycerol; 
Chol, cholesterol; DMPC, dimyristoylphosphatidylcholine; DMPG, dimyristoylphosphatidylglycerol. 
choline and distearoylphosphatidylglycerol stabilised with cholesterol and com-
bined with AMB in a 2,0.8,1,0.4 molar ratio. 
ABLC (Abelcet") contains AMB complexed with two phospholipids L-a-dimyris-
toylphosphatidylcholine (DMPC) and L-a-dimyristoylphosphatidylglycerol (DMPG) 
in a 7,3 molar ratio with a drug, lipid ratio of L 1. ABLC is an assembly of ribbon-
like structures of a bilayered membrane, measuring 1,600-11,000 nm diameter. 
ABCD (Amphocil", Amphotec') is a colloidal dispersion composed o' disk-like 
structures of cholesteryl sulphate complexed with AMB in a 1,1 molar ratio. The 
disk-like structures are approximately 115 nm in diameter. 
AMB in lipid complexes or liposomes has antifungal activity comparable with that 
of AMB-DOC, with respect to MIC/MFC values, but differs in its pharmacological 
and toxicological properties [5,12]. The pharmacokinetics ofthe lipid formulations 
after intravenous administration depend to a large extent on the composition and 
particle size of the liposomes or lipid carriers. Intravenously administered liposomes 
and lipid carriers tend to accumulate in the cells ofthe mononuclear phagocyte sys-
tem. Animal data show that high concentrations of AMB are obtained in the liver 
and the spleen after intravenous administration of lipid formulations of AMB as 
compared to AMB-DOC. Levels in renal tissue after intravenous administration are 
much lower for the lipid formulations than for AMB-DOC. The serum concentrations 
are also highly variable between the formulations. The area under the serum con-
centration time curve (AUC) after a standardised dose is highest for L-AMB and 
lowest for ABLC [52]. The pharmacokinetic differences between the formulations 
seem large, however, the clinical relevance of these differences is not yet clear. 
Although the nephrotoxicity assoc"lated w·1th each of these l"lpid preparations ·,slower 
than with AMB-DOC, the rates of acute infusion related reactions (which differ among 
the three lipid formulations) do not differ substantially from those observed with AMB-
DOC [5,49,53,92,111] exceptthatthey are more frequent with ABCD [109]. 
Current treatment strategies for the management 
of Invasive Pulmonary Aspergillosis 
Invasive pulmonary aspergillosis is life-threatening. The poor prognosis in combi-
nation with the lack of proper means to make a timely diagnosis necessitates the 
administration of prophylaxis or empirical treatment in high risk patients without 
proof of Aspergillus infection (usually when the patient has persistent fever of 
unknown origin that is unresponsive to broad spectrum antibiotics). Both AMB 
and itraconazole can be employed in the management of Aspergillus infection. 
Table 3 gives a summary oftreatment options. 
Patients who are at particular risk for infection are eligible for prophylactic strate-
gies. AMB is poorly absorbed after oral administration and can therefore not be 
employed as an oral prophylactic agent. Intravenous prophylactic use of low dose 
AMB-DOC ( < 1mg/kg) is hampered by the severe side-effects and is associated 
with break-through infections [64,88]. It is not yet clear whether prophylaxis with 
oral itraconazole can prevent invasive pulmonary aspergillosis, since published 
studies report conflicting results [28,39,72, 74,82, 104]. 
Empirical treatment is usually initiated in immunocompromised patients with per-
sistent fever of unknown origin, that is unresponsive to broad spectrum antibiotics or 
when pulmonary infiltrates or cavities compatible with Aspergillus infection are 
detected by CT scan. The treatment of choice for empirical treatment remains the 
parenteral administraf1on of AMB-DOC [7]. However, dose-related toxic'1ty limits the 
flexible use of this agent. Lipid formulations of AMB show a considerable reduction 
in especially nephrotoxicity, which allows the use of much higher doses; higher 
doses lead to an increase in therapeutic index with the potential of higher success 
rates. In the empirical treatment of systemic fungal infections, the lipid-formulations 
of AMB and the itraconazole intravenous formulation are at least as effective as 
AMB-DOC and are less toxic [44,69,71]. There is substantial evidence that L-AMB 
is at least as effective as AMB-DOC, is associated with fewer break-through systemic 
fungal infections [44]. There is little information from randomised trials with regard 
to the clinical use of ABLC and ABCD, but reports from early phase trials and anec-
dotal studies suggest a lower toxicity as compared with AMB-DOC [1 06,1 08]. 
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Table 3. Management options for invasive pulmonary aspergillosis 
Approach Options Route Dosage References 
Prophylaxis HEPA filtration Beyer 
of room 
ltraconazole p.o. 5 mglkgfday Prentice, Vreugdenhil, 
oral solution Glasmacher, Delfaverro, 
Menichetti, 'v1orgenstern 
L-AMB i.v. 1-2 mgfkg/day Tollemar, Kelsey 
Empirical AMB-OOC I.V. 0.6-1 mg/kgldayfor 14 days or Gallis, Pizzo, EORTC 
Treatment until resolution of symptoms 
L-AMB i.v. 3-5 mglkg/dayfor 14 days or Walsh 
until resolution of symptoms 
ABLC I.V. 5 mg/kg/day for 14 days or Wingard, Walsh 
until resolution of symptoms 
ABCD i.v. 4 mg/kg/dayfor 14 days or White 
until resolution of symptoms 
ltraconazole I.V. 400 mg/dayfor 2 days followed Boogaerts 
by 200 mg/day for 14 days or until 
resolution of symptoms 
Treatment of ltraconazole p.o. 400 mg/dayfor 14 days or more van't Wout, Stevens, Lebeau 
Confirmed oral capsules 
Aspergillosis AMB-DOC i.v. 0.6-1 mg/kgfdayfor 14days or Gallis, Lyman, Terrell 
until recovery of granulocytes and 
resolution of symptoms 
L-AMB i.v. 3-5 mg/kg/day for 14 days or until Mills, Ringden, Ellis, 
recovery of granulocytes and Leenders 
resolution of symptoms 
ABLC i.v. 5 mg/kg/day for 14 days or untll Walsh, Anaissie, Clark 
recovery of granulocytes and 
resolution of symptoms 
ABCD l.v. 4 mg/kg/day for 14 days or until White 
recovery of granulocytes and 
resolution of symptoms 
ltraconazole i.v. 400 mg/dayfor 2 days followed by Caillot 
200 mg/day po for 14 days or until 
recovery of granulocytes and 
resolution of symptoms 
Adapted from [71]. 
New approaches in the prevention and 
treatment of Invasive Pulmonary Aspergillosis 
Although potent antifungal agents are available, morbidity and mortality from 
invasive pulmonary aspergillosis remain unacceptably high. Due to the lack of 
specific symptoms in the first stages of infection, the diagnosis of invasive pul-
monary aspergillosis is often delayed and adequate treatment is started too late in 
the course of the infection. Therefore, we are nowadays still faced with the severe 
life-threatening features of invasive pulmonary aspergillosis, which stresses the 
critical need for optimising management of this infection. New strategies, apart 
from optimising diagnosis, focus on better pharmacotherapeutic management in 
developing new antifungal agents or new antifungal strategies for therapy or pro-
phylaxis of invasive pulmonary aspergillosis. 
New antifungal agents 
New developments with regard to AMB for aspergillosis are the development of new 
lipid-carriers of AMB, such as lipid-nanospheres [51,68,79], PEG-ylated liposomes 
[100Jlipid-cochleates [40,91,115], and AMB methoxypoly(ethylene glycol) conju-
gate (mPEG-AMB) [90]. The polyene nystatin is also developed as a liposomal for-
mulation and is currently under investigation for systemic use [77]. Three new 
azole derivatives, voriconazole, ravuconazole and posaconazole, are in th8 process 
of clinical development[36,76]. These agents appear to be more potent than itra-
conazole against filamentous fungi, includingAspergiJ/us. The new azoles are 
administered orally; voriconazole will also be available as an intravenous formula-
tion. Clinical studies with voriconazole show a favourable efficacy and safety profile 
of this agent. [26] Clinical trials of ravuconazole and posaconazole are in progress. 
New classes of antifungal drugs, the echinocandins and pneumocandins, have 
been developed. These candins inhibit fungal cell wall synthesis and therefore 
have been referred to as the 'penicillin for fungi'. Their target in cell wall synthesis, 
(1,3)-B-D-glucan synthase, is not present in mammalian cells [78]. By contrast, 
polyenes and azoles act on a cell membrane common to fungal and mammalian 
cells, accounting for the toxicity of these agents. Echinocandins are active against 
Aspergillus and Candida species; pneumocandins have a similar spectrum but are 
in addition active against Pneumocystis. Ne"1ther, however, is active aga·mst 
Cryptococcus. The pneumocandins are currently evaluated in phase I, II and Ill 
trials for the treatment of oesophageal candidiasis, invasive candidiasis and 
aspergillosis. The pneumocandin caspofungin has recently entered the market and 
has the indication treatment of invasive aspergillosis in patients who are refractory 
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to AMB formulations and/or itraconazole. Chapter 2 ofthis thesis gives an 
overview of new agents which are in development for invasive aspergillosis. 
An alternative administration mod eo Inhalation of AMB 
In the last decades, there has been an increasing amount of attention for drug 
administration via the pulmonary route for either systemic delivery of drugs or 
for drugs with activity at the pulmonary epithelium. This route of administration 
is used in the therapy of a number of respiratory disorders, such as asthma, and 
respiratory infections in patients with cystic fibrosis. The administration of anti-
fungal agents via the inhalational route is a new, relatively unexplored strategy 
for the treatment of invas·lve pulmonary aspergillosis. The use of ·Inhalation 
allows easy access to the respiratory tract, directly to the intended sites of 
action. In general, advantages of inhalation of drugs includeo (l) small amounts 
of drug suffice to prevent or treat symptoms; (2) adverse reactions are usually 
much less than those after systemic administration; (3) there is a rapid and 
more predictable onset of action [l ,93]. 
With invasive aspergillosis, the lungs are usually the organs which are affected 
first. Prior to developing invasive pulmonary aspergillosis, Aspergillus spores are 
inhaled. When local defences fail, like in irnmunocompromised patients, these 
spores eventually grow out to be hyphae which penetrate pulmonary tissue 
with all devastating consequences. By administering antifungal drugs via the 
pulmonary route, it would be expected that the drug is adequately targeted to 
the intended site of action. Furthermore, it would be expected that the drug would 
have minimal systemic toxicity, since there is very little systemic absorption from 
the pulmonary epithelial cells [70]. 
In an in vitro study on AMB aerosols, the dependency of the aerosol droplet size 
and aerosol output on the type of nebuliser was demonstrated [86]. A long 
pulmonary half-life of nebulised AMB experimentalliposomes with different 
surface charges was shown in mice [61]. Administration of nebulised L-AMB 
was effective in the treatment of pulmonary and systemic Cryptococcus 
neoformans infection in mice [37]. Intensive treatment with nebulised L-AMB 
was effective in reducing the number of Candida organ·lsms in kidneys of m·1ce 
and prolonging survival time [38]. Prophylaxis or treatment of invasive pulmonary 
aspergillosis with nebulised (liposomal) AMB was evaluated in a model of 
aspergillosis in mice and rats with corticosteroid induced immunosuppression 
[3,87]. In these studies, the nebulised formulations were effective in decreasing 
the number of Aspergillus viable counts in the lungs and in increasing survival 
of animals. 
lnhalational AMB-DOC has also been studied in humans. The toxicity of 
inhaled AMB-DOC was evaluated in healthy volunteers and in granulocy-
topenic patients [9,30,43]. The results show that cough, bronchospasms, 
dyspnea, nausea and an unpleasant aftertaste are common. Although these 
side-effects were the cause of discontinuation of treatment in 22% of patients 
in one study, it was concluded that the safety profile was acceptable. 
The prophylactic efficacy of nebulised AMB-DOC was investigated in anum-
ber of studies. Among these are several studies in which the value of ·lnhala-
tional AMB was evaluated retrospectively [22,54,84,98]. Although these 
studies all describe the decrease in the incidence of invasive pulmonary 
aspergillosis with nebulised AMB, the retrospective design as well as several 
other factors makes it difficult to draw firm conclusions from these studies. 
A prospective randomised trial was performed by Schwartz et al [89]. In this 
randomised, non-blinded study, inhalational AMB-DOC was compared with 
placebo in 382 neutropenic patients. The incidence in invasive aspergillosis 
decreased from 7 to 4%. This difference was not significant, but the overall 
incidence of invasive pulmonary aspergillosis was lower than expected. 
Nebulising lipid formulations might have the advantage of prolonged retention 
in the lungs [75] and a favourable safety profile due to the pulmonary surfac-
tant like composition of lipid carriers. Up to date, there is only one described 
case of nebulised liposomal AMB. In this report, nebulised L-AMB was well 
tolerated [8]. 
Aim of the present study 
Because current knowledge of inhalational AMB is limited, a rigorous scientific 
approach is warranted to establish opt"1mal dose, frequency and durat"1on of 
administration. We therefore decided to study in detail the fu II potential of 
nebulised AMB in different formulations, with the aim of answering the following 
questions: 
What is the pharmacokinetic behaviour of nebulised AMB, which dose would 
be sufficient and which frequency of dosing? 
Does inhalation of AMB exert any adverse effects? 
What is the value of nebulised lipid formulations of AMB as compared to 
nebulised AMB-DOC? 
Can the efficacy be demonstrated in an animal model of invasive pulmonary 
aspergillosis? 
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The primary aim of the work presented in this thesis was to evaluate the merits of 
inhalational AMB formulations in the prophylaxis and treatment of i.1vasive pul-
monary aspergillosis. 
The thesis starts with an overview of lnvestigationa I antifunga Is. Agents that are 
currently in development for Aspergillus infections are discussed in a review 
(Chapter 2). 
The experimental work addresses the following: 
• Characteristics of nebulised AMB 
The aerosol procedure and detailed characteristics of nebulised AMB-DOC and 
L-AMB, such as aerosol droplet size and aerosol biodistribution are described 
in Chapter 3. 
• Biodistribution of nebulised AM 8 
In Chapter 4, the biodistribufron of both nebulised AMB-DOC and L-AMB were 
determined. Parameters such as pulmonary deposition, systemic absorption, 
retention of AMB were determined in lungs of rats. For this purpose, a model of 
invasive pulmonary aspergillosis in persistently leukopenic rats was used. 
• Toxicity of nebulised AMB 
The toxicity of nebulised AMB formulations to the pulmonary surfactant 
system, a measure of pulmonary toxicity, was determined in vitro (Chapter 5). 
• Treatment of experimental invasive pulmonary aspergillosis with 
nebuiised AMB 
In the same rat model that was used for the biodistribution study, the 
therapeufrc effrcacy of a single dose of nebulised AMB-DOC and L-AMB was 
evaluated (Chapter 5). In addition, the therapeutic efficacy of nebulised L-AMB 
when combined with intravenous therapy, was determined (Chapter 6). 
• Prophylaxis of invasive pulmonary aspergillosis with ne'oulised AMB 
The rat model was used for evaluating the prophylactic efficacy of a single 
dose of nebulised AMB-DOC and L-AMB (Chapter 7) and ABLC and ABCD 
(Chapter 8). 
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Abstract 
The urgent medical need for new potent antifungal agents in the management of 
invasive aspergillosis (lA) has resulted in the development of several compounds 
which may be of value ·m the future for the treatment or prophylaxis of lA. 
In the past years, several novel types of drugs have been discovered and devel-
oped, some of which are already in late-stage clinical trials and ready to enter 
the market. This paper discusses the antifungal agents, classified by their mode 
of action, that are currently available and the agents which are still in develop-
ment for treatment or prevention of lA. 
1. Background 
Invasive fungal infections have continued to increase in incidence during the last 
decade and are now a significant cause of morbidity and mortality [1]. Patients at 
particular risk for invasive fungal disease include: those who receive chemothera-
py, transplant recipients, HIV patients and patients receiving systemic glucocorti-
coids. The pathogens responsible for fungal infections in these patients are usual-
ly Cand;da species or AspergWus. Aspergillus is more commonly observed in 
bone marrow transplant recipients and/or patients with severe and prolonged 
neutropenia [2,3J.Invasive aspergillosis (lA) is the most commonly encountered 
form of infection caused by Aspergillus species. The incidence of lA varies 
per centre and per underlying illness [4]. lA is associated with a mortality of 
25-40% when treated with anti-fungals and nearly 100% if left untreated [5,6]. 
Diagnosis of lA is problematic and infection is often only confirmed at autopsy 
[7]. Several factors which complicate the utility of currently used antifungal 
agents include, 
dose-limiting toxicity 
growing resistance 
multiple drug interactions 
inadequate pharmacokinetic profile 
excessive costs 
The poor outcome in patients despite treatment with antifungal agents, empha-
sises the need for new agents which are superior or supplementary to existing 
therapies. Ideally, new antifungal agents are potent drugs with a broad spectrum 
against a fungal target with no mammalian counterpart. The ideal antifungal agent 
should have favourable pharmacokinetics (oral and intravenous formulation, good 
tissue distribution), should have no interactions with other drugs and have an 
acceptable safety profile. There are several compounds in development which 
might be of value in the future for the treatment or prophylaxis of lA, several novel 
types of drugs have been discovered and developed, some of which are already in 
late-stage clinical trials and ready to enter the market. This paper discusses the 
antifungal agents, classified by their mode of action, that are currently available, 
and the agents which are still in development for treatment or prevention of inva-
sive aspergillosis. 
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2. Targets of antifungal agents 
2.1 Fungal cell membrane 
The fungal plasma membrane contains sterols and phospholipids as its major 
lipid components, just like mamma !"ian cell membranes. It functions as a per-
meability barrier, a conduitforthe transportation of small molecules and sig-
nals, and as a matrix for proteins. The currently used agents for the treatment of 
lA interact with ergosterol in the fungal cell membrane. The polyenes ampho-
tericin B (AMB) and nystatin complex with ergosterol in the plasma membrane, 
causing membrane disruption; th.ls increases membrane permeability which 
leads to the leakage ofthe cytoplasmic contents of the cell and subsequently 
cell death [8]. Polyenes also cause oxidative damage, which may contribute to 
their fungicidal activity [9]. The triazoles (with itraconazole as the only azole 
with anti-Aspergillus activity) inhibit the activity of the fungal cytochrome 
P450. Inhibition of cytochrome P450 leads to blocking of lanosterol demethyla-
tion to ergosterol, leading to an alteration in the structure and function of the 
fungal cell membrane [!OJ. Novel specific antifungal targets in the fungal cell 
membrane could be [llL 
phospholipid synthesis 
sph.mgolipid synthes-Is 
proton ATPases 
efflux pumps 
2.2 Fungal cell wall 
The fungal cell wall is a structure essential to fungi and lacking in mammalian 
cells, and is an obvious target for antifungal agents. The three major components 
are 1,3-B-glucan, chitin and mannoprotein [12]. Glucan and chitin are responsi-
ble for the strength and the shape of the cell wall, while mannoprotems are ·mter-
stitial components responsible for the cell wall's porosity, antigenicity and adhe-
sion [13]. Glucan consists of glucose polymers, constituting- 60% of the cell 
wall. Glucan synthesis is catalysed by B-glucan synthase. This enzy01e is inhibit-
ed non-competitively by the cyclic lipopeptides (echinocandins) and the liposac-
charides (papulacandins) [14-17]. Chitin consists ofglucosamine homopoly-
mers and is a minor but essential cell wall component. The synthesis of chitin is 
catalysed by chitin synthases and is competitively inhibited by nikko-nycins [15]. 
Mannoproteins constitute- 40% of the fungal cell wall. The benanomycins and 
the pradimicins interact with the mannoproteins by complexion, resulting in leak-
age of potass·lum from the fungal cell membrane [18]. 
2.3 Fungal protein synthesis 
Synthesis of proteins unique to fungi represent a novel target for antifungal com-
pounds. The sordarins are a novel class of antifungals that act by inhibiting the 
protein synthesis elongation cycle [19]. 
2.4 Other targets 
Otherfungal targets for novel agents include DNA and topoisomerases, intermediate 
metabolism components (for example, nucleic acids, amino acids, polyamines) and 
cellular functions such as microtubule formation. Other approaches beyond the inter-
action of the drug with the microorganism, such as augmentation of host immune 
response by vaccination or administration of recombinant human cytokines, could 
have a great impact when combined with antifungal therapy [ll]. 
3. Currently used antifungal agents for prophy-
laxis and treatment of invasive aspergillosis 
3.1 Polyenes 
The polyenes (nystatin and AMB) are fungicidal and have a broad spectrum of antifungal 
activity. They act by binding to ergosterol located in fungal membranes, this results in the 
leakage of intracellular constituents and the subsequent death ofthe cell. The affinity of 
polyenes to ergosterol in fungal cells is higher than in mammalian cells, therefore the toxic-
ity of polyenes to mammalian cells is less than to fungal cells. Nystatin is not absorbed 
after oral administration and can not be given parenterally due to high toxicity, therefore it 
has no place in the treatment of lA. AMB has been the drug of choice for most invasive 
fungal infections since its introduction in the 1950s. AMB is a macrolide polyene antibi-
otic derived from Streptomyces nodosus. AMB is not absorbed after oral administration. 
The intravenous formulation consists of the desoxycholate salt of AMB (AMB-DOC, 
Fungizone", Bristol-Myers Squibb Co.). Toxicity associated with AMB-DOC (administered 
intravenously) can be severe and includes acute effects during administration, including: 
fever 
chills 
thrombophlebitis 
nephrotoxicity 
hypokalaemia 
hypomagnesaemia 
anaemia 
thrombocytopenia 
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This toxicity often limits adequate dosing, which results in suboptimal tissue con-
centrations reducing potential clinical efficacy [20-23]. Lipid formulations were 
developed in order to overcome the toxicity of AMB-DOC, and three types of lipid 
formulations are currently ava·llable for clinical use: 
Liposomal AMB (AmBisome', Gilead Sciences) consists of AMB incorporated 
into small unilamellar liposomes; 
AMB lipid-complex (ABLC, Abelcef', The Liposome Company Inc.) contains 
AMB complexed with two phospholipids. ABLC is an assembly of ribbon-like 
structures of a bilayer membrane; 
AMB colloidal-dispersion (ABCD, Amphocii',Amphotec', Alza Corporation) is 
a colloidal dispersion composed of disk! ike structures of AMB complexed with 
cholesteryl sulfate. Although a! I three products are not completely free from 
toxicity, they are generally less toxic than AMB-DOC. However, the lipid formu-
lations are considerably more expensive than AM 8-DOC [24-26]. 
3.2 Azoles 
The discovery of the triazoles in the late 1980s was a major advancement in the 
safe and effective treatment of invasive fungal infections. The azole derivatives are 
synthetic compounds, classified as imidazoles ortriazoles depending on whether 
they have two or three nitrogens in the five-membered azole ring. Depending on 
the particular compound, azole antifungal agents have fungistatic, broad spectrum 
activity that includes most yeasts and filamentous fungi. They inhibit C-14 
demethylation of lanosterol, thereby causing ergosterol depletion and accumula-
tion of aberrant sterols in the membrane [11]. Of the currently used azoles, only 
the triazole itraconazole has activity against Aspergillus spp. ltraconazole 
(Trisporal', Janssen-Cilag, Sporanox®, Gruenenthal GmbH) is systemically 
absorbed after oral administration and is widely distributed in organs that are fre-
quent sites for lA (such as the spleen and lungs) [27]. The recent development of 
an itraconazole oral solution {with better bioavailability) and an itraconazole intra-
venous formulation has increased the options for the use of this drug [28]. 
4. Newly developed antifungal agents with 
activity against Aspergillus 
4.1 Polyenes 
4.1.1 Liposomal nystatin 
Nystatin is a polyene antifungal agent commonly used in the topical treatment or 
prophylaxis of several types of superficial mycoses. Liposomal nystatin (Nyotran', 
Aronex Pharmaceuticals Inc.), where nystatin is incorporated in a multilamellar 
liposome, has similar antifungal activity to that offree nystatin and a significantly 
improved toxicity profile in vitro and in vivo. in vnro experiments show that liposo-
ma I nystatin is effective against a large number of fungi, i ncl udi ng Aspergi I I us 
[29]. Liposomal nystatin was well tolerated and improved survival of mice with 
systemic fungal infections [30,31]. In Phase I and II clinical trials in HIV patients, 
liposomal nystaftn was safe, well tolerated and had an acceptable pharmacokinet-
ic profile. A Phase Ill trial in 31 patients compared liposomal nystatin to AMB-
DOC, with a median duration of therapy of 6 days. There was no significant differ-
ence in the incidence of infusion-related toxicity, with a trend towards a higher 
incidence of grade 3/4 renal dysfunction with AMB-DOC. There was no difference 
between the two drugs in terms of survival, the secondary end point of the trial. 
However, Nyotran' was not equivalent to AMB-DOC with respect to the primary 
efficacy end point as defined in the protocol. In a Phase Ill trial in 538 neutropenic 
patients who had previously failed antibacterial therapy, liposomal nystatin 
(2 mg/kg/day) was compared to AMB-DOC. Both drugs were equivalent in treating 
fungal infections. The primary endpoint in this study was a composite of survival 
to 3.5 days post-therapy, reduction offever for more than 2 days while on therapy, 
afebrile status at 3.5 days post-therapy, no evidence of progressive or emergent 
fungal ·mfection and no disconbnuation due to drug-related toxicities. In addiflon, 
liposomal nystatin showed less renal toxicity than AMB-DOC [32].1n a small 
Phase II trial, the safety and efficacy of liposomal nystatin (4 mg/kg/day) was eval-
uated in 24 patients with definite or probable lA. These patients were either intol-
erant or nonresponsive to liposomal AMB. Liposomal nystatin was well-tolerated 
in these patients and a mycological response was seen in 5/19 patients who were 
refractory to liposomal AMB [33]. 
4.1.2 Cochleate AMB 
Cochleates are lipid cylinders that can serve as vehicles for the delivery of pep-
tides, DNA or drugs, particularly via the oral route [34]. Orally administered 
cochleate AMB is rapidly taken up systemically and yields therapeutic concentra-
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lions of AMB in key organs [35]./n vitro, cochleate AMB had equivalent activity to 
AMB-DOC against several clinically important fungi, including Aspergillus [36]. 
Cochleate AMB administered in a 20 mg/kg/day dose showed equivalent efficacy 
to 4 mg/kg/day AMB-DOC in a mouse model of aspergillosis [37]. 
4.1.3 NS-718 
NS-718 is a lipid nanosphere formulation of AMB. Nanospheres are biodegrad-
able polymeric particles in the nanometer size range. Nanospheres serve as drug 
carriers and can enhance the oral bioavailability of poorly absorbable drugs and 
tissue uptake after intravenous administration [38]. Intravenous NS-817 was well 
tolerated and also showed better efficacy than liposomal AMB in a rat model of lA 
[39]. In rats, NS-817 showed less nephrotoxicity than AMB-DOC [40]. 
4.1.4 Long-circulating liposomes 
A liposomal formulation of AMB was prepared with the incorporation of polyethy-
lene glycol (PEG) in the liposomal membrane. This resulted in liposomes with 
prolonged circulation and increased accumulation at sites of infection [41]. In 
contrast to L-AMB, in which liposomal encapsulation effected reduced toxicity as 
well as reduced antifungal activity of AMB, with the PEGylated AMB liposomal 
formulation it is possible to reduce AMB toxicity without reducing AMB anf1fungal 
activity. The PEGylated AMB liposomal formulation had similar in vitro activity to 
AMB-DOC but had an 18-fold improved single-dose maximum tolerated dose in 
mice. A single dose of 10 mg/kg of PEGylated AMB intravenous was as effective 
as a 10-day treatment with 1 mg/kg AMB-DOC intravenously in a model of 
aspergillosis in persistent neutropenic mice [41]. To further enhance pulmonary 
drug targeting, PEGylated AMB liposomes were complexed with antibodies 
against a lung epithelial surface glycoprotein. These immunoliposomes showed 
enhanced survival and tissue clearance in a murine model of pulmonary 
aspergillosis [ 42]. Clinical usefu I ness of this strategy has not yet been evaluated 
for treating fungal infection ·m humans. 
4.1.5 Other developments in AMB delivery 
By giving AMB via the pulmonary route, it is targeted directly at the site of infec-
tion and systemic toxicity is potentially reduced. The therapeutic value and safety 
of nebulised conventional and liposomal AMB has been shown in a rat model of 
aspergillosis in severely leukopenic rats [43]. Although this alternative route of 
administration has been studied in humans, the prophylactic or therapeutic merits 
still have to be determined [44-46]. Heating AMB is a way of altering the physical 
properties of the drug. Heated AMB had a maximum tolerated dose which was 
increased sixfold as compared to AMB-DOC. The heated AMB showed improved 
survival and lowered fungal tissue burden in a murine candid-Iasis model [47]. 
AMB methoxypoly(ethylene glycol) conjugate (mPEG-AMB) was shown to be as 
effective as AMB-DOC in preliminary in vitro screening [48]. AMB hydrosomes are 
heparin-surfaced nanoparticles designed to target infected sites. These nanoparti-
cles tend to accumulate more in the lungs than AMB-DOC but in vivo studies still 
have to demonstrate potential value in the treatment of lA [49]. 
4.1.6 SPA-S-843 
SPA-S-843 is a derivative of the polyene antibiotic patricin A. The semisynthetic 
agent SPA-S-843 is water-soluble and chemically stable in an intravenous formu-
lation. The in vitro inhibitory and fungicidal activity against Aspergillus spp. was 
equivalent to or even more potent than AMB [50]. Pharmacokinetic evaluation of 
SPA-S-843 in rats showed that SPA-S-843 has an extensive serum and tissue 
halflife, longer than AMB [51]./n vivo experiments in mice which were intra-
venously infected with Aspergillus fumigatus show a prolonged survival of ani-
mals treated with SPA-S-843 as compared to animals treated with AMB [52]. 
4.2 Azoles 
Azole compounds have become increas·mgly importantforthe treatment of oppor-
tunistic fungal infections, as well as superficial and endemic mycoses. Although lim-
ited information is available on the new azole antifungals, it seems they all have an 
excellent in vitro profile against a wide range of fungi, including Aspergillus [53]. 
4.2.1 ltraconazole intravenous formulation 
The triazole itraconazole exhibits activity against both Candida and Aspergillus 
but the absence of an intravenous formulation has restricted its use for the prima-
ry treatment of invasive mycoses in neutropenic patients. However, the intra-
venous cyclodextrin itraconazole formulation may overcome this. Cyclodextrins, 
given as an intravenous vehicle, serve as solubilisers for the hydrophobic itra-
conazole but do not alter the pharmacokinetics [54]. Intravenous administration 
for 2 weeks followed by oral administration of itraconazole for 12 weeks, was 
shown to yield complete or partial responses in about half of immunocompro-
mised patients with invasive pulmonary aspergillosis [55]. In an open, ran-
domised, controlled, multi centre equivalence trial, 384 neutropenic patients with 
cancer who had persistent fever unresponsive to antibiotic therapy received 
either itraconazole (200 mg bid, i.v. for the first 48 h, then 200 mg/day i.v., fol-
lowed by oral itraconazole solutiOn from day 15) or AMB-DOC (0. 7-l mg/kg). 
The efficacy of itraconazole was equivalent to AMB-DOC but itraconazole was 
associated with less toxicity [27]. Since itraconazole is metabolised by the liver 
and cyclodextrin is excreted renally, the drug should be used with caution in 
patients with impaired renal function. The adverse effects of itraconazole are: 
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dose-related nausea, hepatic dysfunction, hypokalaemia, and oedema [56]. 
ltraconazole is metabolised by the cytochrome P450 system and therefore signif-
icant drug interactions are likely. 
4.2.2 Voriconazole 
Voriconazole is a triazole antifungal agent with an antifungal spectrum similar to 
itraconazole. Voriconazole can be administered both orally and intravenously. 
Voriconazole is registered for use in some countries or is currently being evaluated 
for registration. The Phase Ill clinical trials have largely been completed for effica-
cy against a wide range of fungal pathogens. The activity of voriconazole is target-
ed specifically to include invasive moulds such as Aspergillus spp. to which 
voriconazole has demonstrated fungicidal activity [57-60]. Voriconazole was 
more effective than itraconazole in different animal models of Aspergillus 
infection [58,61,62]. This new azole inhibits both 14-a-sterol demethylase and 
24-methylenedihydrolanosterol demethylation, which might explain its increased 
activity against some moulds [63]. The pharmacokinetics ofvoriconazole demon-
strate intravenous as well as oral bioavailability, with an excellent absorption of up 
to 90%. The drug is distributed widely in tissues and the pharmacokinetics of 
voriconazole are non-linear with extensive hepatic metabolism. The half-life of 
voriconazole has been reported to be approximately 6 h, which demands twice 
daily dosing to maintain steady-state plasma concentrations [64]. Cytochrome 
P450 isoenzymes identified in the metabolism of voriconazole include CYP2C9, 
CYP2C18 and CYP3A4 [65]. In initial clinical trials, voriconazole was well-tolerat-
ed. The most common adverse event in Phase I and II studies was transient and 
reversible visual disturbance (altered light perception) in 15% of the individuals 
receiving the drug [65-67]. Other adverse events included [67,68], 
hepatic disturbances 
skin rash 
nausea 
vomiting 
anorexia 
In an open-label Phase II clinical trial, 102 immunocompromised patients with 
acute lA received voriconazole (6 mglkg b.i.d. i.v. then 3 mglkg b.i.d. i.v.l for 
6-27 days, followed by 200 mg b.i.d. p.o. for a total duration of 4-24 weeks. 
Complete resolution was observed in 17% of all patients, 36% showed partial 
response and 20% showed stable disease [66]. In acute lA with ha:t of the 
patients refractory to standard therapy, orally administered voriconazole (200 mg 
b.i.d.) yielded a favourable response in 11/19 patients. In an open, randomised 
trial in 392 patients with lA, patients received either AMB-DOC (1 mglkg) or 
voriconazole (6 mglkg b.i.d., then 4 mglkg b.i.d. followed by 200 mg p.o., b.i.d.). 
The primary end point was response at week 12. At week 12, complete remission 
was 53% in patients receiving voriconazole versus 32% in patients receiving AMB 
[69]. Two case-reports show that due to the extensive penetration in the central 
nervous system CCNS) fluid, voriconazole has good potential for the treatment of 
CNS mould infections [68, 70]. In a randomised, international, multi centre trial, 
voriconazole was compared to liposomal AMB for empirical antifungal therapy. 
837 patients received either voriconazole (loading dose of 6 mglkg i.v. every 12 h 
for two doses and then continued at a dose of 3 mglkg i.v. or 200 p.o. every 12 h) 
or liposomal AMB 3 mglkg. The overall success rates were 26% with voriconazole 
and 31% with iposomal AMB. Although voriconazole failed to meet the specified 
criteria for non-inferiority as compared to liposomal AMB, on the basis of the com-
posite end point, it was concluded from this study that voriconazole could be a 
suitable alternative to AMB preparations for empirical antifungal therapy [71]. 
Voriconazole promises to be an important new agent in the treatment of lA, with 
moderate toxicity. 
4.2.3 Posaconazole 
Posaconazole is a second generation triazole and a structural analogue of itracona-
zole. The drug has a very low watersolubility and currently only comes in an oral 
form as a tablet or as a suspension. Overall, the in vitro profile of posaconazole is 
broad and it is fungicidal against a variety of filamentous fungi, including 
Aspergillus [72]. Posaconazole showed better activity (on a milligram to milligram 
basis) against different Aspergillus spp. in vitro than itraconazole and voriconazole 
[73-75]. The efficacy of posaconazole appears to be both dose- and time-depen-
dent. In a model of lAin neutropenic rabbits, posaconazole was more effective 
than itraconazole and as effecf1ve as AMB-DOC [76]. In a temporarily neutropenic 
mouse model of disseminated aspergillosis, posaconazole was superior to AMB in 
terms of survival and quantitative organ cultures, and superior to itraconazole 
when used against infection caused by both itraconazole-sensitive and -resistant 
strains [77]. A recent study in persistently neutropenic rabbits showed that 
posaconazole at :e 6 mglkglday was as effective in the treatment and prevention of 
invasive pulmonary aspergillosis as AMB-DOC at 1 mglkg and more effective than 
itraconazole at :e 6 mglkglday [78]. In a model of lAin immunocompetent and 
immunocompromised mice, posaconazole was effective in terms of survival and 
quantitative lung cultures [79]. Pharmacokinetic evaluations in humans show that 
posaconazole has a half-life of- 25 hand that adequate plasma concentrations 
are yielded with once daily dosing. Posaconazole has extensive tissue distribution 
[80]. When the drug is taken with food, the bioavailabity is increased as compared 
., (') 
" 
6f ~ '0 
n ~ 0 
~- '-' 
"-
• ~
ro 
0 
" 5. 
0 
~ 
0 
~ 
3 
ro 
2. 
to the drug taken when fasting and the bioavailability of the suspension is about 
40% higher than that of!he tablet [81]. A randomised, double-blind, placebo-
controlled study in healthy volunteers to evaluate the safety and tolerance of esca-
lafmg doses of posaconazole for 14 days showed that posaconazole was well tol-
erated. There was no difference in incidence or type of adverse events reported by 
either the subjects taking the drug or the placebo [80]. Posaconazole has currently 
entered Phase Ill clinical trials, which are largely complete. 
4.2.4 Ravuconazole 
Ravuconazole (BMS-207147, ER-30346) is a synthetic triazole with structural 
similarities to voriconazole. Ravuconazole has activity against a number of moulds 
and yeasts [82,83]. It shows excellent activity against Aspergillus spp. [73,83, 
84]. Ravuconazole was more effective than the echinocandin anidulafungin and 
as effective as AMB in a rabbit model of lA [85]. Ravuconazole was developed for 
oral administration but an intravenous formulation is in development. In a ran-
demised, double-blind study on the safety of ravuconazole in humans, healthy 
male persons received escalating doses of ravuconazole (a maximum of 800 mg) 
or placebo. No serious adverse events were reported, w·1th headache and abdomi-
nal pain reported most frequently. The bioavailability of ravuconazole was 50% 
and the half-life 3.5-7.5 days. Ravuconazole showed no induction ofthe 
cytochrome P450 isoenzyme CYP3A4. Ravuconazole has currently entered sever-
al Phase Ill trials [86]. 
4.2.5 Otr.er azoles 
Other new azoles with in vitro anti-Aspergillus activity include R-102557 [87], 
SS-750, TAK-456 and its prodrugTAK-457 [86], T-8581, SYN-2836, SYN-
2869, SYN-2903, SYN-2921 [88] and UR-9825 (low activity) [89]. The thera-
peutic eff1cacy of SS-750 was evaluated ·m murine models of systemic 
aspergillosis. SS-750 had excellent activity in vivo, with equivalence shown 
for the intravenous and oral administration. SS-750 was more effective than 
itraconazole [86]. 
4.3 Gluccn synthase inhibito~s 
One ofthe three components of the fungal cell wall is B-1 ,3-glucan [12,15,90,91]. 
B -1 ,3-glucan synthesis is catalysed by the enzyme B-1 ,3-glucan synthetase 
which is inhibited non-competetively by the cyclic lipopetides echinocandins and 
the papulacandins [17,92,93]. The papulacandins are no longer pursued since 
their in vitro activity is limited to Cand;da species and does not translate to ;n v;vo 
activity [92]. 
4.3.1 Echinocandins 
The echinocandins are a novel class of cyclic lipopeptide fungicidal agents which 
inhibit the synt~esis of 1 ,3-B-glucan, an essential polysaccharide found in the cell 
wall of many pathogenic fungi [11,94,95]. The inhibition offungal cell wall syn-
thesis is highly specific and brief exposure of fungal cells to echinocandins leads to 
cell death [94]. The echinocandins all have a consistent spectrum of antifungal 
activity, no cross-resistance to existing antifungal agents and lack of a mechanism-
based toxicity [95]. They all possess favourable pharmacokinetiCS but can only be 
administered intravenously. 
4.3.2 Caspofungin 
Caspofungin (Cancidas", MK-991, L-743,872, Merck & Co.) is a semisynthetic 
echinocandin derivative being developed as an antifungal and antipneumocystic 
agent. It has activity against a number of clinically important yeasts and fungi, 
including Aspergillus spp. It is fungicidal against Candida spp. [96] but fungistatic 
against Aspergillus [72,75,97-100] and inactive against Fusarium, Rhizopus, 
Cryptococcus and Trichosporon species [201]. Caspofungin has shown in vitro 
activity against refractory clinical isolates of Aspergillus [101]. The in vivo activity 
against Aspergillus infections was shown in models of neutropenic [102] and 
immunocompetent mice [103, 104]. Phase I studies were performed in healthy 
male adult volunteers. The half-life of caspofungin was 9-10 h with an average 
plasma cleararce of 11 ml!min. A 70 mg/day once-daily dosing regimen main-
tained mean trough plasma levels above the reported minimum inhibitory concen-
tration (M I C) values for most susceptible fungi throughout the treatment period 
from day 1 forward [105,106]. A Phase II trial was conducted in 128 HIV-positive 
patients with Candida oesophagitis. Caspofungin was as effective as AMB and 
had less side-effects. No serious adverse events were reported for caspofungin 
[107]. In a multicentre, non-comparative study of lA, 56 immunocompromised 
patients were treated w·1th 70 mg dose of caspofung·m on the first day, followed by 
50 mg once-daily. All patients had refractory lA or were intolerant to AMB, liposo-
mal AMB or azole therapy. A favourable response was noted in 41% of the 
patients. One serious adverse event was reported and three patients discontinued 
therapy because of adverse events. Infusion-related reactions and nephrotoxicity 
were uncommon. Caspofungin is not subject to drug interactions based on 
CYP3A4 inhibition [108]. The FDA has recently approved caspofungin intra-
venous infusion, for the treatment of patients who are unresponsive to or cannot 
tolerate standard therapies for lA. Caspofungin is thereby the first approved drug in 
a new class of antifungals. 
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4.3.3 Micafungin 
Micafungin (FK-463) is a water-soluble semisynthetic echinocandin-like lipopep-
tide. FK-463 has in vitro activity against a number of yeasts and filamentous fungi 
including Aspergillus [109]. However, in contrast to AMB, FK-463 does not exert 
fungicidal activity against Aspergillus spp. [109,110]. The efficacy of treatment 
with FK-463 in mouse models of aspergillosis was comparable or inferior to that of 
amphotericin B [111, 112]. The safety and pharmacokinetics of FK-463 have been 
·mvestigated ·m healthy adult volunteers, in febrile neutropenic paediatric patients 
and in patients receiving haematopoietic stem cell transplantation [113-115]. In 
these studies, FK-463 was well-tolerated. Similar to caspofungin and VER-002, 
FK-463 is not metabolised to a significant extent through the cytochrome P450 
enzyme system [95]. Phase II studies with FK-463 have only been performed in 
HIV-infected patients with oropharyngeal and oesophageal candidiasis [116]. 
Currently, a non-comparative, open-label trial is performed for assessing the value 
of FK-463 75 m~day for the treatment of newly diagnosed lA and lAin patients 
who have not responded to systemic therapy with other antifungal drugs [117]. 
4.3.4 Anidulafungin 
An.ldulafungin (VER-002, V-echinocandin, LY-303366) is also a potent non-com-
petitive inhibitor of B -1 ,3-glucan synthase [118]. In vitro, anidulafungin showed 
activity against AMB-resistantA. fumigatus [119]. The in vivo efficacy of anidula-
fungin was evaluated in a large number of animal models of candidiasis, 
aspergillosis and pneumocystis carinii pneumonia (PCP). It was shown to be effec-
tive in the treatment of Aspergillus infections in these experiments [85]. The phar-
macokinetics of orally [120,121] and intravenously administered [122,123] 
anidulafungin were investigated in healthy volunteers. The terminal half-life was 
reported to be 25-42 h, and the use of anidulafungin was not correlated with seri-
ous adverse events. Common side-effects were: dizziness, nausea, headache, 
fac·lal flushing, dyspnea, increased aspartate aminotransferase [122]. In a non-
controlled Phase II trial in patients with oesophageal candidiasis anidulafungin 
was shown to be effective [124]. Anidulafungin is currently being evaluated in 
Phase II clinical trials. 
4.3.5 Other echinocandins 
The echinocandin HMR-3270 shows in vitro activity against Aspergillus 
[125,126]. Furthermore, this candin was effective in reducing aspergillosis-relat-
ed mortality in an experimental mouse model [125,126]. The echinocandin-
derived A-192411.29, which has good in vitro activity against clinically relevant 
Candida spp., showed no activity against Aspergillus [127]. Pneumocandin BO 
and other related macrocycle agents, seem not to have anti-Aspergillus activity. 
L-705589, L-733560 and L-692289 are all echinocandin-like lipopeptides with 
reported anti-Aspergillus activity but the development of these entities has been 
discontinued. 
4.3.6 Other B-~ ,3-glucan synthase inhibitors 
Arborcandins are novel cyclic peptides that inhibit B-1,3-glucan synthase in the 
fungal cell wall. The arborcandins are structurally different from echinocandins, 
they show in vitro activity against Candida and Aspergillus [128]. FR-901469 is 
a water-soluble, non-echinocandin-type lipopeptide. This agent showed activity 
against Aspergillus in vitro as well as in vivo [129]. 
4.4 Mcnno~rotein-acting compounds 
Pradimicins and structurally-related benanomycins act by a calcium-dependent 
complexing with the saccharide portion of surface mannoproteins of fungal cells; 
this causes perturbation ofthe cell membrane, leakage of intracellular contents 
and, ultimately, cell death [130]. The water soluble pradimicin BMS-181184 has 
broad spectrum antifungal activity in vitro [131, 132]. BMS-181184 was shown 
to be effective in aspergillosis in persistently neutropenic rabbits [95,133]. Due to 
hepatotoxicity in human volunteers, clinical trials were stopped and this agent is 
no longer under clinical investigation [95]. Several other water soluble mannopro-
tein compounds are in very early development [94,95]. 
4.5 Chitin synthase inhibitors 
Nikkomycin-Z 
Chitin is a minor but essential cell wall component of fungi. Chitin synthesis is 
inhibited by the naturally-occurring nucleoside-peptides polyoxins and by the 
nikkomycins [15]. Nikkomycins are peptidyl nucleoside antibiotics which 
selectively inhibit chitin synthase in fungi. Nikkomycin Z is the only agent that 
was developed beyond the in vitro stage. Although nikkomycin Z shows good 
antifungal activity against several chitin-rich fungi, it has no activity against 
A. tumigatus. Only when combined with itraconazole does nikkomycin Z show 
inhibitory or fungicidal effects against Aspergillus spp. in vitro [134, 135]. 
Due to its modest antifungal activity, nikkomycin Z has not been further developed 
for clinical use. 
4.6 Allylamines and thiocarbamates 
Terbinafine inhibits squalene epoxidase, a key enzyme in ergosterol biosynthesis. 
Although terbinafine is highly active in vitro against Aspergillus spp., especially in 
combination with azoles, clinical use has been associated with failure [136,137]. 
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4.7 Sordari~s 
Sordarins are antifungal agents with a completely new mode of action. Sordarins 
selectively inhibit fungal protein synthesis by impairing the function of elongation 
factor 2, thereby selectively inhibiting the fungal protein synthesis machinery. 
They do not interfere with mammalian prote"1n synthesis, since fungal and mam-
malian protein translation differs significantly at the molecular level [138]. 
Although sordarins showed remarkable activity against different yeasts and fungi, 
they have moderate in vitro activity against Aspergillus spp. [139]./n vivo experi-
ments in murine models of lA also show a limited effect of GM-237354 on the 
survival of animals [127, 140]. 
4.8 O~her agents 
4.8.1 Immunisation/vaccination 
A study on the immunisation of mice with a Candida albicans membrane fraction, 
showed that th.ls procedure did not only reduce mortality from C. a/bicans sys-
temic infection but also increased resistance to systemicAspergWus infection. 
Vaccination of mice with Aspergillus vaccine preparations protected the animals 
from developing lA [141]. Clinical experience with immunotherapy for invasive 
fungal infections is largely limited to anecdotal case reports and small studies. 
Nevertheless, the outcomes noted with this treatment modality are encouraging 
and call for controlled trials to evaluate the efficacy of immunotherapy with and 
without concomitant antifungal therapy [142]. 
4.8.2 Cationic peptides 
Cationic peptides can be a component of the early innate defences against invad-
ing microbes. Both naturally-occurring and synthetic cationic peptides bind to 
ergosterol and cholesterol in fungal cell membranes, which ultimately leads to cell 
lysis. These peptides have antifungal activity against Aspergillus spp., Candida 
spp., Cryptococcus neoformans and Fusarium spp. [143,144]. Naturally-occur-
ring peptides include cecropins, dermaseptins, indolicins, histatins, bactericidal 
permeability increasing factor (BPI), lactoferrins and defensins [95, 143,144 ]. 
The in vitro synergistic effect of histatin analogues in combination with AMB was 
shown against several fungi, including Aspergillus [145]. The clinical value of 
these compounds remains to be determined. 
4.8.3 Other developments 
Synthetic cationic poly-heterocyclic molecules (Gl-047296, GL-886217, 
GL-478057) showed in vitro activity against A. fumigatus and Candida spp. Their 
activity is based upon high affinity binding with double-stranded DNA [146, 147]. 
A new antifungal target is presented by sphingol'lp.ld, an essential membrane com-
ponent ofthe fungal cell wall. Aureobasidin A is a peptide inhibitor of inositol 
phosphorylceramide synthase and inhibits sphingolipid synthesis. Aspergillus 
showed low sensitivity for aureobasidin A but the MIC was dramatically decreased 
when aureobasidin A was combined with the efflux inhibitorverapamil [148]. 
Recently, it was shown that aureobasidin A alone was an in vitro inhibitor of 
growth of Aspergillus fumigatus isolates [149]. Studies on the in vitro antifungal 
activities of a number of dication-substituted carbazole, furans and benzimida-
zoles show that some of these compounds have activity against A. fumigatus. 
The mechanism of action of these dicationic molecules is probably based on bind-
ing of DNA but the exact mechanism still has to be elucidated [150]. The activity 
of 3-phenyl-5-acyloxymethyi-2H,5H-furan-2-ones was tested in vitro against 
A. fumigatus and they were shown to be as effective as AMB [151]. The in vitro 
activity of a novel class of antifungal peptides, bifunctional inhibitors (ATBI) was 
studied. ATBI showed antifungal activity against several fungi, including 
Aspergillus [152]. Spongistatin 1 is an experimental antineoplastic agent that also 
has broad spectrum antifungal activity [153]. Spongistatin 1 is an antimicrotubule 
agent in Aspergillus nidulans [154]. The indole alkaloid venenatine exhibited 
antifungal activity against Aspergillus flavus in vitro. 
5. ConciL:sion and potential development issues 
The currently used agents in the treatment of lA have several limitations and the 
outcome of patients is generally disappointing. The critical need for antifungal 
agents with improved efficacy and safety has led to the discovery of many com-
pounds. This paper presents an overview of current and new antifungal agents that 
hold potential for the management of lA. 
Although AMB has been used for lA for many years, new strategies such as other 
modes of administration and different formulations are all focused on the broad-
ening of the therapeutic window of AMB, which would allow more flexible dosing. 
The new azoles bring improved potency and a broader spectrum than previous 
azoles, while c:inical experience with voriconazole, ravuconazole and posacona-
zole has been positive. 
With the arrival of the echinocandins, we have the first new class of antifungal 
agents with a novel mode of action. The echinocandins are fungistatic against 
Aspergillus species. Therefore, their role as a single agent for treatment of proven 
invasive Aspergillus infections in the neutropenic host should be carefully investi-
gated. The echinocandins may prove useful in combination with agents that target 
the cell membrane, such as AMB or triazoles. Entering the field of agents which 
are in development for lA are several compounds from different structural classes, 
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these target different functions within the target cell. At present. there are limited 
data on the clinical utility of these compounds but some ofthem definitely hold 
promise for the future. 
5. Expert opinion 
Discovery of new antifungal agents for filamentous fungal infections and lA has a 
high priority, as the rate of these infections is increasing and the outcome is poor. 
Given the limitations of the in vitro testing of filamentous fungi, many newly 
described agents show promising in vitro fungicidal activity butfew make it 
through to Phase I investigat"lons. Although the newer described agents have an 
increased potency, fewer side-effects and a broader antifungal spectrum, the most 
important ·Intervention in lA is the prevention of infection and the reversal of host 
risk factors. Two major noteworthy contributions to antifungal chemotherapy will 
dominate the treatment of lAin the coming years. The licensing of caspofungin 
brought a new class of potent anti-Aspergillus drugs to the market with a lower 
potential for cross-resistance. Furthermore, the drug seems to be an ideal candidate 
for combination therapy with fungal cell membrane active drugs. The second major 
breakthrough involves the promising results shown by the new azole voriconazole, 
with regard to efficacy and survival in a large worldwide comparative trial in lA. 
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Abstract 
In the treatment or prophylaxis of invasive pulmonary aspergillosis, it may be 
attractive to administer the antifungal agent amphotericin B (AMB) directly to the 
pulmonary route via aerosol inhalation. In this study, we describe the aerosol char-
acteristics of aerosolised amphotericin B desoxycholate (AMB-DOC) and liposomal 
amphotericin B (L-AMB), and the in vivo aerosol deposition. 
Aerosols were generated with a Collison nebuliser. Aerosol AMB concentrations 
and mass median diameters (MMDs) were measured./n vivo pulmonary deposi-
tion was evaluated by measuring AMB concentrations in lungs of treated animals. 
Whole body aerosol deposition was determined by measuring radioactivity in 
tissues of rats after treatment with radiolabeled liposomes. For AMB-DOC and 
L-AMB, aerosol AMB concentrations were 24.5 ± 4.9 ~>VL and 23.8 ± 3.0 ~>VL, 
respectively. MMDs were 1.38 ~m and 2.26 ~m, for AMB-DOC and L-AMB, 
respectively. AMB concentrations in lungs after 60 min nebulisation of AMB-DOC 
or L-AMB were 24.2 ± 6.4 ~&fgand 21.7 ± 2.6 ~&fg, respect·,vely. After nebuli-
sation of radiolabelled liposomes, no radioactivity was retrieved from other tissues 
than the lungs or the gastrointestinal tract. 
Nebulisation of either AMB-DOC or L-AMB leads to respirable aerosols and results 
in a substantial lung tissue concentration of AMB and low systemic exposure of 
AMB. Aerosol administration of either AMB-DOC or L-AMB may be an attractive 
approach to prevent or treat pulmonary aspergillosis. 
Introduction 
Aspergillus spp., and especially Aspergillus fumigatus, are increasingly recog-
nised as major fungal pathogens in severely immunosuppressed or neutropenic 
patients [l]. The most encountered form of disease due to Aspergillus is invasive 
pulmonary aspergillosis. The polyene antifungal agent AMB has been the drug of 
choice since many years in the treatment of many fungal infections, including 
invasive pulmonary aspergillosis [1]. However, use of this drug is hampered by 
considerable toxicity following intravenous injection, such as renal toxicity, anemia 
and hypokalemia [2]. New (lipid based) formulations of AMB, which have an 
increased therapeutic index as compared to AMB-DOC, are currently available [3]. 
However, treatment of immunocompromised patients with an established 
pulmonary infection with Aspergillus spp. is to date often unsuccessful and 
optimisation of antifungal treatment of invasive pulmonary remains a challenge. 
Aspergillus spp. are respiratory pathogens and pulmonary infections leading to 
invasive pulmonary aspergillosis are usually acquired through inhalation of 
Aspergillus conidia. However, concentrations of AMB after intravenous injection of 
both non-liposomal as liposomal AMB are mainly seen in liver and spleen [4,5]. 
This may be the cause of treatment failure often observed in invasive pulmonary 
aspergillosis. Improvement in the treatment of invasive pulmonary aspergillosis 
can therefore be sought in the aerosol administration of AMB as such or of lipid 
formulations of AMB. Aerosol inhalation is an important drug delivery method in 
pulmonary diseases since it targets the lungs and reduces exposure of other organs 
to the drug, thus minimising side-effects [6,7]. 
In this study, a system for aerosol administration of the commercially available prod-
ucts AMB desoxycholate (AMB-DOC) and liposomal AMB (L-AMB) is described in 
order to evaluate several aspects of stability of nebulised suspensions, output of mass 
and volume of AMB suspensions and delivered dose of AMB. Furthermore, in vivo 
deposition in lungs and biodistribution in other organs of rats have been evaluated. 
Materials and Methods 
Materials 
AMB desoxycholate (AMB-DOC, Bristol Myers-Squibb, Woerden, The Netherlands) 
and liposomal AMB (L-AMB, NeXstar, San Dimas, CAl were reconstituted in dis-
tilled water according to the manufacturer's instructions and further diluted in 5% 
glucose in water up to a concentration of 4 mg1mL AMB. AMB (activity 916 ~g1g) 
)> (") 
ro 
"'" ~ 
"' 2. u 
~ w ~ 
• w 
" [ 
~ 
~ 
~ 
for calibration was from Bristol Myers-Squibb, Woerden, The Netherlands. 
Hydrogenated soy phosphatidylcholine (HSPCl and distearoyl phosp'latidylglycerol 
(DSPG) were from Avanti Polar Lipids, Inc. (Alabaster, AL). Cholesterol (Chol), 
dimethylsulphoxide (DMSO) and 8-hydroxyquinone sulfate were from Sigma 
Chemical Co (St. Louis, MOl. "Gallium-citrate was from Mallinckrodt Medical BV 
(Petten, The Netherlands). Desferoxamine mesylate (Desferal) was from Novartis 
(Basel, Switzerland). All other reagents were of analytical grade. 
Animals 
Female RP strain rats (specified pathogen free, 18-25 weeks, 185-225 g) were 
used. Experiments were approved by the animal experiments ethical committee of 
the Erasmus University Medical Center. 
Nebulisation apparatus and procedure 
The aerosol inhalation system is schematically depicted in Figure l. Compressed air 
was supplied to the nebuliserwith a flow rate of 20 Umin and 37.5 psi as measured 
Collison 
nebuliser 
Vacuum pump 
indicator 
Max24 
animals 
indicator 
f- (liposomal) Suspension 
Compressed air 
Reducing valve 
Figure 1. Schematic representation of the aerosol inhalation system. 
by a flow indicator (Sho-rate, Brooks Instrument BV, Veenendaal, The Netherlands) 
and a pressure indicator (ITI Fluid Technology, St. George, SC). Aerosols were gener-
ated by a Collison six jet nebuliser (Model CN, BGIInc., Waltham, MAl. A glass neb-
uliser reservoir with a small fill hole at the jar bottom ensured high efficiency nebuli-
sation of fluids. Generated aerosols were led through a nose-only exposure inhalation 
chamber (CH Technologies USA Inc., Westwood, NJ). This inhalation chamber is 
suitable for aerosol treatment of 24 individual animals. A continuous flow was pre-
sent inside the system, due to a vacuum pump at the end, operating with a flow rate 
of 23 Umin. In connection with this vacuum pump was a filter house containing two 
filters, one main filter to extract aerosol droplets from outgoing air, the other filter to 
compensate for over or under pressure developing during nebulisation. In the in vivo 
experiments, animals were constrained in cone-ended plastic animal holders such, 
that only their nose was in contact with the aerosol. 
AMB spectrop~otometrical analysis and liposomal characterisation 
AMB concentrations in the nebuliser reservoir and in the inhalation chamber sam-
ple were determined spectrophotometrically. After diluting the samples in 
DMSO,methanol 1,1 v/v the observed extinctions at 410 nm could be interpolated 
in a standard calibration curve. Mean particle size of liposomes was determined by 
dynamic light scattering (4700 system, Malvern Instruments, Malvern UK) [8]. 
Phospholipid content was determined by phosphorus assay [9]. 
Measurement of volume and mass output 
Volume output of nebulised liquid was determined gravimetrically by subtracting 
the weight of the complete reservoir containing the residue after nebulisation from 
the weight ofthe reservoir containing the liquid to be nebulised. Mass output of 
AMB was determined by subtracting the amount of AMB (mg) in the reservoir after 
nebulisation from the amount of AMB in the reservoir before nebulisation. 
Aerosol concentration measurement 
Aerosol samples were extracted from the inhalation chamber at the breathing level 
of animals as depicted in Figure 2. A 10 mL syringe was used to extract with fre-
quent intervals in total an amount of 1 L during 60 min of nebulisation. This sam-
pling volume provided sufficient drug for spectrophotometrical analysis. The sam-
pled air was led through 10 ml collection medium consisting of a mixture of 
DMSQ,methanol1,1 v/v, which could thereafter directly be measured according to 
the method described above. 
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Figure 2. Inhalation chamber sampling procedure. 
Droplet size measurements 
Droplet size distribution was measured using a laser velocity particle sizer (Aerosol 
Particle Sizer 3320A, TSI Inc., St. Paul, MN). Aerosols were generated with com-
pressed air at a flow rate of 10 Umin. Distribution of the number of generated 
aerosol particles was directly measured with this technique. For extrapolation of 
mass distribution from the number distribution, specific gravity was set at that of 
the solvent (1 gjcm') and relative humidity at 60%. From the mass distribution, 
the parameters mean diameter (MMD), geometric standard deviation (GSD) and 
percentage of particles with a mass diameter <5 11m were calculated. 
Preparation of radiolabelled liposomes 
Liposomes were labelled with "Ga according to the method described by 
Gabizon et al [10]: Liposomes were prepared using the film hydration method. 
Liposomal membranes consisted of HSPC:DSPG:Chol in a molar ratio of 
2:1:0.8, similar to the lipid composition of L-AMB. Lipids were dissolved in 2 mL 
chloroform:methanol (1:1, v/v). The lipid mixture was evaporated to dryness in 
a round bottom flask at 65°C. The lipid film was hydrated by vortex mixing with 
a buffer solution containing 10 mM sodium-succinate, 10% (w/v) sucrose 
(pH 5.5) and 5 mM desferoxamine. Liposomes were sonicated which resulted 
in vesicles with an average particle size of 100 nm, as measured by dynamic 
light scattering. Unencapsulated desferoxamine was removed by eluting the 
suspension over a Sephadex G-50 column (Pharmacia, Uppsala, Sweden), 
followed by ultracentrifugation at 280,000 x gfor 2 h at 4°C. Phosphol"lpid con-
tent was determined by phosphorus assay [8]. "Ga-citrate (370 MBq/mU was 
diluted 1:9 in a 0.5 mglmL 8-hydroxyquinone sulfate solution and incubated for 
1 hat 50"C to yield "Ga-oxine. The liposome suspension was incubated 
overnight at 4"C with 3. 7 x 10·' MBq of "Ga-oxine per 11mole of lipid. 
Unencapsulated "Ga-oxine was removed by gelfiltration (Sephadex G-50 
column, Pharmacia, Uppsala, Sweden), and liposomes were concentrated by 
ultracentrifugation as described above. 
Deposition of radiolabelled liposomes 
Animals were treated with nebulised 67Ga-labelled liposomal suspension according 
to the nebulisation method described above. Groups of 2 animals were euthanised 
with pentobarbital (100 mglkg i.v.) after 10, 20, 30, 40, 50 and 60 min of nebuli-
sation. Directly after, approximately 0.3 mL blood was sampled via an orbital punc-
tion and left lung, right lung, trachea, tongue, oral cavity, lower jaw, snout, stomach 
and esophagus, intestines, spleen, liver and kidney were dissected. Organs, tissues 
and blood were weighed and analysed for y-irradiation with a Minaxi autogamma 
5000 gamma counter (Packard Instrument Company, Meriden, CTJ. 
Calculation of percentage deposition of radioactivity 
Measured counts per minute (cpm) of "Ga-la belled liposomal suspension before 
and after 60 min of nebulisation were 6.5 x 10' and 1.2 x 10' cpm/mL respective-
ly. From these values, total cpm nebulised and the inhalation chamber concentra-
tion can be calculated. Delivered doses at the breathing point of animals can 
subsequently be derived as follows, 
delivered dose (cpm) = 
minute volume (Umin) x aerosol chamber concentration (cpm/L) 
x duration of nebulization (min) (l) 
Minute volume of animals was calculated according to Guyton [1 n 
minute volume (Umin) = (body weight (g))'-" x 0.0021 (2) 
Measured cpm in organs and tissues divided by the delivered dose gives the 
relative deposition. 
Maximum pulmonary concentration of AMB after nebulisation of AMB-DOC or L-AMB 
Directly after 60 min nebulisation of either AMB-DOC or L-AMB, animals were 
euthanised and lungs were removed. Right and left lung lobes were weighed and 
homogenised in 20 mL 5% glucose. AMB was extracted from the homogenate with 
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ethanol in a 4:6 (v/v) ratio. The extracts were centrifuged for 5 min at 13,000 x g 
and concentrations of AMB in the supernatants were determined by HPLC with a 
UV detector operating at 382 nm. The mobile phase consisted of a 0.1 M sodium 
acetate solution (pH 7.2) containing 0.2% (v/v) triethylamine and 60% (v/v) acetoni-
trile and was pumped through a Guard pre-column (Chromguard, 10 x 3 mm; 
Chrompack, Middelburg, The Netherlands) followed by a reverse-phase C18 column 
(Chromspher, 100 x 3 mm, Chrompack, Middelburg, The Netherlands) at a flow rate 
of 0.5 mUm in. The lower quantity of determ·mation ofth.ls assay was 0.2 mg/L. 
Results 
Solute concentration during the process of nebulisation 
Table l gives mean concentrations of AMB in the nebuliser reservoir before and after 
nebulisation of AMB-DOC and L-AMB. For L-AMB, total lipid concentration and AMB-
Iipid ratio (pgAMB/mmol total lipid) are given. After 60 min of nebulisation, concen-
trations of AMB in the reservoir were increased with both AMB-DOC and L-AMB. 
Increase ·m concentraf1on of AMB with nebulisaf1on of AMB-DOC was more pro-
nounced than with L-AMB (P = 0.006). Total lipid concentration in the L-AMB sus-
pension increased linearly with concentration of AMB in L-AMB (Table 1). As a result, 
AMB-Iipid ratio of the liposomal suspension did not change during nebulisation. 
Stability of liposomes to nebulisation 
Diameters of liposomes in the L-AMB suspension before nebulisation, in the 
remnant volume in the reservoir after nebulisation, and of the inhalation chamber 
sample taken during 60 min of nebulisation are shown in Table 2. A significant 
increase in mean liposomal size was observed after nebulisation in the residue 
suspens·lon after nebu1"1saf1on (P = 0.004) as well as in the inhalation chamber 
sample W = 0.013) as compared to liposomal diameter of the suspension to be 
nebulised. 
Volume and mass output 
The nebulised volumes of glucose 5%, AMB-DOC or L-AMB were similar during a nebu-
lisation period of 60 min (Table3). Mass output in terms of mgAMB was 35.40 ± 6.20 
mgfor AMB-DOC and 57.13 ± 10.17 mgfor L-AMB. AMB output after nebulisation of 
AMB-DOCwassignificantly lower than afternebulisation of L-AMB (P- 0.031). 
Table l. Amphotericin concentration, total lipid concentration and amphotericin/lipid 
ratio in the reservoir suspension before and after 60-min nebulisation of AMB-DOC and 
L-AMB. 
AMB-DOC L-AMB 
AMB AMB Total lipid 
cone (mg mL·') cone (mg m L·') (~mol mL·') 
Before 
nebulisation 4.1 ±0.6" 4.1 ± 0.2 38.6 ± 2.2 
After 
nebulisation 12.9 ± 1.0 8.4± 2.2 81.6 ± 13.9 
Ratio concn.n •• / 
con en before 3.1 ± 0.2b 2.1 ± 0.6 2.3 ±0.4 
•Each value represents the mean:!:s.d. of three individual experiments. 
'Pc:=0.006 vs AmBisome. 
Amphotericin/lipid 
(~gmmol·') 
104.1 ± 9.0 
106.5± 11.6 
1.0 ± 0.0 
Tab:e 2. Liposomal diameters of L-AMB before and after nebulisation in the 
nebuliser reservoir and in the inhalation chamber sample. 
Before nebulisation 
After nebulisation 
Inhalation chamber sample 
Liposomal diameter (nm) 
74.0 ± 6.1'·" 
84.1 ± 5.2 
86.1 :': 1.4 
·Each value represents the mean±s.d. of at the least three individual experiments. 
"P=0.004 and 0.013 vs liposomal diameter after nebulisation and of the chamber sample, respectively. 
Table 3. Volume output and mass out[ put of amphotericin after 60 min 
nebulisation of AMB-DOC and L-AMB. 
Glucose (5%) Fungizone (4 mg mL·') AmBisome (4 mg mL·') 
Volume (ml) 23.7 ± 1.0' 23.4 ± 1.2 23.2 ± 1.3 
Mass (mg amphotericin) 35.4 ± 6.2" 
•Each value represents the mean±s.d. of three individual experiments. 
•P=0.031 vs AmBisome. 
57.1 ± 10.2 
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Aerosol concentration measurement 
Aerosol concentrations measured at the breathing-points of animals were the 
same for AMB-DOC and L-AMB per liter of collected air over one hour period 
(24.53 ± 4.93 and 23.75 ± 2.97 J.lg/L, respectively). 
Aerosol size distribution 
Figure 3 shows the droplet size distribution of aerosol droplets for AMB-DOC, 
L-AMB and for 5% glucose ·m water. A sim·,!ar homogenous distribution for all 
formulations was observed (median droplet size for AMB-DOC 0.743 J.lm and 
0. 758 J.lm for L-AMB). Figure 4 shows the calculated cumulative mass distribu-
tion. Percentages of particles <5 J.lm mass diameter were 83.20 and 86.60 for 
nebulised AMB-DOC and L-AMB, respectively. Derived mean mass diameter 
(MMD) and geometric standard deviation (GSD) for nebulised AMB-DOC were 
1.38 j.lm and 2.26 j.lm and 2.43 J.lm and 1.97 J.lm for L-AMB. 
In vivo deposition of 67 Ga labelled liposomes 
Distribution of delivered dose in relevant organs and tissues after 60 min nebulisa-
tion calculated as percentage of the delivered dose is shown in Table 4. The largest 
part was retrieved from the intestines (26%). 2% and 4% ofthe delivered dose was 
retrieved from the left lung and right lung, respectively. Less than 1% was observed 
in blood, kidneys, liver and spleen. During the 60 min nebulisation period, linear 
accumulation of radioactivity in the lungs of animals was observed (Figure 5). 
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Figure 3. Aerosol particle number distribution of aerosolised AMB-DOC (e), 
L-AMB (o) and 5% glucose in water(---) as determined by laser diffraction. 
~aJie L. Recovery of radioactivity(% of delivered dose) in different organs and 
tissues of rats after aerosolisation (60 min) of "Ga-la belled liposomes. 
Organ/tissue % deposition 
Left lung 2.06 ± 0.22 
Right lung 3.84 ± 0.58 
Trachea 1.40 ± 0.25 
Tongue 1.06 ± 0.14 
Lower jaw 1.37 ± 0.82 
Snout 13.36 ± 1.42 
Oral cavity 0.32 ± 0.23 
Stomach/oesophagus 2.69 ± 0.01 
Intestines 25.30 ± 3.82 
Liver 0.27 ± 0.10 
Spleen 0.01 ± 0.00 
Kidney 0.31 ± 0.08 
Blood 0.03 ± 0.02 
Each value represents the mean:':s.d. of three individual experiments. 
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Figure 5. Radioactivity in lungs of rats (n=2) at differenct times during 
aerosolisation (60 min) of "Ga-la belled liposomes. Each point represents the 
mean and range. 
Deposition of AMB in lungs after nebulisation oi AMB-DOC and L-AMB 
Table 5 shows the absolute amount of AMB (~g) and the concentration of AMB 
(~gAM B/g tissue) retrieved from both left and right lung lobes of rats treated with 
aerosols of AMB-DOC and L-AMB. Both the absolute deposited dose of AMB in ~g 
and the concentration of AM B in lung tissue reached directly after nebulisation 
were similar for AMB-DOC and L-AMB. Furthermore, concentrations of AMB were 
similar in both lung lobes in all animals. 
T:;. -c ·e.- S. Amount and concentration of amphotericin Bin left and right lungs of rats after 
60-min nebulisation of AMB-DOC or L-AMB. 
Formulation Left lung Right lung 
AMB (~g) AMB concn (~gg') AMB (~g) AMB concn (~gg') 
AMB-DOC 15.3 ± 1.1 24.2 ± 6.4 21.5 ± 0.2 19.9 ± 4.8 
L-AMB 12.5 ± 2.5 21.7 ± 2.6 20.8 ± 3.8 21.6 ± 0.9 
Each value represents the mean:ts.d. of three individual experiments. 
Discussion 
Aerosol administration of non-liposomal as well as liposomal AMB in treatment or 
prophylaxis offungal infections was reported by others and appeared to be promis-
ing [12-17]. W'th respect to future studies on the efficacy of AMB products in the 
treatment of invasive pulmonary aspergillosis in a rat model, we describe in this 
study the nebulisation of non-liposomal (AMB-DOC) as well as liposomal AMB 
(L-AMB) with a Collison nebuliser. 
Before assessing efficacy of nebulised products in an experimental model of pul-
monary aspergillosis, it is important to gain insight in several aspects of nebuliser 
function, since parameters like design, operating conditions and ancillary equip-
ment are pivotal for final delivered dose and product stability [18,19]. The 
Collison nebuliser has been widely used in aerosol research for many years and is 
documented in detail [20,21]. 
Volume output of the Collison nebuliser under the experimental conditions used 
was the same for both AMB preparations examined. For both AMB-DOC and 
L-AMB, concentration of AMB in the nebuliser reservoir occurred during the nebu-
lisation process. The phenomenon of concentration of nebulised solution or dis-
persed materia: was previously described as a consequence of evaporative loss of 
water needed for humidification of inflowing air [22,23]. This indicates that deter-
minations of mass output should not be calculated from initial reservoir concentra-
tions. Increase in AMB concentration after nebulisation of AMB-DOC was higher 
as compared to L-AMB, which was directly correlated with a lower mass output of 
AMB for nebulised AMB-DOC. Previous work by Sorensen et al. showed that 
inhalation chamber air AMB concentrations during nebulisation of AMB-DOC 
decreased as a function of time, which could explain the difference in aerosol con-
centration between AMB-DOC and L-AMB. Foaming of AMB-DOC due to presence 
of the detergent desoxycholate has been given as an explanation for th'1s phe-
nomenon [24]. 
It is an option to calculate AMB aerosol concentrations from solute concentrations 
before and after nebulisation (mass output). However, without considering inertial 
impaction and gravimentational sedimentation of aerosol droplets inside the 
aerosol inhalation system this method results in an inaccurate (overestimation) of 
delivered dose. More precise estimations of AMB output are made by direct mea-
suring of aerosol concentrations. Despite the observed differences in mass outputs 
of AMB, we have seen a similar measured aerosol concentration for nebulised 
AMB-DOC and nebulised L-AMB. This is in correspondence with others [13]. 
AMB-Iipid ratio of L-AMB was not influenced by nebulisation. It can be concluded 
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from this that AMB remains associated with the liposomal membrane during neb-
ulisation. Liposomal size was, however, affected by the nebulisation process. The 
mean liposome size increased slightly during 60 min nebulisation, probably 
because affusion of a small population of vesicles as result of air pressure upon 
passage through the nebuliser orifices. This size increase was however small, 
which indicates that liposomal integrity was hardly influenced. A formulation with 
similar lipid composition and liposomal size as L-AMB (26 mol% cholesterol) has 
shown to be relaf1vely stable to nebulisaf1on [25,26]. In addition, an increase in 
liposomal size will not influence deposition pattern of nebulised L-AMB, since lipo-
somes are still several-fold smaller than average aerosol droplet size. 
Droplet size and shape play a significant role in the drug deposition in the respira-
tory passageways. Preferably, more than 90% of the generated droplet population 
should be in the 0.5 to 10 ~m range to maximize delivery in pulmonary tissues 
and fluid. In general, droplets of 1 to 5 ~mare considered optimal for penetrating 
the lower respiratory tract [27,28]. Particles of this size have been demonstrated 
to deposit in the lung v"1a grav·lmentational sedimentation, inertial impaction or by 
diffusion into terminal alveoli by Brownian motion [29]. 
Aerosol droplet sizing by laser based analysis offers a few advantages over the 
impaction approach frequently used to characterise aerosol droplets. The nebulis-
er cloud can be measured directly after leaving the nebuliser reservoir, and there-
fore information is collected on the 'true' droplet size which enters the respiratory 
tract of laboratory animals. Moreover, this technique is much faster than the 
impaction technique and no chemical analysis of solute is required. Laser diffrac-
tion has proven to be robust and reliable for measuring droplet sizes directly after 
nebulisation [30]. Some care must however be taken with interpreting number 
distribution results from laser scattering data. It should be kept in mind that with 
using this method, extrapolation of number distribution to mass distribution must 
be made in order to predict the final mass deposition in pulmonary regions of inter-
est. Forth is, the specific gravity of droplets should be known. 
As seen from the number distribution, a very homogenous aerosol cloud was gen-
erated by the Collison nebuliser under the experimental conditions of this 
research. A high number (>80%) of droplets with both AMB-DOC and L-AMB was 
below 5 mm mass diameter. Therefore, a substantial deposition in the alveo-
bronchial region can be expected. 
In order to evaluate the biodistribution of nebulised materials in rats, we have used 
67Ga-labelled liposomes. We chose this indirect measure of biodistribution since 
radiolabelled L-AMB is not available and analysis of AMB in all organs and tissues 
is difficult to measure accurately. The radiolabelled liposomes however, had a lipo-
some composition similar to L-AMB and results can therefore directly be correlated 
to the biodistribution of nebulised L-AMB. The percentage deposition was calcu-
lated on the basis of the aerosol concentration. Total in vivo counts only accounted 
for 52% of the calculated delivered dose. Two important factors can attribute to 
the relatively low in vivo counts compared to the calculated delivered dose. 
Impaction and subsequent loss of nebulised material inside the system is not 
taken into account. Furthermore, the exhaled fraction of aerosol clouds can add up 
to loss of material. Highest deposition of radioactivity was seen in the gastroin-
testinal tract (28.0%), due to deposition of inhaled particles inside the oral region 
and on the snout. Swallowing of deposited material will lead to high intestinal drug 
levels. Gastrointestinal absorption of AMB is however very small ( <5%) and 
biodistribution through this route will thus not lead to significant systemic drug 
levels. Deposition of radioactivity in lungs accumulated linearly in time and was 
11.3% oftotal in vivo counts. Very little ( < 1 %) radioactivity was found in the 
internal organs. 
As could be expected from the similar aerosol concentrations measured, AMB con-
centrations reached in lung tissues oftreated rats directly after 60 min of nebulisa-
tion were similar with AMB-DOC and L-AMB. For Aspergillus fumigatus, the 
pathogen of interest in our animal model, the in vNro minimal inhibitory concen-
tration is 0.4- 0.8 m!YL. Final concentrations of AMB in pulmonary tissues 
reached with both formulations should be sufficient for in vivo killing. The results 
of this study were obtained in healthy rats. Whether deposition in diseased lungs 
will be equivalent remains to be examined. 
In summary, we have reported on the nebulisation of AMB-DOCI and L-AMB with 
a Collison nebulizer. AMB-DOC is less efficiently nebulised than L-AMB, when 
mass output of AMB is considered. However, aerosol concentration of AMB is sim-
ilar with the two products. The delivered dose of AMB can therefore be considered 
the same. Aerosols of AMB-DOC and L-AMB are highly respirable and result in 
sufficient lung tissue concentrations of AMB. Distribution of inhaled AMB to other 
organs than the lungs or the gastro-intestinal tract is expected to be negligible. 
Furthermore, liposomes containing AMB are physically stable to nebulisation. 
It appears that aerosol administration of AMB formulations is a promising 
approach to target the lungs and may offer a valuable strategy in the treatment 
or prevention o~ invasive pulmonary aspergillosis. 
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Abstract 
The pulmonary kinetics of amphotericin B (AMB) after aerosol administration of 
amphotericin B desoxycholate (AMB-DOC) and liposomal amphotericin B (L-AMB) 
were studied in rats. Rats were treated with a single dose of nebulised AMB-DOC 
or L-AMB. At different times after aerosol treatment, AMB was measured in lungs, 
broncho-alveolar lavage fluid, blood, liver, spleen and kidneys. Pulmonary deposi-
tion of AM B after aerosol treatment was compared with that after treatment with a 
single dose of 10 mgikg intravenous L-AMB. Influence of infection on aerosol 
deposition was determined by analysis of AMB in lungs of rats suffering from pul-
monary aspergillosis, as well as by histopathological examination of infected lungs 
after aerosol treatment with colloidal-gold labelled liposomes. Pulmonary tissue 
concentrations of AMB directly after aerosol treatment were 26.9 (:t: 8.5) ~gig and 
46.7 (:t: 10.5) ~gig for AMB-DOC and L-AMB, respectively. AMB was retained in 
the lungs for more than 5 weeks for both formulations. Pulmonary concentrations 
after a single intravenous dose of 10 mgikg L-AMB were substantially lower than 
that after aerosol administration, and AMB was not retained in the lungs after 
intravenous admin·1straflon. After nebulisaf1on, no AMB was detected in blood or 
other organs than the lungs. The amount of deposited nebulised AMB in infected 
lungs did not significantly differfrom that in uninfected lungs. Histopathological 
examination revealed that nebulised liposomes deposited in the alveoli, close to 
the fungal mycelium. In conclusion, the pulmonary kinetics of nebulised AMB-
ODC and L-AMB are favourable and underscore the possible value of aerosol AMB 
products for the treatment or the prophylaxis of pulmonary aspergillosis. 
Introduction 
Amphotericin B (AMB) is a broad spectrum polyene antifungal agent which is used 
intravenously for the treatment of most serious fungal infections such as pulmonary 
aspergillosis. Unfortunately, conventional AMB, amphotericin B desoxycholate (AMB-
DOC), has considerable toxicity which can be dose-limiting [1]. Liposome encapsulated 
AMB (L-AMB) has an increased therapeutic index as compared to that of conventional 
AMB [2]. However, treatment failure after intravenous administration of L-AMB is still 
frequently obseNed in patients with invasive pulmonary aspergillosis [3]. 
Administration of AMB via the inhalational route might be an attractive alternative 
approach in the management of pulmonary fungal disease, since aerosol delivery direct-
ly targets the lungs and systemic AMB exposure is reduced. Nebulised AMB-DOC or 
L-AMB has proven to be valuable in the treatment or prophylaxis of fungal pulmonary 
infections in different animal models [1-7]. Several clinical studies have been performed 
with nebulised AMB-DOCfor prophylaxis of IPA [8-10]. Although deposition of nebu-
lised (liposomal) AMB has been studied in animals little is known about the exact pul-
monary deposition and kinetics of AMB after nebulisation [11,12]. Thus, it is not clear 
what dose or regimen should be used in the management of IPA. 
AMB-DOC and L-AMB can both be efficiently nebulised [13]. Pulmonary deposition is 
dependent on type of nebuliser system and duration and frequency of nebulisertreat-
ments [4,11,14]. Previous studies on nebulised AMB-DOC and nebulised AMB lipid 
complex show that pulmonary deposited AMB is cleared slowly from the lungs [11, 14]. 
In the present study we have detenmined AMB concentrations in lungs and other organs 
after a single dose of nebulised AMB-DOC or L-AMB. We have determined the half-life 
of AMB in lungs after this single dose, and alveolar deposition by means of histology. 
In addition, we have determined the influence of infection on the deposition of AMB 
after aerosol treatment with AM B-DOC and L-AM B. 
With this work, we collect support for the profitable pulmonary deposition and retention 
of AMB after aerosol administration as opposed to that after intravenous administration. 
Materials and Methods 
Materials 
AMB-DOC was from Bristol Myers-Squibb (Woerden, The Netherlands) and 
L-AMB was from NeXstar (San Dimas, CAl. Cyclophosphamide, cholesterol 
and AuCb were from Sigma Chemical Co. (St. Louis, MOl. Hydrogenated soy 
phosphatidylcholine (HSPC) and distearoyl phosphatidylcholine (DSPG) were 
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from Avanti Polar Lipids, Inc. (Alabaster, AU. All other reagents were of 
analytical grade. 
Animals 
Female R-strain albino rats, specified pathogen free, 18- to 25- weeks old (own 
breed), weighing 185-225 g were used for all experiments. Animals received a nor-
mal, pathogen free diet and water ad libitum. Experiments were approved by the 
a.nimal exper"1ments ethical committee of the Erasmus university Medical Center. 
Experimental lung infection 
Infection of the lung was established according to the method described by Leenders 
et al. [15]. Granulocytopenia was induced by intraperitoneal administration of 
90 m~kg cyclophosphamide at 5 days before fungal inoculation followed by an addi-
tional dose of 60 m~kg at 1 day before inoculation. Conidia were collected from a 
clinical isolate of Aspergillus fumigatus (MlC 0.4 m~l). Under general anaesthesia 
the left main bronchus was ·mtubated. A canula was passed through the tube and the 
left lung was inoculated with 1.5 x 10' conidia, resulting in a left sided pneumonia. 
Aerosol administration of antifungal agents 
AMB-DOC and L-AMB were reconstituted according to the manufacturer's instruc-
tions and further diluted in 5% glucose up to an AMB concentration in the nebuliser 
reservoir of 2 m~ml in the case of AMB-DOC and 4 m~ml in the case of L-AMB. 
Previous work in our laboratory showed that these concentrations are the optimal 
concentrations for effective treatment of rats suffering from pulmonary aspergillosis 
[6]. The nebulisation procedure was described previously [16]. In short, aerosols 
were generated by a Collison six-jet nebuliser system (Model CN, BGI Inc., Waltham, 
MAJ. The nebuliser operated at 20 I/ min airflow. Under these conditions, more than 
80% of generated aerosol droplets are below 5!im, which ensures substantial depo-
sition of material in the alveobronch·lal reg"1on. Rats were exposed to aerosols ·m a 
nose-only inhalation system (CH Technologies USA Inc., Westwood, NJ). Animals 
were exposed to aerosol treatment for a period of 60 minutes. In the case of aerosol 
treatment of infected rats, treatment was started at 30 h after fungal inoculation. 
Intravenous administration of L-AMB 
To compare AMB lung deposition after aerosol and intravenous treatment, L-AMB 
was reconstituted according to the manufacturer's instructions and further diluted in 
5% glucose. Uninfected rats received a dose of 1 x 10 m~kgintravenous L-AMB. 
Concentration of AMB in organs and blood 
Animals were treated with nebulised or intravenous AMB-DOC or L-AMB. At different 
time points after nebulisation, groups of 3 animals were euthanised with intravenous 
pentobarbital (100 mglkg). Directly after, blood was sampled via cardiac punction, 
and lungs, trachea, liver, kidneys and spleen were dissected. Broncho-alveolar lavage 
(SAL) was performed by washing the lungs via the trachea with 8 ml glucose 5%. 
Subsequently, the lungs were divided in left and right lung lobe. Organs were weighed 
and homogenised in 5 ml giucose 5%. AMB was extracted from the homogenate, 
blood and SAL-fluid with ethanol in a 2:3 (v/v) ratio. The extracts were centrifuged for 
5 min at 13,000 x g and concentrations of AMB in the supernatants were determined 
by HPLC with an UV detector operating at382 nm. The mobile phase consisted of a 
0.1 M sodium acetate solution (pH 7.2) containing 0.2% (vjv) triethylamine and 60% 
acetonitrile and was pumped through a Guard pre-column (Chromguard, 10 x 3 mm; 
Chrompack, Middelburg, The Netherlands) followed by a reverse-phase C18 column 
(100 x 3 mm, Chrompack, Middelburg, The Netherlands) at a flow rate of 
0.5 ml/min. The lower limit of quantification of this assay was 0.2 mglml. 
Determination of half-life of AMB in pulmonary tissue 
Pulmonary tissue concentration-data were analysed by a non-compartmental 
curve-fitting program (TopFit version 2.0, Gustav Fischer, Germany). 
Deposition of colloidal gold-labelled liposomes in infected lung tissue 
Colloidal-gold labelled liposomes were prepared as described previously by Daemen 
et al. [17]. Briefly, a lipid film containing HSPC, DSPG and cholesterol, was prepared 
by film hydration. The lipid film consisted of the same lipids as the liposomal mem-
brane of L-AMB, in the same molar ratio (HSPC:DSPG:cholesterol=2:1:0.8). The 
lipid film was hydrated at 4oC with a sodium citrate-potassium carbonate buffer con-
tarning 0.3% (w/v) AuCb. Liposomes were prepared by the mulfrple extrusion ofthe 
hydrated lipids through two stacked 100 nm membranes (Nuclepore, Pleasanton, 
CA). Unencapsulated colloidal gold was removed by gelfiltration of the liposomes 
over a Sephacryl SF S1000 column (Pharmacia, Uppsala, Sweden) using 
Hepes/NaCI buffer as the eluens. This method yielded liposomes with an average 
particle size of 100 nm. 
Colloidal-gold labelled liposomes were nebulised at 30 h after fungal inoculation. 
The nebuliser reservoir lipid concentration was similar to that used for nebulising 
L-AMB. Directly after nebulisation, left and right lung lobes were excised, washed 
in 2.5% buffered formaldehyde, fixed in 10% buffered formaldehyde and embed-
ded in paraffin. Five ,um sections were cut longitudinally onto a microtome and 
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mounted on slides. Sections were deparaffinised with xylene and hydrated. 
Colloidal gold was silver-enhanced using a silver enhancement-kit (Sigma, St. 
Louis, MO) according to the manufacturer's instructions. Adjacent sections were 
counterstained with either eosin/haematoxylin or Grocott methenamine stain. 
Results 
Pulmonary deposition and clearance of AMB 
The pulmonary concentration-time profiles of AMB in uninfected lungs for nebulised 
AMB-DOC (nebuliser reservoir concentration 2 m,Vml) and nebulised L-AMB (neb-
uliser reservoir concentration 4 mglml) are shown in Figure 1. The concentration 
AMB in lung tissue directly after nebulisation (CO) was 26.9 (± 8.5) m,Vg for AMB-
DOC and 46.7 (± 10.5) m,Vgfor L-AMB. AMB was cleared very slowly from the 
lungs for both AMB-DOC as for L-AMB (tl/2B = 33.7 days and 41.6 days, respec-
tively). AM B was detectable in lung tissue up to 5 weeks after nebulising either for-
mulation. Co is also shown in Table 1, together with the percentage of AMB thereof 
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Figure l. Concentration- time profile of nebulised AMB-DOC (e) and L-AMB (o) 
in lungs of healthy rats, as determined by HPLC. tl/2B is 33.7 days for AMB-DOC 
and 41.6 days for L-AMB, respectively. Each value plotted is the mean± SD of 
three rats.---- is the lower limit of quantification of AMB. 
which was recovered in BAL. The percentage AMB found in BAL after nebulisation 
of AMB-DOC was higher than thatfound after nebulisation of L-AMB, which indi-
cates that the liposomal formulation was more rapidly taken up by the lung tissue. 
Table 2 shows that nebulising AMB-DOC or L-AMB yielded higher AMB concentra-
tions than intravenous administration of 1 x 10 mg/kg of L-AMB. At 48 h after 
intravenous administration, no AMB was retained in the lungs. Furthermore, no 
AMB was detected in blood or other organs than lungs after aerosol administration 
of either AMB-DOC or L-AMB, whereas intravenous administration of L-AMB obvi-
ously resulted in systemic exposure of AMB (Table 2). 
Table 1. Pulmonary AMB concentrations (Col directly after aerosol administration 
of AMB-DOC and L-AMB (nebuliser reservoir AMB concentration 2 and 4 mg/ml, 
respectively) and% of deposited AMB in broncho-alveolar lavage (BALl 
AMB-DOC 
L-AMB 
11g AMB/g lungs (Co)' 
26.9 (8.5)' 
46.7 (10.5) 
%of AMB in BAL 
35.7 (13.0) 
16.1 (8.7) 
·concentrations in lung tissue including bronchoalveolar lavage 
J>values are mean (SOl, n=3 
Table 2. Deposition of AMB in lungs (Jlg/g) and blood (Jlg/ml) directly after (Oh), 
at 24 hand at 48 h after aerosol administration of AMB- DOC and L-AMB and 
after intravenous admin·1strat'1on of 1 x 10 mg/kg L-AMB 
aerosol AMB-DOC aerosol L-AMB intravenous L-AMB 
Oh 24h 48 h Oh 24 h 
lungs• 26.9 32.4 32.6 46.7 42.8 
(8.5)' (8.4) (4.7) (10.5) (10.8) 
blood nd' nd nd nd nd 
•concentrations in lung tissue including bronchoalveolar lavage 
"values are mean (SDl, n=3 
'nd is not detectable 
48 h Oh 24h 48 h 
31.8 16.4 nd nd 
(15.0) (2.4) 
nd 48.4 nd nd 
(2.4) 
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Table 3. Pulmonary concentrations of AMB (Co) directly after aerosol administration of 
AMB-DOC and L-AMB (nebuliser reservoir concentration 2 and 4 mwml, respectively) in 
lungs of uninfected rats and in infected left lung lobes of rats with pulmonary aspergillosis 
AMB-DOC 
L-AMB 
11gAMB/glungS' 
uninfected lungs 
26.9 (8.5) 0 
46.7 (10.5) 
·concentrations in lung tissue including bronchoa!veolar lavage 
"Values are mean {SD), n=3 
Deposition of AMB in infected lungs 
11g AMB/g lungs 
infected lungs 
29.4 (4.2) 
36.7 (5.9) 
Table 3 shows the concentrat"lons of AMB depos.lted directly after nebul"lsation of 
AMB-DOC and L-AMB in infected lungs versus deposition in uninfected lungs, as 
measured by HPLC. AMB deposition in infected lungs did not differ statistically 
significant from that in uninfected lungs. 
Deposition of colloidal-gold labelled liposomes in infected lungs 
Localisation of liposomes in infected left lung lobes was visualised using silver 
enhancement of nebulised colloidal gold-labelled liposomes (Figure 2). The black 
clusters are silver-enhanced colloidal-gold labelled liposomes. The liposomes are 
deposited at the pulmonary epithelium of bronchioles, but also in the alveolar 
regions of the lungs (Figure 2a). Liposomes deposited in the alveolar sacs and 
ducts are partially internalised by alveolar macrophages (Figure 2b). Grocott 
methenamine staining of a section of infected left lung lobes at 30 after inocula-
tion of 1.5 x 105 Aspergillus conidia shows that radially grown hyphae are 
formed out of conidia (Figure 2c). Combined eosin/haematoxylin staining and 
silver enhancement of the adjacent section shows that nebulised liposomes are 
deposited close to the Aspergillus hyphae (Figure 2d). (See pages 82-83) 
Discussion 
Pharmacokinetic evaluation of nebulised AMB-DOC or L-AMB is essential in order 
to rationalise aerosol treatment of invasive pulmonary aspergillosis with these 
agents. We have shown that using the nebuliser system we have described earlier, 
AMB-DOC as well as L-AMB can be efficiently nebulised in rats [6]. Pulmonary 
concentrations reached directly after a single dose of nebulised AMB-DOC and 
L-AMB were 26.9 ~g/g and 46.7 ~g/g, respectively. These concentrations exceed 
by far the MlC for Aspergillus fumigatus which is 0.4- 0.8 mg/L for sensitive 
strains. The pulmonary AMB deposition after aerosol administration exceeded that 
found after intravenous administration of a single dose of 10 mg/kg L-AMB. After 
nebulising either AMB-DOC or L-AMB, pulmonary concentrations were retained in 
the lungs for a long period of time. The slow clearance of AMB from the lungs is 
probably the result of the fact that AMB binds extensively to tissues. At all times 
after aerosol treatment, no AMB was detected in blood or other organs than the 
lungs. This indicates that aerosol administration leads to low systemic exposure of 
AMB. The substantial pulmonary deposition as well as the extensive pulmonary 
retention of AMB renders the aerosol delivery of both AMB-DOC as L-AMB very 
suitable for prophylactic treatment of pulmonary aspergillosis. 
The nebuliser reservoir concentration of AMB-DOC was half that of L-AMB. This 
explains differences in pulmonary concentrations reached directly after treatment. 
Previous work has shown that these concentrations are optimal to treat rats with 
severe invasive pulmonary aspergillosis [6]. Clearance of both differs little, indicat-
ing that lung retention is determined largely"by AMB itself and for a smaller part by 
the liposomal formulation. Differences between AMB-DOC and L-AMB were seen 
in the AMB concentrations in the broncho-alveolar lavage fluid, which were rela-
tively lower for the liposomal formulation. Apparently, L-AMB was more rapidly 
distributed into pulmonary tissue. Background or clinical implications of this 
finding are not clear. 
HPLC analysis of infected lung lobes revealed that deposition in infected, impaired 
lungs is similar to that in uninfected lungs. Aerosol administration can thus be 
regarded as an attractive treatment option in cases of established fungal infection. 
However, the method we have used to analyse AMB is a rather crude one, since 
the complete lung lobe is excised and healthy tissue and infected tissue is mixed. 
Therefore, we also did a localisation experiment of nebulised liposomes. 
Colloidal-gold labelled liposomes were utilised as histochemical markers of 
liposome tissue deposition and cellular uptake. Microscopic evaluation of silver-
enhanced colloidal-gold labelled liposomes showed that nebulised liposomes 
-o 
0 
3 
a 
~ 
• 
" ~,.
• g 
0 
=> 
"' "0 §" 
.,. 
Figure 2. Localisation of nebulised colloidal-gold labelled liposomes in infected 
lung tissue 
2:. Localisation of silver-enhanced colloidal gold-labelled liposomes in alveoli is visualised as black dots 
(arrows). The liposomes are deposited at the alveolar epithelium. Alveolar epithelium consists of alveolar type 
I and type II epithelium cells which are identified as well as blood vessels. Counterstain haematoxylin/eosin. 
!J. Liposomes deposited in the alveolar sacs and ducts are partially internalised by alveolar macro phages 
(black clusters indicated by arrows). 
.. 
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C. Grocott methenamine stain of pulmonary tissue at 30 h after inoculation of 1.5 x 10" Aspergillus 
conidia. The conidia are inoculated deep in the left lung lobe, internalised by pulmonary epithelial tissue 
and germinated into hyphae at this time. 
d. Silver-enhanced colloidal-gold liposomes are deposited in and around pulmonary tissue (arrow). 
Counterstain haematoxylin(eosin. Leukocytes are identified as purple cells. Section adjacent to that shown 
in Figure 2c. 
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could be visualised in the infected lung. The prepared liposomes had the same 
lipid-bilayer as L-AMB, which was stable under the influence of nebulisation [13]. 
Therefore, we assumed that the colloidal-gold labelled liposomes could also with-
stand nebulisation. Schiffelers et al. [18] showed that with the described method, 
intact liposomes and uptake of liposomes by macrophages could be visualised. 
Liposomes were present throughout the whole respiratory tract, in the large 
bronchi, small bronchi-bronchioles, and alveolar ducts and sacs. The deposition 
pattern of colloidal-gold labelled liposomes indicated that nebulised L-AMB was 
able to penetrate deep in the lower respiratory tract, since the membrane charac-
teristics and partde s"1zes of both l"1posomal products were similar. Our data show 
that the liposomal formulation reached the infected regions of the lung, was 
deposited close to the mycelium of the fungus and was furthermore partially incor-
porated by alveolar macrophages. Uptake of liposomes by alveolar macrophages is 
believed to be succeeded by release of the drug [15]. 
Unfortunately, we were not able to determine whether the deposited AMB was bio-
logically active, because the agar plate diffusion assays that are employed to this 
purpose are, in our opinion, not suitable for reliable quantification of AM B activity. 
However, in other experiments we have seen that IPA can be prevented in part by 
nebulised AMB-DOC or L-AMB administered up to weeks before fungal inoculation 
(unpublished results). This observation might be seen as an indication for the bio-
logical prolonged activity of single-dose nebulised AMB. 
Nebulising AMB-DOC or L-AMB did not result in systemic AMB levels. From the 
point of toxicity, this is a major advantage. However, Aspergillus usually d·lssemi-
nates from the lungs to other organs and pulmonary administered AMB will not be 
able to prevent this. It is our opin.lon that optimal therapy of an establ.lshed infec-
tion of invasive pulmonary aspergillosis therefore combines the pulmonary route 
w·1th intravenous admin.1straf1on of adequate dosages of AMB-DOC or L-AMB. 
In summary, aerosol administration of AMB-DOC or L-AMB efficiently delivered 
AMB to healthy or ·Infected lungs, while avoiding systemic exposure and accumu-
lation of AMB in other organs. Absence of systemic exposure makes it highly 
unlikely that the aerosol route will cause extrapulmonary toxicity. AMB was elimi-
nated very slowly from the lungs, with a half life of more than 30 days. The phar-
macokinetic characteristics of nebulised AMB imply long term protection against 
IPA. The fact that AMB deposition was visualised in the consolidated regions of 
infected lungs, suggests that not only prophylaxis but also treatment of Aspergillus 
pneumonia, when combined with systemic administration of AMB, can benefit 
from aerosol treatment. 
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Abstract 
The effects of treatment with aerosolised amphotericin B desoxycholate (AMB-
DOC) and aerosolised liposomal amphotericin B (L-AMB) were evaluated in 
severely immunosuppressed rats with invasive pulmonary aspergillosis. Aerosol 
treatment with AMB-DOC consisted of a single dose (60 min) with amphotericin B 
concentrations in the nebuliser reservoir of 1, 2 and 4 mglml, respectively. 
For liposomal amphoter"1cin B, aerosol treatment cons·lsted of single, double or 
quadruple doses with a nebuliser reservoir concentration of 4 mglmL of AMB. 
Treatment, started at 30 h after inoculation, with aerosolised AMB-DOC (nebuliser 
reservoir concentration 2 mglml) significantly prolonged survival of rats as com-
pared with placebo-treated rats, whereas treatment with aerosolised AMB-DOC 
with nebuliser reservoir concentration of 1 or 4 mglmL did not have a significant 
effect on survival. Treatment with aerosolised L-AMBsignifcantly prolonged sur-
vival with all treatment regimens when compared with placebo-treated animals. 
Aerosol treatment did not prevent dissemination of the infection. The effects of 
AMB-DOC and L-AMB on pulmonary surfactantfunction were also evaluated in 
vitro. AMB-DOC inhibited surfactant function in a dose-dependentfashion. L-AMB 
had no detrimental effect on surface activity of surfactant. These results indicate 
that aerosol administration of AMB, especially the liposomal formulation, could be 
an additional approach to optimising treatment of invasive pulmonary aspergillosis. 
Introduction 
An increase in the number of immunosuppressed patients at risk of developing fungal 
infections due to increasing advances in transplantation medicine has led to a substan-
tial increase in the number of cases of invasive pulmonary aspergillosis (!PAl in the last 
few decades[l]. Standard treatment of IPA with intravenous amphotericin B desoxy-
cholate (AMB-DOCl is often unsuccessful and complicated by severe, dose-limiting 
toxicity. Newly developed lipid-based modalities of AMB have an increased therapeutic 
index as compared with AMB-DOC [2]. However, treatment of established infection 
with Aspergillus spp. in patients with persisting granulocytopenia is correlated with 
high failure rates. Thus, there is a continuing need for optimisation of antifungal treat-
ment in pulmonary aspergillosis. The portal of entry of Aspergillus is often the respira-
tory tract, since the spores of this fungus are ubiquitous and easily inhaled. 
Spores descend to the lowest regions of the lungs and invasive disease subse-
quently develops. Further improvement in the treatment of IPA can therefore be 
sought in the administration of AMB products via the pulmonary route. With this 
mode of administration, the therapeutic agent targets the lungs directly, and sys-
temic toxicity is reduced. Improvement in efficacy as well as reduction of systemic 
side effects could be anticipated. 
Few clinical studies exist on the use of aerosolised AMB in the prophylaxis or treat-
ment of fungal disease. These studies do not demonstrate a convincing beneficial 
effect of aerosolised AMB, probably because of a lack of power or adequate study 
design [3-5]. Preclinical animal work therefore has to be performed in order to 
determine the value of aerosolised conventional and lipid preparations of AMB. 
Aerosol administration of different formulations of AMB has been described and 
shown to be effective in the prophylaxis of pulmonary aspergillosis in animal mod-
els [6-8]. However, in these studies only temporary or mild immunosuppression 
was applied in the experimental models. In the clinical situation however, patients 
are generally persistently granulocytopenic and diagnosis of IPA is often late in the 
course of infection. An important feature of the experimental design of the present 
study is therefore the treatment of an established infection under severe, persisting 
immunosuppression. 
Results from our laboratory and from others show that after aerosol administration 
of liposomal amphotericin B, little or no drug was deposited in organs other than 
the lungs, which suggests that systemic toxicity following aerosol administration 
would be minimal [6,9-ll]. Pulmonary toxicity of inhaled AMB however, could be 
an important detrimental effect of inhalation therapy. There are many in vivo and in 
vitro parameters that could be indicative of damaged pulmonary tissue or impaired 
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pulmonary function. In this study we chose pulmonary surfactant function as a toxi-
city indicator, since this is an important basic physiological function. Surface activi-
ty of pulmonary surfactant is relatively easily measured in vitro, and provides rele-
vant information on the possible harmful influence of inhaled AMB formulations. 
In the present study, we describe the efficacy of aerosolised AMB desoxycholate and 
aerosolised L-AMB in the treatment of established IPA in rats with severe, persistent 
immunosuppression. Furthermore, we describe the influence of AMB products on 
surfactant function in vitro. 
Materials and methods 
Materials 
AMB-DOC (containing 50 mg AMB and 41 mg desoxycholate per vial) was from 
Bristol Myers-Squibb (Woerden, The Netherlands) and L-AMB was from NeXstar 
(San O'lmas, CA, USA). Hydrogenated soybean phosphatidylcholine (HSPC) and 
distearoylphosphatidylglycerol (DSPG) were from Avanti Polar Lipids (Alabaster, AL, 
USA). Cholesterol and cyclophosphamide were from Sigma Chemical Co. (StLouis, 
MD, USA). Sabouraud dextrose agar (SDA) was from Oxoid (Basingstoke, UK). 
Animals 
Female R-strain albino rats, specified pathogen free, 18-25 weeks old (own breed), 
weighing 185-225 g were used for all experiments. Animals received a normal, 
pathogen-free d·1et and water ad lib.ltum. Experiments were approved by the animal 
experiments ethics committee of the Erasmus university Medical Center. 
Aspergillus strain 
A clinical isolate of Aspergillus fumigatus from an immunocompromised patient 
with IPA was used. The MIC and minimal fungicidal concentration (MFC) of AMB 
for this strain were 0.4 and 0.8 mf1L, respectively [12]. This strain was stored 
under oil on SDA. At least once every 2 months, the strain was passed through a 
rat to maintain its virulence. For ·maculation, conidia were harvested and suspend-
ed in sterile phosphate-buffered saline (PBS), as described previously [12]. 
Immunosuppression and supportive care 
Granulocytopenia was induced by i.p. administration of 90 mf1kg cyclophos-
phamide 5 days before fungal inoculation, followed by add.1f1onal dosages of 
60 mf1kg every 4 days throughout the study. This treatment resulted in a persis-
tent granulocytopenia ( <0.5 x lO' cells/U from the time of A. fumigatus inocula-
tion up to the end of the study [12].To prevent bacterial superinfection, strict 
hygienic care was applied, and animals received ciprofloxacin (660 mg/L) and 
polymyxin E (100 mg/L) in their drinking water throughout the experiment. 
Furthermore, im administration of amoxicillin (40 mg/kg/day) was added to this 
regimen. Shortly before and after inoculation, gentamicin (6 mg/kg) was adminis-
tered i.m. 
Experimental lung infection 
Infection of the lung was established according to the method described by 
Leenders et al [12]. Briefly, under general anaesthesia the left main bronchus was 
intubated. A canula was passed through the tube and the left lobe of the lung was 
inoculated with 0.02 ml of a suspension containing 2 x 104 conidia. This resulted 
in a lett-sided pneumonia. 
Antifungal treatment 
AMB-DOC and L-AMB were reconstituted according to the manufacturers' instruc-
tions and further diluted in 5% glucose up to an AMB concentration in the nebulis-
er reservoir of 4 mg/ml in the case of L-AMB or 1, 2 or 4 mg/mL in the case of 
amphotericin B desoxycholate. Since calculation of the actual dose delivered is 
a rather complicated measure, in this study nebuliser reservoir concentration is 
given as an indirect dose indication. Treatment was started 30 h after fungal 
inoculation, at which time mycelial growth was established by histopathological 
examination (periodic acid-Schiff stain). The aerosolisation procedure for L-AMB 
and AMB-DOC was as described previously.[13J In short: infected rats were con-
strained in cone-ended plastic tubes and placed in a nose-only inhalation appara-
tus (CH Technologies USA Inc., Westwood, NJ, USA). Aerosols were generated by 
a Collison six-jet nebulisersystem (Model CN: BGIInc., Waltham, MA, USA). 
The nebuliser operated at 20 Umin airflow. Under these conditions, >80% of the 
aerosol droplets that are generated are <5 pm mass diameter, which ensures sub-
stantial deposition of material in the alveobronchial region. Animals were exposed 
to aerosol treatment for one or more periods of 60 min. 
Liposome preparation 
Placebo liposo:nes with similar lipid composition (HSPC: DSPG:Chol, 2:1:0.8) and 
similar liposomal diameter to L-AMB were prepared by the film hydration method. 
Lipids were dissolved in 2 mL chloroform:methanol (1 :1, v/vl. The lipid mixture 
was evaporated to dryness in a round bottom flask at 65°C. The lipid film was 
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hydrated by vortex mixing with a buffer solution containing 10 mM sodium succi-
nate, 10% (w/V) sucrose (pH 5.5). Liposomes were sonicated, which resulted in 
vesicles with an average particle size of 100 nm, as measured by dynamic light 
scattering. The liposome suspension was concentrated by ultracentrifugation at 
280,000 x gfor 2 hat 4°C in a Beckman ultracentrifuge L-70 (Beckman, Palo Alto, 
CA, USA) and further dilUted in buffer to a concentration of 40 ,umol/ml of lipid 
(similar to the lipid concentration in aerosolised liposomal amphotericin B). 
Phospholipid content was determined by phosphorus assay [14].Piacebo liposomes 
were aerosolised as described above during a single treatment period of 60 min. 
Efficacy of aerosolised AMB-DOC and aerosolised liposomal amphotericin B 
Groups comprised of 15 infected rats each were treated with aerosolised AMB-
DOC or aerosolised liposomal amphotericin B. For AMB-DOC, treatment consist-
ed of a single nebulisation period of 60 min with a nebuliser reservoir concentra-
tion of 1, 2 or 4 mg/ml amphotericin B. For liposomal amphotericin B, treatment 
consisted of a single, double (q 24 h) or quadruple (q 24 or q 12 h) nebul"lsation 
period. Controls received aerosolised glucose 5% or placebo liposomes. In one 
experiment, pure AMB suspended in glucose 5% (nebuliser reservoir concentra-
tion 4 mg!ml) was nebulised in order to evaluate survival after treatment with this 
agent alone. Animals were checked twice daily and mortality was recorded for the 
12 days following fungal inoculation, after which time post-mortem studies were 
conducted on all animals. The left lung, right lung and liver were dissected and 
homogenised in 20 ml PBS for 45 sat 20 000 rpm in a VirTis homogeniser 
(Vir Tis, Gardiner, NY, USA). Volumes of 0.2 and 2 ml and the remainder of each 
homogenate were spread on to or poured into SDA plates. Plates were incubated 
for 24 hat 37°C followed by 24 hat 25°C. 
Surfactant function experiments 
Freeze-dried natural surfactant prepared from bovine lavages was a gift from the 
Department of Anaesthesiology of the Erasmus university Medical Center 
Rotterdam. It consisted of c. 90-95% phospholipids, 1% hydrophobic proteins 
(surfactant proteins Band Cl and 1% free fatty acids. This surfactant is highly sur-
face active at low concentrations. Influence of different AMB formulations on sur-
factant functiOn was determined by means of a modified Wilhelmy balance system 
(E. Biegler GmbH, Mauerbach, Austria). This system records the surface tension of 
an air-liquid film over several cycles of mechanical compression and expansion of 
this film. The lower the surface tension at minimal surface area, the higher the 
surface activity of the applied film. The trough of the Wilhelmy balance was filled 
with warm saline (3JOC) and calibrated. After calibration, 100 J.lL of surfactant 
(1 mglmL total lipids) alone or in the presence of various concentrations of AMB 
formulations was applied on to the saline hypophase and allowed to spread for 
2 min. The surface area was compressed and expanded with a cycling speed of 
one cycle per 3 min and an area reduction from 100% to 20%. Minimal surface 
tension (ymin) was measured after three cycles at 20% surface area, and is 
expressed as m N/m. Inhibition of surfactantfunction of natural surfactant by AM B 
formulations resulted in increased surface tens·lan at m·lnimal surface area. 
Statistical analysis 
Survival curves were generated by the method of Kaplan and Meier. Statistical 
evaluation of differences in the survival curves was performed by the log rank 
test. This test examines the decrease in survival with time as well as the final 
percentage survival. 
Differences in proportions of animals with A. fumigatus in the left lung and dis-
semination to the right lung and liver at the time of death were exam·med by 
Fishers exact test. Data of surface activity measurements were compared using 
the two-sided t-test. P values of 0.05 were considered significant. 
Results 
Effect of aerosolised AMB-DOC and aerosolised L-AMB on survival 
The effect of aerosol treatment on survival of rats with pulmonary aspergillosis is 
shown in Figures 1 and 2. In this model of pulmonary aspergillosis placebo-treat-
ed rats died between days 4 and 9 after inoculation. At a nebuliser reservoir con-
centration of 2 r:1glmL administration of aerosolised AMB-DOC 30 h after inocula-
tion led to a significantly prolonged survival (P = 0.006) as compared with 
controls (Figure 1). Administration of aerosolised AMB-DOC with a nebuliser 
reservoir concentration of 1 or 4 mg/ml however, showed no beneficial effect on 
the survival of rats as compared with controls. Administration of a single dose of 
aerosol"1sed L-AMB (nebuliser reservoir concentration 4 mglmU resulted in signifi-
cantly prolonged survival (P = 0.002) as compared with glucose controls as well 
as empty liposome controls (Figure 2a). Aerosolised L-AMB adminstered as a dou-
ble (q = 24 h) or quadruple (q = 24 and 12 h) dose also significantly prolonged 
survival (P 0.005) as compared with glucose-treated animals (Figure 2b). 
Intensification of treatment yielded no further improvement in surv·1val as com-
pared with single dose treatment. No statistically significant differences were 
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Figure l. Effect of a single dose of aerosolised AMB-DOC with a reservoir 
concentration of 1 mgiml (o), 2 mgiml (e) or 4 mgiml ('")on survival of severely 
immunosuppressed rats with pulmonary aspergillosis (Kaplan-Meier plot). 
Each group consisted of 15 animals. Control animals received aerosolised 
5% glucose(----). Treatment was started 30 h after inoculation, at which time 
mycelial growth was established. *P = 0.006 versus control rats. 
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Figure 2. Effect of single (a) or multiple (b) dose aerosolised L-AMB versus glucose 
or empty liposome controls on survival of severely immunosuppressed rats with pul-
monary aspergillosis (Kaplan-Meier plot). Groups of 15 animals each were treated 
w·lth aerosol"1sed L-AMB (reservoir concentration 4 mf1mll as a single dose (e), as a 
double dose (q 24 h) (,o.) or as a quadruple dose, either delivered every 24 h (v) or 
every 12 h (v). Controls were treated w·1th placebo 1"1posomes (o), or 5% glucose 
(----). *P < 0.05 versus placebo liposomes or glucose controls. 
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observed between aerosolised AMB-DOC and the four different regimens of 
aerosolised L-AMB. 
Effect of aerosolised AMB-DOC and aerosolised L-AMB on the presence of viable 
A. fumigatus in the left lung and on dissemination to the right lung and liver 
The results of post-mortem quantitative cultures of A. fumigatus from lungs and 
liver after treatment are shown in Table l. Cultures revealed that at the time of 
death the infection had disseminated to the right lung and liver in the majority of 
rats. Aerosol treatment had no significant beneficial effect on prevention of dis-
semination to the right lung or the liver. 
Table l. Effect of aerosolised AMB-DOC and L-AMB versus aerosolised glucose 5% con-
trois on the presence of viable A.fumigatus in the left lung and dissemination to the right 
lung and liver at the time of death' 
Aerosol AMB nebuliser Dosing frequency %culture positive organs 
treatment reservoir and interval 
concentration 
(mg/ml) Left lung Right lung 
Glucose 5% 1 x 60 min 100 60 
AMB-DOC 1 1 x 60 min 100 53 
AMB-DOC 2 1 x60 min 80 40 
AMB-DOC 4 1 x 60 min 100 87 
Placebo 
liposomes 1 x 60 min 100 53 
L-AMB 4 1 x60 min 100 40 
L-AMB 4 2 x 60 min, q = 24 h 100 47 
L-AMB 4 4 x 60 min, q = 24 h 100 47 
L-AMB 4 4 x 60 min, q = 12 h 100 33 
•Leukopenic rats (n = 15) were inoculated in the left lung at time zero with 2 x 10• conidia A. fumigatus. 
Start of treatment was at 30 h. 
Liver 
53 
40 
60 
87 
53 
40 
73 
67 
53 
Influence of AM 8 products on surfactant function 
Table 2 shows the mean ym1n of surfactant alone or in combination with different con-
centrations of AMB alone, AMB-DOC, L-AMB and desoxycholate. The natural surfac-
tant was highly surface active at the concentrations examined (ym'" 1.97 ± 1.23). 
Minimal surface tensions after mixing of surfactant with AMB-DOC or L-AMB in dif-
ferent concentrations yielded similar low values. Addition of increasing concentra-
tions of AMB-DOC to natural surfactant resulted in significantly increased ym<o, 
indicating a loss of surface activity of the mixtures. An increase in ymln of natural 
surfactant was also seen with addition of increased concentrations of desoxycholate. 
Table 2. Mean minimal surface tension (ym'") of surfactant (1 mg'ml) together 
with saline, AMB, AMB-DOC, L-AMB or DOC 
Saline 
AMB 
AMB-DOC" 
L-AMB 
Desoxycholate 
Concentration (mg'ml) 
AMB DOC 
0.02 
0.2 
2 
0.02 0.016 
0.2 0.16 
2 1.6 
0.02 
0.2 
2 
0.008 
0.08 
2.1 
21 
•each value represents the mean ± sd of three individual experiments 
Minimal surface tension 
(mN/m)• 
1.97 ± 1.23 
2.81 ± 0.63 
2.65 ± 0.47 
2.70 ± 0.53 
7.53 ± 1.51' 
14.76 ± 1.85' 
47.53 ± 0.89' 
2.44 ± 0.41 
1.11 ± 0.72 
1.42 ± 0.83 
1.94 ± 0.77 
5.59 ± 1.80' 
23.13 ± 1.16' 
45.21 ± 2.08' 
'In AMB-DOC, 54% (g/g) is AMB, 46% is DOC, corresponding with 0.02 mg/ml AMB and 0.016 mg/ml DOC 
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Discussion 
The importance of invasive aspergillosis has progressively increased and it is now 
a major direct or contributory cause of death at leukaemia treatment centres and 
bone marrow and solid organ transplantation centres [1]. In the present study, the 
efficacy of aerosolised AMB-DOC and aerosolised L-AMB were evaluated in a rat 
model of severe pulmonary aspergillosis. In this aspergillosis model, rats received 
cyclophosphamide injecf1ons before fungal inoculation and throughout the whole 
experiment. This resulted in persistent deep granulocytopenia, in order to closely 
mimic a highly relevant, difficult to treat clinical situation. Treatment was started 
at 30 h after fungal inoculation, at which time hypha I formation was confirmed by 
histological examination of pulmonary tissue. 
Significant prolongation of survival was observed after aerosol treatment with 
AMB-DOC with a nebuliser reservoir concentration of 2 mg/ml. Lack of efficacy 
with a lower dose of AMB-DOC was probably due to inadequate concentrations of 
AMB in the lung tissue, whereas lack of efficacy with the high dose could be a con-
sequence of pulmonary toxicity that overshadowed antifungal efficacy. Prolonged 
survival was also seen in animals treated with a single dose of aerosolised L-AMB 
(nebuliser reservoir concentration 4 mglml). Similar results were obtained after 
double or quadruple dosing with aerosolised L-AMB, therefore it appears that 
intensifying the aerosol regimens does not lead to improvement in efficacy in terms 
of survival. The lack of a dose~effect relationship after aerosol administration is 
probably due to inadequate deposition of bioactive AMB at the site of the infection, 
which is not ameliorated by giving extra doses. The survival of rats after treatment 
with the optimal dose of aerosolised AMB-DOC and with aerosolised L-AMB 
seems to be similar to survival seen after 10 day treatment with iv L-AMB 
(10 mgjkg) in the same animal model [12]. 
The observations in terms of survival·m the present study resemble those found in 
clinical practice, where, despite intravenous antifungal treatment, survival is 
<10-20% in persistently immunosuppressed patients with an established infec-
tion. However, the observed prolongation of survival after aerosol treatment may 
be useful in cases of temporary granulocytopenia. When leucocyte counts are 
restored early enough in the course of infection, improvements in the outcome of 
treatment can be expected, since it is known from clinical experience that bone 
marrow recovery and increasing numbers of circulating leucocytes are crucial fac~ 
tors in the favourable outcome oftreatment [1]. Aerosol treatment with AMB could 
be an alternative to current intravenous regimens, which offer good prognosis with 
neutrophil recovery. 
Treatment of animals with a suspension of 4 m,YmL pure AMB in glucose 5% had 
no effect on survival as compared with controls (data not shown). The lack of effi-
cacy may be the result of poor aerosolisation characteristics and/or poor aqueous 
solubility and therefore poor availability of the drug at the site of deposition. 
Aerosol treatments with either AMB-DOC or L-AMB had no effect on dissemination 
of A. fumigatus to the right lung or liver. It was shown previously that intravenous 
administration of L-AMB in the same rat model of IPA does reduce dissemination 
[12]. This difference can be explained by the d.1fferent pharmacokinetic profile of 
aerosol administration as compared with intravenous administration. Previous 
work in our laboratory has shown that aerosol treatment results in negligible sys-
temic exposure to AMB and subsequent negligible tissue concentrations in organ-
sother than the lungs in contrast to the extensive tissue distribution following 
intravenous administration. Considering this, it would be interesting to study the 
efficacy of high dose aerosol treatment in combination with low dose systemic 
administration of AMB in order to optimise drug delivery to the lungs and reduce 
dissemination at the same time. 
Although limited data are available, inhaled L-AMB seems to be well-tolerated by 
humans [15]. With inhaled AMB-DOC side effects such as cough, nausea and mild 
bronchospasms are reported. These pulmonary side effects were in some cases dose 
limiting or even necessitated discontinuation of inhalation therapy [16-18]. The 
major side effect, which is cough, is presumed to be caused by desoxycholate rather 
than by AMB [18]. In our study, no acute toxicities in terms of death or increased 
breathing frequencies were observed in animals during aerosol treatment with either 
AMB-DOC or liposomal amphotericin B. in vitro surfactant function tests were per-
formed in order to evaluate the disturbance of surfactant function after disposition of 
the AMB-DOC and L-AMB. The lowestAMB concentrations and therefore the corre-
sponding desoxycholate concentrations were based upon our observed lung deposi-
tion results, which were c. 20 JlWg lung tissue for AMB-DOC and for L-AMB. L-AMB 
alone (data not shown) showed high surface activity, similar to that of the surfactant, 
which can be explained by the presence in the formulation of phospholipids that are 
surface active components. As expected, L-AMB did not influence surface activity of 
the surfactant. However, there was a dose-dependent inhibition of surfactant func-
tion by AMB-DOC. This was due to the detrimental effects of desoxycholate on sur-
factant function, since this agent alone showed high influence on surface activity of 
natural surfactant in comparison with AMB without desoxycholate. These results are 
in accordance with those found by Griese et al [19]. Our results suggestthat inhala-
tion of AMB-DOC but not L-AMB may lead to surfactant dysfunction and this should 
be considered when choosing a formulation to be nebulised. 
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In this refractory model of IPA, survival of infected animals was prolonged after 
even a single dose of aerosolised AMB-DOC or L-AMB. Despite the uncertainties 
about pathogenesis and the precise antifungal activities of administered agents, 
these results encourage further investigations of the potential of aerosolised AMB 
products in other settings such as prophylaxis or empirical treatment. Furthermore, 
it would be interesting to detemnine efficacy for other lipid formulations of AMB that 
are currently on the market, since these products have different structural properties. 
In summary, both aerosolised AMB-DOC and L-AMB are effective ·m prolonging 
survival of persistently leucopenic rats infected with A. fumigatus. L-AMB demon-
strated no negative effect on pulmonary surfactant, as opposed to AMB-DOC, and 
therefore would be the formulation of choice for aerosol administration in patients 
suffering from invasive pulmonary aspergillosis. 
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Abstract 
The efficacy of aerosolised liposomal amphotericin B (L-AMB) in addition to stan-
dard intravenous amphotericin B desoxycholate (AMB-DOC) or intravenous L-AMB 
was evaluated in persistently leukopenic rats with invasive pulmonary aspergillo-
sis. Endpoints were survival of animals and dissemination of infection to the liver. 
In this model, untreated rats die between day 4 and day 9 after fungal inoculation. 
Intravenous treatment was started at 16 h afterfungal·moculation and continued 
for 10 days and consisted of AMB-DOC (1 mglkg), L-AMB (10 mglkg) ora combi-
nation of both. Aerosol treatment consisted of a single period of 60 minutes 
nebulisation of L-AMB at 16 after fungal inoculation. Aerosols were generated by 
a Collison nebuliser. Treatment with intravenous AMB-DOC, L-AMB or a combina-
tion of these, significantly prolonged survival as compared to controls. However, 
addition of aerosol L-AMB to these intravenous regimens further improved 
survival. Aerosol treatment with L-AMB alone yielded similar results as the 
intravenous regimens. 
The intravenous regimens reduced dissemination of the infection to the liver as com-
pared to controls as well as the regimens were intravenous treatment was combined 
with aerosol treatment. Aerosol treatment alone did not reduce dissemination. 
The results of the present study show that addition of aerosol treatment with 
L-AMB to the standard intravenous treatment with AMB-DOC or L-AMB can be 
valuable in optimising treatment of invasive pulmonary aspergillosis. 
Introduction 
Invasive pulmonary aspergillosis (IPA) is a serious life-threatening infection with 
a high mortality in leukopenic patients. Ever since the first description of IPA in 
1953, there has been a substantial increase in the frequency of the disease. 
This is due to growing numbers of patients at risk, such as those treated with 
cytotoxic chemotherapeutic agents or aggressive immunosuppressants [1]. 
Intravenous amphotericin B desoxycholate (AMB-DOC) remains the standard 
treatment for most serious fungal infections, including invasive pulmonary 
aspergillosis. However, the use of AMB-DOC is often limited due to toxic side 
effects such as nephrotoxicity [2]. The liposomal formulation of AMB (L-AMB) has 
been developed in order to diminish the side effects of AMB-DOC. Consequently, 
L-AMB can be administered in higher dosages than AMB-DOC [3,4]. 
Although intravenous administration of AMB-DOC or L-AMB leads to a reduction 
in mortality due to IPA, treatment of such an established infection in patients with 
prolonged persistent leukopenia is correlated with high failure rates [5]. Therefore, 
there is still a critical need to optimise treatment of invasive aspergillosis. 
Failure of treatment of invasive pulmonary aspergillosis with intravenous AMB is 
probably the result of several factors. Due to the nature of the infection, the fungus 
resides predominantly in the airways and can spread to other body tissues. 
Inadequate pulmonary deposition of AMB after intravenous administration of 
AMB-DOC or L-AMB can be a reason forfailure of treatment. It has been shown in 
preclinical work, that only a small percentage of intravenously administered AMB 
is actually delivered to the lungs [6, 7]. By administration of drugs via the inhala-
tion route the lungs are directly targeted which results in high pulmonary drug con-
centrations. We have shown in a rat model of IPA that administration of a single 
dose of aerosolised AMB, either liposomal or non-liposomal, yields substantial, 
long lasting pulmonary AMB concentrations and improves survival in rats as com-
pared to controls [8]. Addition of aerosolised AMB to intravenously administered 
AMB could be an attractive way to enhance pulmonary deposition of AMB. 
The hypothesis of the present study is that aerosol treatment additive to standard 
intravenous treatment can result in a treatment which has a higher success rate in 
terms of improvement of survival in experimentallPA. The study describes the 
combination of intravenous AMB-DOC and/or L-AMB with aerosolised L-AMB in 
the treatment of leukopenic rats suffering from IPA. Therapeutic endpoints were 
survival as well as dissemination of infection in treated animals as compared to 
untreated controls. 
Materials and Methods 
Materials 
AMB-DOC was from Bristol Myers-Squibb (Woerden, The Netherlands) and L-AMB 
was from NeXstar (San Dimas, CA). Cyclophosphamide was from Sigma Chemical 
Co. (St. Louis, MD). Sabouraud dextrose agar (SDA) was from Oxoid (Basinstoke, 
England). 
Animals 
Female R-strain albino rats, specified pathogen free, 18-to 25- weeks old (own breed), 
weighing 185-225 g were used for all experiments. Animals received a normal, 
pathogen free diet and water ad libitum. Experiments were approved by the animal 
experiments ethical committee ofthe Erasmus university Medical Center Rotterdam. 
Aspergillus strain 
A clinical isolate of Aspergillus fumigatus from an immunocompromised patient 
with invasive pulmonary aspergillosis was used. MIC and minimal fungicidal con-
centration of AMB forth is strain are 0.4 and 0.8 mgjl, respectively [9]. The strain 
was stored under oil on SDA. At least once every two months, the strain was passed 
through a rat to maintain its virulence. For inoculation, conidia were harvested and 
suspended in sterile phosphate buffered saline, as previously described [9]. 
Immunosuppression and supportive care 
Leukopenia was induced by intraperitoneal administration of 90 mgjkg cyclophos-
phamide at 5 days before fungal inoculation followed by additional dosages of 
60 mgjkg every 4 days throughout the study. This treatment resulted !.1 a persistent 
leukopenia ( < 0.5 x 1 0'/l)from the time of A. fumigatus inoculation up to the end of 
the study [10]. To prevent bacterial superinfection, strict hygienic care was applied, 
and animals received ciprofloxacin (660 mgjl) and polymyxin E (100 mgjl) in their 
drinking water during the whole experiment. Furthermore, intramuscular administra-
tion of amoxicillin (40 mgjkgjday) was added to this regimen. Shortly before and 
after inoculation, gentamicin (6 mgjkg) was administered intramuscularly. 
Experimental lung infection 
Infection of the lung was established according to the method described by 
Bakker-Woudenberg eta!. [10], and adapted for Aspergillus fumigatus by 
Leenders eta!. [9]. Briefly, under general anaesthesia the left main bronchus was 
intubated. A canula was passed through the tube and the left lobe of the lung was 
inoculated with 0.02 ml ofthe conidial suspension containing 1.5 x 10' conidia. 
This resulted in a left sided pneumonia. 
Antifungal treatment 
Treatment was started at 16 h after fungal inoculation. Histopathologic examination 
(Periodic Acid-Schiff stain) confirms that mycelial outgrowth begins at 16 h. 
Treatment regimens are given in Table 1. Groups of 15 animals received monotherapy 
(only intravenoL.:s or only aerosol treatment) or combination therapy (intravenous and 
aerosol treatment). AMB-DOC and L-AMB were reconstituted according to the manu-
facturers instructions and further diluted in 5% glucose. Intravenous treatment started 
at 16 h or directly after aerosol treatment when combination treatment was given. The 
intravenous regimens showed optimal efficacy in the treatment of IPA in rats [9,11]. 
For aerosol treatment, L-AMB was diluted with 5% glucose up to an AMB concen-
tration in the nebuliser reservoir of 4 mglml AMB. The aerosol procedure of L-AMB 
and AMB-DOC was as previously described [13]. In short: infected rats were con-
strained in cone ended plastic tubes and placed in a nose-only inhalation appara-
tus (CH Technologies USA Inc., Westwood, NJ). Aerosols were generated by a 
Collison six-jet nebulisersystem (Model CN, BGI Inc., Waltham, MA). The nebulis-
er operated at 20 I/ min airflow. Under these conditions, more than 80% ofthe 
aerosol droplets that are generated are below 5 J.lm mass diameter, which ensures 
substantial deposition of material in the alveobronchial region. Animals were 
exposed to aerosol treatment for a period of 60 minutes. 
Table 1. Treatment regimens 
Treatment 
I ntravenousa 
AMB-DOC< 
AMB-DOC< 
L-AMB' 
L-AMB' 
AMB-DOC• +L-AMB' 
AM B-DOC' + L-AMB' 
Aerosol' 
L-AMB 
L-AMB 
L-AMB 
L-AM 
•Intravenous treatment during 10 days. 
~Aerosol administration of a single period of 60 minutes. 
'Daily dosages of 1 mg/kg. 
dDaily dosages of 10 mglkg. 
•Single dose of 1 mg/kgat day 1. 
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Efficacy of antifungal treatments 
Two endpoints were chosen: survival and fungal dissemination to the liver. Animals 
were checked twice daily and mortality was recorded for 12 days after fungal inocu-
lation. Surviving animals were sacrificed after day 12. Post mortem, the left lung 
and liver were dissected and homogenised in 20 ml phosphate buffered saline for 
45 sec at 20,000 rpm in a Vir Tis homogeniser (The Vir Tis Co. Inc., Gardiner, NY, 
USA). Volumes of 0.2 ml and 2 ml and the remainder of each homogenate were 
spread onto or poured into Sabouraud dextrose agar plates. Plates were ·mcubated 
for 24 hat 37 'C followed by 24 hat 25 'C. After incubation, plates were checked 
to exclude bacterial superinfection and second to that, colonies of viable Aspergillus 
were counted in order to determine dissemination to the liver. 
Statistical analysis 
Survival curves were generated by the method of Kaplan and Meier. Statistical 
evaluation of differences in the survival curves was performed by the logrank test. 
This test examines the length of surv·rval as well as the percentage of survival. 
Differences in proportions of animals with A. fumigatus in the left lung and dis-
semination to the right lung and liver at the time of death were examined by the 
Fischer's exact test. 
Results and Discussion 
In the present study, the effrcacy of d'rfferent AMB treatment modal'lties was evaluat-
ed in leukopenic rats with IPA. IPA was studied in rats under severe persistent 
leukopenia, in order to closely mimic a difficult-to-treat clinical situation. In this 
model, untreated rats die between day 4 and day 9 after fungal inoculation. 
Treatment was started at 16 h after fungal inoculation, at which time hypha I out-
growth begins. The efficacy endpoints were survival and dissemination of infection 
to the liver. The effect of different treatment regimens on survival is shown in 
Figure 1. The control group did not receive any treatment. Previous work has demon-
strated that sham treatment resulted in similar results as no treatment at all [8]. 
We have chosen the liposomal formulation of AMB for nebulisation since L-AMB 
showed no toxicity in-vitro to the pulmonary surfactant as opposed to AMB-DOC, 
which was detrimental to the surfactant and may lead to inhalation toxicity 
[8,12]. The nebuliser reservoir concentration of4 mg/ml was chosen because it 
has been shown that nebulising higher, more viscous, concentrations ·rs techn-Ically 
not possible with the Collison nebuliser [13]. 
100 
80 
~ 60 
-ro 
> -~ 40 
=> 
U) 
20 
0 
0 2 4 6 8 10 12 
Days after inoculation 
Figure 1. Effect of different treatment regimens on survival of persistently leukopenic rats with inva-
sive pulmonary aspergillosis. {Kaplan-Meier plot). Each group consisted of 15 animals. Control animals 
received no treatment(---). Treatment was started at 16 h afterfungal inoculation at which time mycelial 
growth begins. Animals were treated with intravenous AMB-DOC (c), intravenous AMB-DOC in combina-
tion with aerosolised L-AMB (e), aerosolised L-AMB{*), intravenous L-AMB (D), intravenous L-AMB in 
combination with aerosolised L-AMB (II), intravenous AMB-DOC plus L-AMB (L\), intravenous AMB-DOC 
plus L-AMB in combination with aerosolised L-AMB (.t.). 
Treatment with monotherapy of a high dose of intravenous AMB-DOC (daily 
1 mglkg) resulted in significantly prolonged survival as compared to controls 
(P = 0.03). These results are in agreement with those of Leenders et al [9]. 
Addition of aerosol treatment with L-AMB to this intravenous regimen resulted in a 
prolonged survival of rats as compared to controls (P = 0.0001) but also as com-
pared to the intravenous AMB-DOC alone (P = 0.0001). Thus, the addition of just 
a single aerosol treatment to the intravenous regimen of AMB-DOC, yields better 
results in terms of survival. Treatment of animals with monotherapy of aerosolised 
L-AMB was as effective as monotherapy with intravenous AMB-DOC. 
Treatment with a high dose of intravenous L-AMB (daily 10 mg/kg) resulted in a 
significantly prolonged survival as compared to controls (P = 0.0001). The results 
are not different from that obtained after administration of intravenous AMB-DOC, 
which is in agreement with Leenders et al. [9]. Addition of a single dose aerosol 
treatment to this regimen also improved survival as compared to controls 
(P = 0.0001), but also as compared to the intravenous L-AMB (P = 0.0001). 
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Administration of intravenous L-AMB (daily 10 mglkg) plus a single dose of intra-
venous AMB-DOC (1 mglkg) at the first day of treatment resulted in a prolonged sur-
vival as compared to controls (P = 0.0001). Addition of aerosol L-AMB to this regi-
men also resulted in an improved survival as compared to controls (P = 0.0001) 
and as compared to treatment with the intravenous regimen alone (P = 0.0001). 
We found no difference between the intravenous regimen of L-AMB plus AMB-DOC 
and the intravenous monotherapies (P > 0.05), which is in discrepancy with 
Becker et al. [11], who showed that the effrcacy of the comb'rnation of L-AMB with 
a single injection of AMB-DOC was superior to that of one of both agents alone. The 
discrepancy between these results may be explained by the difference in severity of 
leukopenia resulting from a different cyclophosphamide regimens in both studies. 
The effect of the different treatment regimens on dissemination is shown in Table 2. 
Results are expressed as percentage culture positive organs. Cultures revealed that 
at the time of death the infection had disseminated to the liver of all untreated 
rats. Monotherapy with intravenous AMB-DOC, L-AMB or L-AMB plus AMB-DOC, 
resulted in a reduction of dissemination to the liver. Combination of intravenous 
Ta :::12 2. Effect of different treatment regimens on the presence of viable A. fumigatus in 
the left lung and dissemination to the liver at the time of death' 
Treatment 
None 
l.v. AMB-DOC" 
l.v. AMB-DOC" +aerosol L-AMB 
Aerosol L-AMB 
l.v. L-AMB' 
l.v. L-AMB'+ aerosol L-AMB 
l.v. AMB-DOC' + i.v. L-AMB' 
l.v. AMB-DOC' + i.v. L-AMB' +aerosol L-AMB 
%culture positive organs 
Left lung Liver 
100 100 
100 7' 
100 13' 
100 87 
100 o· 
100 0' 
100 o· 
100 o· 
'leukopenic rats (n = 15) were inoculated in the left lung at time zero with 1.5 x 10• conidia A. fumigatus. 
Start of intravenous treatment was at 16 h after inoculation and continued for 10 days. Aerosol administration 
of a single dose of 60 min at 16 h after fungal inoculation. 
"Daily dosages of 1 mg!kg. 
'Daily dosages of 10 mg/kg. 
"Single dose of AMB-DOC 1 mg/kg at day one. 
'P< 0.01 as compared to untreated controls. 
with aerosol treatment also showed a significant reduction in dissemination to the 
liver as compared to untreated rats. Treatment with only aerosol L-AMB did not 
prevent dissemination to the liver. It seems that intravenous treatment is crucial to 
prevent dissem·mation from the infection from the lungs to other organs such as 
the liver. Aerosol treatment deposits AMB in the lungs and not systemically and 
can therefore not prevent spreading of the infection via the bloodstream. 
The positive results in terms of survival of animals which are shown in the present 
work, prove the benefit of adding local treatment to intravenous treatment. 
The added value of local treatment is that AM B is deposited directly at the site of 
the infection and thus can prevent further outgrowth of hyphae and thus further 
damage to pulmonary tissue. Furthermore, pulmonary deposited AMB can prevent 
reinfection of the lungs from foci elsewhere. 
There are no clinical data on the safety of a treatment with intravenous AMB-DOC 
combined with intravenous L-AMB, nor on the combination of aerosolised L-AMB 
combined with an intravenous regimen of AMB-DOC or L-AMB. Administration of 
intravenous AMB-DOC in a dose of 1 mgjkg, can lead to nephrotoxicity [14]. 
Treatment with intravenous L-AMB can be given at a dose of 10 mgjkg w·1thout s·,g-
nificant toxicity [ 15]. L-AMB showed no in vitro toxicity on pulmonary surfactant 
when administered as an aerosol [8]. Furthermore, L-AMB administered via an 
aerosol is not systemically absorbed and will thus not exert systemic toxicity. 
In conclusion, we have described the efficacy of intravenous AMB, either liposo-
mal or non-liposomal, combined with aerosolised liposomal AMB in the treatment 
of leukopenic rats with IPA. The combination of systemic and local administration 
of AMB is superior to that of either systemic or local treatment alone. Intravenous 
treatment is crucial for preventing dissemination of the infection from the lungs. 
This f1nding is clinically relevant as current treatment strategies of aspergillosis in 
leukopenic patients are still disappointing and there is a critical need for new anti-
fungal therapies which are both effective and have little toxicity. We suggest that 
L-AMB delivered via the pulmonary route, additive to the current standard of care 
(intravenous administration of AMB), can be a major step forward in the optimisa-
tion of treatment of invasive pulmonary aspergillosis. 
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Abstract 
The efficacy of nebulised amphotericin B desoxycholate (AMB-DOC) and liposomal 
amphotericin B (L-AMB) in the empirical and prophylactic treatment of invasive 
pulmonary aspergillosis (IPA) was studied in rats. A model of IPA in persistently 
leukopenic rats was used. The endpoint in this model is survival of animals. In this 
model, untreated rats die between day 4 and day 9 after fungal inoculation. Rats 
were treated with nebulised AMB-DOC or L-AMB (nebuliser reservoir concentration 
2 mg/ml and 4 mg/ml, respectively) at 16 h after (empirical treatment), or 2 h, 
1 day, 1 week, 2 weeks, 4 weeks or 6 weeks before (prophylactic treatment) fungal 
inoculation. Aerosol treatment consisted of a single period of 60 minutes of nebuli-
sation. Aerosols were generated by a Collison nebuliser. Treatment started at 16 h 
after fungal inoculation, resulted in a significantly prolonged survival for both formu-
lations. There was no difference between the efficacy of nebulised AMB-DOC and 
nebulised L-AMB. Aerosol treatment with both formulations given at 2 h, 1 day, 
1 week, or 2 weeks before fungal inoculation prolonged survival as compared to 
untreated controls. Aerosol treatment given at 4 weeks before fungal inoculation 
also resulted in prolonged survival for both formulations, however, the nebulised 
L-AMB was more effective than nebulised AM B-DOC. When aerosol treatment was 
given at 6 weeks before fungal inoculation, only L-AMB resulted in prolonged sur-
vival of rats as compared to controls. These results suggest that nebulised AMB-
DOC and L-AMB can be used in the empirical and prophylactic treatment of IPA. 
The duration of protection to IPA is longer for the liposomal formulation. 
Introduction 
Advances in medical treatment have improved the prognosis for patients with can-
cer. While significant progression has been made in eradicating certain malignant 
diseases, a growing concern for patients who receive cytotoxic chemotherapy is 
the development offungal infections. Invasive pulmonary aspergillosis (I PAl is the 
second most common mycosis, after candidiasis, encountered in patients with 
cancer, particularly in those w·1th haematologkal malignancies. Major predispos-Ing 
factors include absolute neutrophil count and the duration of neutropenia [1 ,2]. 
Standard treatment for IPA is intravenous administration of amphotericin B desoxy-
cholate (AMB-DOC). Newly developed lipid-based modalities of amphotericin B 
(AMB) show an increased therapeutic index as compared to conventional AMB-
DOC [3]. However, up to now, treatment of an established infection with 
Aspergillus spp. in neutropenic patients is still correlated with high mortality rates. 
There are no rapid, accurate diagnostic tests that can confirm with certainty the 
presence of invasive fungal disease. 30% of cases of IPA remain undiagnosed and 
untreated at death [ 4]. The fact that diagnos·,s of I PA during life ·,sa significant 
problem complicates adequate antifungal treatment. Preventing the development of 
IPA by giving antifungal prophylaxis may be the best approach to improve outcome. 
The route of infection of IPA is by inhalation of the infective particles, the conidia, 
from the environment. Administration of AMB via the pulmonary route can be an 
attractive alternative approach in the treatment or prophylaxis of pulmonary 
aspergillosis. little clinical data are available on the efficacy of inhaled (liposomal) 
AMB [5,6]. Studies with inhaled AMB in humans describe partial prevention of 
pulmonary aspergillosis. However, up to date, significant beneficial effects have 
not been proven, probably because the published studies lack adequate power or 
design. Animal studies have shown that AMB administration via the pulmonary 
route can be effective in preventing or treating IPA [7-10]. However, these studies 
all applied temporary or mild immunosuppression in the experimental model. In 
the clinical situation however, patients are generally persistently granulocytopenic 
and diagnosis of IPA is late in the course of infection which emphasises the need 
for effective treatment of IPA. An important feature of the experimental set-up of 
our study is therefore that we use an established Aspergillus infection under 
severe, persisting immunosuppression. 
In the present study, we use an animal model of IPA in rats which are severely 
immunosuppressed. In this clinically relevant model, we have recently shown that 
treatment of an established infection with nebulised AMB-DOC or with L-AMB 
results in significant beneficial effect on survival of treated animals versus controls. 
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To explore other ways to optimise outcome in IPA, we investigated in this study the 
possibilities of empirical and prophylactic treatment in a rat model of severe IPA. 
Materials and Methods 
Materials 
AMB-DOC was from Bristol Myers-Squibb (Woerden, The Netherlands) and 
L-AMB was from NeXstar (San Dimas, CA). Cyclophosphamide was from Sigma 
Chemical Co. (St. Louis, MOl. Sabouraud dextrose agar (SDA) was from Oxoid 
(Basinstoke, England). 
Animals 
Female R-strain albino rats, specified pathogen free, 18- to 25-weeks old (own 
breed), weighing 185-225 g were used for all experiments. Animals received a nor-
mal, pathogen free diet and water ad libitum. Experiments were approved by the 
animal experiments ethical committee of the Erasmus university Medical Center. 
Aspergillus strain 
A clinical isolate of Aspergillus fumigatus from an immunocompromised patient 
with IPA was used. M!C of AMB forth is strain is 0.4 mg/L[ll]. This strain was 
stored under oil on SDA. At least every two months, the strain was passed through 
a rat to maintain its virulence. For inoculation, conidia were harvested and sus-
pended in sterile phosphate buffered saline as previously described (11]. 
Immunosuppression and supportive care 
Granulocytopenia was induced by intraperitoneal administration of 90 mg/kg 
cyclophosphamide at 5 days before fungal inoculation followed by dosages of 
60 mg/kg every 4 days throughout the study. This treatment resulted in a persis-
tent granulocytopenia ( <0.5 x 10'/L) from the time of A. fumigatus inoculation 
up to the end of the study (11]. To prevent bacterial superinfection, strict hygienic 
care was applied, and animals received ciprofloxacin (660 mg/L) and polymyxin E 
(100 mg/L) in their drinking water during the whole experiment. Furthermore, 
daily intraperitoneal administration of amoxici!lin (40 mg/kg/day) was added to 
this regimen. Shortly before and after inoculation, gentamicin (6 mg/kg) was 
administered intramuscularly. 
Experimental lung infection 
Infection ofthe lung was established according to the method described by 
Leenders et al [11]. Briefly, under general anaesthesia, the left main bronchus was 
intubated. A canula was passed through the tube and the left lobe of the lung was 
inoculated with 0.02 mL ofthe conidial suspension containing 1.5 x 10' conidia. 
This resulted in a left sided pneumonia. 
Aerosol treatment 
The nebu!isation procedure was previously described [12]. Aerosols were generat-
ed by a Collison 6-jet nebuliser system (Model CN, BGIInc, Waltham, MA). The 
nebuliser operated at 20 Umin airflow. Under these conditions, more than 80% of 
the aerosol droplets that are generated are below 5 ~m mass diameter, which 
ensures substantial deposition of aerosol in the alveobronchial region. Rats were 
constrained in cone ended plastic tubes and placed in a nose-only inhalation 
apparatus (CH Technologies USA Inc., Westwood, NJ). Animals were exposed to 
aerosol treatment for one (single dose) or two periods (double dose) of 60 minutes. 
Antifungal treatment 
AMB-DOC and L-AMB were reconstituted according to the manufacturers instruc-
tions and further diluted in 5% glucose up to an AMB concentration in the nebuliser 
reservoir of 2 m~Vml in the case of AMB-DOC and 4 m!Vml in the case of L-AMB. 
These nebuliser reservoir concentrations were chosen based upon results of previ-
ous work with this animal model. Aerosol treatment with AMB-DOC is limited to a 
nebuliser reservoir concentration of 2 mgfml because higher dosages are not toler-
ated. The nebuliser reservoir concentration of L-AMB is limited not because of in 
vivo tolerability, but because oftechnicallim·ltations, since the liposomal suspen-
sion can not be nebulised efficiently when the concentration is above 4 mwml. 
The treatment regimens are given in Table 1. Empirical aerosol treatment with 
AMB-DOC or L-AMB was started at 16 h after fungal inoculation. Histopathological 
examination (Periodic Acid-Schiffstain) confirms that mycelial outgrowth begins at 
16 h. When rats were treated twice, the second aerosol treatment was given at 
40 h after fungal inoculation. Prophylactic aerosol treatment with AMB-DOC or 
L-AMB was given at 2 h, 1 day, 1 week, 2 weeks, 4 weeks or 6 weeks before 
fungal inoculation. Aerosol treatment consisted of a single dose of 60 minutes. 
Efficacy of nebulised AMB-DOC and L-AMB 
Groups of 15 rats each were treated with nebulised AMB-DOC or L-AMB. Efficacy, 
or lack thereof, in each experiment was assessed by the rate of survival of treated 
" 
0 a 
"" " "' 
~ ~ 'S. ~ ~-
'-J Q_ 
~ 
Table l. Treatment regimens of nebulised AMB-DOC and nebulised L-AMB 
Start of aerosol treatment Treatment regimen 
16 hours after fungal inoculation single dose 
16 hours after fungal inoculation double dose 
2 
1 
1 
2 
4 
6 
hours before fungal inoculation single dose 
day before fungal inoculation single dose 
week before fungal inoculation single dose 
weeks before fungal inoculation single dose 
weeks before fungal inoculation single dose 
weeks before fungal inoculation single dose 
animals as compared with that of controls. Control rats received nebulised 
glucose 5%. Animal were checked twice daily and mortality was recorded for 
12 days after fungal inoculation. Surviving animals were sacrificed after day 12. 
To check for bacterial superinfections, left and right lung lobes and liver were 
dissected and homogenised in 20 mL phosphate buffered saline and cultured in 
SDA agar as described above. 
Statistical analysis 
Survival curves were generated by the method of Kaplan and Meier. Statistical 
evaluation of differences in the survival curves was performed by the log rank test. 
This test examines the degree in survival with time as well as the final percentage 
of survival. 
Results 
Effect of nebulised AMB-DOC and nebulised L-AMB on survival 
The effect of aerosol treatment on survival of rats with pulmonary aspergillosis is 
shown in Figures 1 and 2. In this model of pulmonary aspergillosis untreated rats 
die between day 4 and day 9 after fungal inoculation. Empirical aerosol treatment 
started at 16 h afterfungal inoculation with AMB-DOC or L-AMB showed a statis-
tically significant prolonged survival as compared to controls (P < 0.05) (Fig. 1a). 
The efficacy of AMB-DOC did not differ from that of L-AMB. Administration of a 
double dose of both agents also showed a statistically significant prolonged sur-
vival as compared to controls (P < 0.05) (Fig. 1b). However, this effect was not 
different from the single dose treatment. 
Figure 1. Effect of a single (a), or double dose (b) of nebulised AMB-DOC (e) 
and nebulised L-AMB (o) on survival of severely immunosuppressed rats with 
pulmonary aspergillosis (Kaplan-Me.ler plot). Nebuliser reservo·~r concentraf1ons 
were 2 mg/mL in the case of nebulised AMB-DOC and 4 mg/mL in the case of 
L-AMB. Each group consisted of 15 animals. Control animals received nebulised 
5% glucose(---). Treatment was started 16 h after fungal inoculation, at which 
time mycelial growth begins. *P < 0.05 versus controls. 
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Figure 2. Effect of single dose of nebulised AMB-DOC (•) and nebulised L-AMB (o) 
on survival of severely immunosuppressed rats with pulmonary aspergillosis 
(Kaplan-Meier plot). Treatment was started at 2 hours (a), l day (b), 1 week (c), 
2 weeks (d), 4 weeks (e) or 6 weeks (f) before fungal inoculation. Nebuliser reservoir 
concentrations were 2 mg/mL in the case of AMB-DOC and 4 mg/mL in the case of 
L-AMB. Each group consisted of 15 animals. Control animals received aerosolised 
5% glucose(---). *P < 0.05 versus controls. tP < 0.05 versus AMB-DOC. 
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The effects of single dose prophylactic aerosol treatment started at different time 
points before fungal inoculation are shown in Fig. 2a to Fig. 21. Administration of 
a single aerosol dose directly preceding inoculation (2 h) resulted in a statistically 
significant prolonged survival (P < 0.05) for both the non-liposomal as the liposo-
mal formulation (Fig. 2a). When aerosol treatment was started at 1 day, 1 week 
or 2 weeks before fungal inoculation, the beneficial effect on survival remains for 
both formulations (Fig. 2b-d). At these time points, no difference is seen between 
AMB-DOC and L-AMB. Administration of nebulised AMB-DOC and L-AMB at 
4 weeks before fungal inoculation results in statistically significant prolonged sur-
vival for both products (P < 0.05) (Fig. 2e & 2f). With this regimen, the liposomal 
formulation resulted in a statistically significant prolonged survival as compared to 
the non-liposomal formulation (P < 0.05). When aerosol treatment was given at 
6 weeks before fungal inoculation, only L-AMB resulted in a significantly prolonged 
survival (P < 0.05). 
Discussion 
Pulmonary aspergillosis is a serious opportunistic disease in patients with 
immunosuppression. Aerosol administration of antifungal agents directly deposits 
the drug at the site of the intended action and could therefore be an attractive ther-
apeutic approach. Empirical or prophylactic measures would be highly beneficial 
because treatment often fails after infection is diagnosed. In the present study, we 
have investigated the possibilities of empirical and prophylactic aerosol adminis-
tration of AMB-DOC and L-AMB in a rat model of severe pulmonary aspergillosis. 
We have used a difficult-to-treat, animal model of IPA. This model is highly clini-
cally relevant since it is characterised by profound and persistent neutropenia and 
shows hyphal invasion of pulmonary tissue and vessels. The Collison nebul"lser 
and inhalation system for treatment of rats with nebulised AMB-DOC and L-AMB 
was validated in a previous study [12]. Nebulisation of AMB-DOC and L-AMB with 
this device leads to respirable aerosols and yields substantial lung tissue concen-
trations of AMB (above the minimal inhibitory concentration of A. fumigatus) and 
negligible systemic exposure. We have shown previously that aerosol treatment of 
an established infection results in prolonged survival in the same rat model as 
used in the present study [13]. However, in view of sub-optimal treatment after 
the infection has fulminated, we suggested that early empirical treatment or pro-
phylactic treatment would be an interesting approach to further optimise outcome 
of pulmonary aspergillosis. Empirical treatment with maximal dosages of AMB-DOC 
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and L-AMB at 16 hours after fungal inoculation, the time at which the hypha I out-
growth of the fungus begins, resulted in a prolonged survival of animals as com-
pared to controls. No difference is seen between the liposomal and the non-liposo-
mal formulation. Administering an additional dose at 40 hours after fungal 
inoculation did not further improve efficacy. 
When a single dose of nebulised AMB-DOC or L-AMB was given directly before 
fungal inoculation, a significantly prolonged survival is seen as compared to con-
trols. Administeringthe opf1mal nebul.lsed dose of e"1ther agent just before inoculat-
ing the conidial suspension is close to an in vitro experiment. Surprisingly, the 
mortality rate in this experiment is still high, with only 30-40% ofthe rats surviv-
ing. This observation illustrates the severity of the animal model we have used 
for our experiments. The Kaplan Meier curves for the prophylaxis given at 1 day, 
1 week or 2 weeks before fungal inoculation are similar to that seen at 2 hours 
before inoculation, whites demonstrates that a single dose of nebulised AMB, 
either liposome-encapsulated or not, will be retained in the lungs for a long period 
oftime. A long half-life of AMB in pulmonary tissue after lung deposition was 
already described [14]. The extensive retention is probably due to extensive tissue 
binding as a result of a high affmity of AMB for cholesterol. In this study, we have 
shown that the deposited AMB remains biologically active. This suggests that pro-
phylactic administration of only a single dose of AMB can be beneficial for several 
weeks for neutropenic patients at risk for acquiring aspergillosis. 
Single dose prophylaxis, given at 4 weeks before fungal inoculation, still results 
in a beneficial effect on survival for both formulations. With aerosol administra-
tion at 6 weeks before inoculation, only L-AMB is effective. We see here that the 
effect of L-AMB is more pronounced than that of AMB-DOC. Liposomal encapsu-
lation may result in an extended half life of AMB in the lungs, as compared to 
non-liposomal AMB. 
An add-Itional advantage of administering the liposomal formulation is that in vitro 
data show that it will probably be less irritating for pulmonary mucosa than the 
desoxycholate formulation [13]. 
Next to the effect of treatment on survival of animals we have also investigated the 
effect of aerosol treatment of AMB-DOC and L-AMB on number of viable aspergilli 
in order to examine the direct antifungal effect of administered agents (unpub-
lished data). We have seen that number of colony forming units did not seem to be 
corresponding to the severity of the infection. Possibly, nuclear multiplication of 
inoculated conidia and mycelial growth are not expressed as increase in the num-
ber of colony forming units. We therefore decided not to use the parameter of the 
viable fungal load to determine antifungal efficacy of administered agents. 
However, this measure is used in a number of studies to express antifungal activity 
of investigational drugs [7, 14]. 
In summary, the present study shows that administering a single dose of nebulised 
liposomal or non-liposomal AMB to animals before they develop fulminant 
aspergillosis, is effective in prolonging survival. The effect of the liposomal formu-
lation is longer lasting than that ofthe conventional formulation of AMB. These 
results suggest that a single dose of nebulised AMB-DOC, but preferentially 
L-AMB, could prevent pulmonary aspergillosis in patients at risk. 
if 
"0 
~ 
• ti· 
a 
~ 
() 
::c 
"' 
" m-
" 
Denning OW. Therapeutic outcome in invasive 
aspergillosis. Clin Infect Dis 1996;23:608-15. 
Denning OW. Invasive aspergillosis. Clin 
Infect Dis 1998;26:781-803. 
3. Hiemenz JW, Walsh TJ. Lipid formulations of 
amphotericin B. J Liposome Res 
1998;8:443-467. 
4. Vogeser M, Wanders A, Haas A, Ruckdeschel 
G. A four-year review of fatal aspergillosis. Eur 
J Clin Microbiollnfect Dis 1999;18:42-45. 
5. Purcell, I. F., and P. A. Carris. 1995. Use of 
liposomal amphotericin 8 in the treatment of 
Aspergi/lus fumigatus empyema. Thorax 
50:1321-1323 
Schwartz S, Behre G, Heinemann V, et al. 
Aerosolized amphotericin B inhalations as 
prophylaxis of invasive aspergillus infections 
during prolonged neutropenia: Results of a 
prospective randomized multicenter trial. 
Blood 1999;93:3654-3661. 
Allen SO, Sorensen KN, Nejdl MJ, Durrant, 
and R. T. Proffit. 1994. Prophylactic efficacy 
of aerosolized liposomal (AmBisome) and 
non-liposomal (Fungizone) amphotericin 8 in 
murine pulmonary aspergillosis. J Antimicrob. 
Chemother. 34:1001-1013. 
Cicogna CE, White MH, Bernard EM, 
lshimura T, Sun M, Tong WP, Armstrong D. 
Efficacy of prophylactic aerosol amphotericin 
B lipid complex in a rat model of pulmonary 
aspergillosis. Antimicrob Agents Chemother 
1997:41:259-261. 
Schmitt HJ, Bernard EM, Hauser M, 
Armstrong D. Aerosol amphotericin 8 is effec-
tive for prophylaxis and therapy in a rat model 
of pulmonary aspergillosis. Antirnicrob Agents 
Chemother 1988;32:1676-9. 
10. Sorensen KN, Allen SO, Nejdl MJ, Proffit RT. 
Aerosolisation of liposomal (Ambisome) and 
non-liposomal (Fungizonel amphotericin B 
as treatment for pulmonary fungal infections. 
J Control Release 1994;28:346-347. 
11. Leenders ACAP, de MarieS, ten Kate MT, 
Bakker-Woudenberg IAJM, Verbrugh HA. 
Liposomal amphotericin B (AmBisome) 
reduces dissemination of infection as com-
pared to amphotericin B deoxycholate 
(Fungizone) in a newly developed animal 
model of one-sided pulmonary aspergillosis. 
J Antimicrob Chemother 1996;38:215-225. 
12. Ruijgrok EJ, VultoAG, van Etten, EWM. 
Aerosol delivery of amphotericin B desoxy-
cholate (Fungizone) and liposomal ampho-
tericin B (AmBisome): aerosol characteristics 
and in-v'1vo amphotericin B deposition in rats. 
J Pharm Pharmacol2000:52:619-627. 
13. Ruijgrok EJ, Vulto AG, van Etten EWM. 
Efficacy of aerosolized amphotericin B desoxy-
cholate and liposomal amphotericin Bin the 
treatment of invasive pulmonary aspergillosis 
in severely immunocompromised rats. J 
Antimicrob Chemother 2000;48:89-95. 
14. Lambros MP. Bourne DWA, Abbas SA, Johnson 
DL. Disposition of aerosolized amphotericin B. 
J Pharm Sci 1997;86:1066-1069. 
15. Niki Y, Bernard EM, Schmitt HJ, Tong WP, 
Edwards FF, Armstrong D. Pharmacokinetics 
of aerosol amphotericin Bin rats. Antimicrob 
Agents Chemother 1990;34:29-32. 
Nebulisation of four commercially 
available amphotericin B formulations in 
persistently leukopenic rats with invasive 
pulmonary aspergillosis: evidence for 
long-term biological activity 
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Abstract 
The nebulisation of amphotericin B desoxycholate (AMB-DOC), liposomal ampho-
tericin B (L-AMB), amphotericin B lipid complex (ABLC) and amphotericin B col-
loidal dispersion (ABCD) was investigated. Particle sizes of generated aerosol 
droplets were measured. Pulmonary amphotericin B (AMB) deposition and AMB 
concentration in blood directly after nebulisation and at 6 weeks after nebulisation 
was measured in healthy rats. The efficacy of nebulised AMB formulations was 
evaluated in persistently leukopenic rats with invasive pulmonary aspergillosis 
(lPA). Aerosols were generated with a Collison nebuliser. Treatment consisted of a 
single inhalation period of 60 min. The nebuliser reservoir AMB concentration was 
4 mg/mL for the lipid preparations and 2 mg/mL for AMB-DOC. Treatment was 
given either at 16 h after fungal inoculation, or at 1 week, 2 weeks or 6 weeks 
before fungal inoculation. The endpoint was survival of animals. Aerosol particle 
sizes, expressed as the values for the mass median diameter were 1.38, 2.43, 
0.90 and 2.29 I'm for AMB-DOC, L-AMB, ABLC and ABCD, respectively. For all 
formulations, AMB concentrations in the lungs directly after nebulisation exceeded 
the MlC of Aspergillus fumigatus and AMB was still detected in lungs of rats at 
6 weeks after nebulisation. Treatment, started at 16 h after fungal inoculation, 
resulted in a significantly prolonged survival as compared to sham-treated rats for 
all 4 formulations. Prophylactic treatment at 1 week before fungal inoculation 
resulted in a significantly prolonged survival for all 4 formulations. Aerosol treat-
ment given at 2 weeks before inoculation was effective only for AMB-DOC and 
L-AMB, whereas treatment given at 6 weeks resulted in a significantly prolonged 
survival only for L-AMB. 
All commercially available AMB preparations can be nebulised efficiently and may 
be of value in the prophylactic treatment of lPA. 
Introduction 
An increase in the number of immunosuppressed patients in the last decades has led 
to an increase in the number of invasive fungal infections such as invasive pulmonary 
aspergillosis (IPA) [1 ,2]. For many years, conventional amphotericin B, in the form of 
amphotericin B desoxycholate (AMB-DOC), has been considered as the treatment of 
choice for IPA, due to its potent fungicidal activity [3]. Its use, however, is limited by its 
narrow therapeutic index. A number of toxic side effects, especially nephrotoxicity, 
have made this drug difficult for patients to tolerate [4]. Lipid-based formulations of 
AMB were developed in order to diminish side effects of AMB. Lipid-based AMB for-
mulations have a broader therapeutic index as compared to AMB-DOC, which permits 
higher dosing schedules. Currently, there are 3 marketed lipid formulations of AMB. 
Liposomal amphotericin 8 (L-AMB) consists of small unilamellarvesicles with AMB 
incorporated within the bilayer membrane of phopholipids. Amphotericin B lipid com-
plex (ABLC) has AMB complexed to two phospholipids in a ribbonlike structure. 
Amphotericin B colloidal dispersion (ABCD) is composed of disklike structures of 
cholesteryl sulphate complexed with AMB. In the emp.~rical treatmentofsystemicfun-
gal infections, all3 lipid-formulations of AMB are at least as effective asAMB-DOC and 
show less toxicity [5]. Little direct comparative data are available on the relative effica-
cy of the different lipid formulations or on the comparative efficacy against AMB-DOC. 
Despite the choice of several available AMB formulations, mortality rates from IPA 
are still unacceptably high and most neutropenic patients with proven I PA die from 
this infection [2,6]. These severe life-threatening features of I PA stress the critical 
need for optimising management of this infection. 
Failure of treatment of I PA with intravenous AM 8 is probably the resu It of several fac-
tors. The fungus resides predominantly in the airways and can spread to other body tis-
sues. Inadequate penetration of AMB in the airways after intravenous administration of 
any AMB formulation can contribute to failure of treatment. It has been shown that 
only a small percentage of intravenously administered AMB is actually delivered to the 
lungs [7 ,8]. By administration of drugs via the inhalation route, the lungs are directly 
targeted which results in high pulmonary drug concentrations. Nebulised AMB-DOC, 
L-AMB, and ABLC in different animal models of IPA resulted in substantial, long lasting 
pulmonary AMB concentrations and significantly improvec survival of rats [9-12]. 
However, data on the comparative value of the AMB formulations are scarce. 
Aerosol administration of AMB formulations can be valuable in the optimisation of 
the management of IPA. Which formulation is most suitable forth is approach has 
not yet been investigated. This study presents a head-to-head comparison of the 
biodistribution, efficacy and toxicity of nebulised AM B formulations. 
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Materials and Methods 
Materials 
AMB-DOC was from Bristol Myers-Squibb (Woerden, The Netherlands), L-AMB 
was from Nexstar (San Dimas, CA), ABLC was from The Liposome Company 
(Princeton, NJ) and ABCD was from Alza Corporation (Palo Alto, CA). 
Cyclophosphamide was from Sigma Chemical Co. (St. Louis, MO). Sabouraud 
dextrose agar (SDA) was from Oxoid (Basingstoke, UK). 
Animals 
Female R-strain albino rats, specified pathogen free, 18- to 25- weeks old (own 
breed), weighing 185-225 g were used for all experiments. Animals received a 
normal, pathogen free diet and water ad libitum. Experiments were approved by 
the animal experiments ethical committee ofthe Erasmus university Medical 
Center Rotterdam. 
Aspergillus strain 
A clinical isolate of Aspergillus fumigatus from an immunocompromised patient 
with IPA was used. MIC and minimal fungicidal concentrations of AMB for this 
strain are 0.4 and 0.8 mg1L, respectively [13]. This strain was stored under oil on 
SDA. At least once every two months, the strain was passed through a rat to main-
tain its virulence. For inoculation, conidia were harvested and suspended in sterile 
phosphate buffered saline, as previously described [13]. 
Immunosuppression and supportive care 
Leukopenia was induced by intraperitoneal administration of 90 mglkg cyclophos-
phamide at 5 days before fungal inoculation followed by additional dosages of 
60 mg1kg every 4 days throughout the study. This treatment resulted in a persis-
tent leukopenia ( < 0.5 x 10'/L) from the time of A. fumigatus inoculation up to 
the end of the study [13]. To prevent bacterial superinfection, strict hygienic care 
was applied, and animals received ciprofloxacin (660 mgll) and polymyxin E 
(100 mg1L) in their drinking water during the whole experiment. Furthermore, 
intramuscular administration of amoxicillin (40 mg1kg1day) was added to this regi-
men. Shortly before and after inoculation, gentamicin (6 mg1kg) was administered 
intramuscularly. 
Experimental lung infection 
Infection of the lung was established according to the method described by 
Bakker:Woudenberg et al. [14]. Briefly, under general anaesthesia the left main 
bronchus was intubated. A canula was passed through the tube and the left lobe 
of the lung was ·maculated w·rth 0.02 mL ofthe conid·ral suspension containing 
1.5 x 10' conidia. This resulted in a left sided pneumonia. 
Nebulisation procedure 
AMB-DOC, L-AMB, ABLC and ABCD were reconstituted according to the manu-
facturers instructions and further diluted in 5% glucose. L-AMB, ABLC and ABCD 
were diluted with glucose up to an AMB concentration in the nebuliser reservoir 
of 4 mg/mL. AMB-DOC was diluted up to a nebuliser reservoir concentration of 
2 mgfml. Previous work in our laboratory describes the rationale for these concen-
trations [12]. In short' for AMB-DOC, 2 mg/mL is the maximum dose which is 
tolerated by rats, whereas the dose ofthe lipid formulations is limited to 4 mg/mL 
because of technical limitations to nebulisation. The aerosol procedure was as 
previously described [15]: rats were constrained in cone ended plastic tubes and 
placed in a nose-only inhalation apparatus (CH Technologies USA Inc., Westwood, 
NJ). Aerosols were generated by a Collison six-jet nebuliser system (Model CN, 
BGIInc., Waltham, MA). The nebuliser operated at 20 Umin airflow. Animals 
were exposed to aerosol treatment for one or more periods of 60 minutes. 
Droplet size measurements 
The droplet size distribution of aerosols was measured using a laser velocity 
particle sizer (Aerosol Particle Sizer 3320 A, TSI, Inc., St Paul, MN). Aerosols 
were generated with compressed air at a flow rate of 10 Umin. Distribution of the 
number of generated aerosol particles was directly measured with this technique. 
For extrapolation of mass distribut"1on from the number distribution, specific 
gravity was set at that ofthe solvent (1 g/cm') and relative humidity at 60%. 
From the mass distribution, the mass median diameter and the percentage of 
particles< 5!lm were calculated. 
Deposition of AMB in lungs after nebulisation of AMB-DOC. L-AMB. ABLC, or ABCD 
Deposition experiments were performed in healthy rats. Directly after and at 
6 weeks after nebulisation of AMB-DOC, L-AMB, ABLC or ABCD, rats were killed 
and blood was sampled via a cardiac punction. Right and left lung lobes were 
removed and weighed. Lungs were homogenised in 5 mL glucose 5%. AMB 
was extracted from blood and homogenate with ethanol in a 2,3 (v/v) rafro. 
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The extracts were centrifuged for 5 min at 13,000 x g and concentrations of AMB 
in the supernatants were determined by HPLC with an UV detector operating at 
382 nm. The mobile phase consisted of 0.1 M sodium acetate solution (pH 7 .2) 
containing 0.2% (v/v) triethylamine and 60% acetonitrile and was pumped 
through a guard pre-column (Chromguard, 10 x 3 mm; Chrompack, Middelburg, 
The Netherlands) followed by a reverse-phase ODS 2 C18 column (100 x 3 mm 
ID; particle size 5 mm; Chrompack, Middelburg, The Netherlands) at a flow rate of 
0.5 mUm in. The recovery was 70% for blood and 75% for lung tissue. The lower 
limit of quantification of this assay was 0.2 mg/mL. 
Effect of AMB-DOC, L-AMB. ABLC and ABCD on survival of rats 
Groups of 15 infected rats each were treated with a single dose of nebulised AMB-
DOC, L-AMB, ABLC or ABCD at different times after or before fungal inoculation. 
Treatment given after fungal inoculation started at 16 h from inoculation. 
Histopathological examination (Periodic Acid-Schiff stain) confirmed that mycelial 
outgrowth begins at 16 h. Prophylactic treatment was given at 1 week, 2 weeks, 
or 6 weeks before fungal inoculation. The endpoint was survival of treated animals 
as compared to controls. Controls received nebulised glucose 5%. Animals were 
checked twice daily and mortality was recorded for 12 days after fungal inocula-
tion. Surviving animals were sacrificed after day 12. To check for bacterial super-
infections, the left lung, right lung and liver were dissected post mortem and 
homogenised in 20 ml phosphate buffered saline for 45 sec at 20,000 rpm in a 
VirTis homogeniser (The VirTis Co. Inc., Gardiner, NY, USA). Volumes of 0.2 ml 
and 2 ml and the remainder of each homogenate were spread onto or poured into 
Sabouraud dextrose agar plates. Plates were incubated for 24 hat 37 °C followed 
by 24 hat 25 °C. 
Influence of AMB products on surfactant function 
Freeze dried natural surfactant prepared from bovine lavages was a gift of the 
Department of Anaesthesiology of the Erasmus university Medical Center 
Rotterdam. It consisted of approximately 90-95% phospholipids, 1% hydrophobic 
proteins (surfactant protein B & C) and 1% free fatty acids. This surfactant is high-
ly surface active at low concentrations. Influence of different AMB formulations 
on surfactant function was determined by means of a modified Wilhelmy balance 
I system (E. Biegler GmbH, Mauerbach, Austria). This system records surface 
tensions of an air-liquid film over several cycles of mechanical compression and 
expansion of this film. The lower the surface tension at minimal surface area, 
the higher the surface activity ofthe applied film. 
The trough of the Wilhelmy balance was filled with warm saline (37°C) and cali-
brated. After calibration, 100 Ill of surfactant (1 mg/ml total lipids) alone or in 
the presence of AMB formulations was applied onto the saline hypophase and 
allowed to spread for 2 min. The surface area was compressed and expanded with 
a cycling speed of 1 cycle per 3 min and an area reduction from 100% to 20%. 
Minimal surface tension (ymin) was measured after 3 cycles at 20% surface area, 
and is expressed as mN/m. Inhibition of surfactant function of natural surfactant 
by AMB formulations results in increased surface tension at minimal surface area. 
Statistical analysis 
Survival curves were generated by the method of Kaplan and Meier. Statistical 
evaluation of differences in the survival curves was performed by the log rank test. 
This test examines the length of survival as well as the percentage of survival. 
Results 
Aerosol droplet size 
Aerosol droplet sizes of all4 formulations defined as the mass median diameter 
and the percentage of particles< 5 /lm are given in Table 1. For all formulations, 
more than 80% of the particles was below 5 ,um mass diameter. 
Deposition of AMB in lungs after nebulisation of AMB-DOC. L-AMB, ABLC, ABCD 
The pulmonary concentrations of AMB in uninfected lungs for aerosolised AMB-
DOC (nebuliser reservoir concentration 2 mg/ml) and aerosolised L-AMB, ABLC 
and ABCD (nebuliser reservoir concentration 4 mg/ml) are given in Table 2. The 
concentrations were determined directly after and at 6 weeks after a single aerosol 
dose of either formulation. For all formulations, substantial AMB concentrations 
were deposited in the lungs directly after nebulisation. There was no statistically 
Table 1. Mass median diameter and% of aerosol particles< 5 /lm as 
determined by laser diffraction analysis 
Mass median diameter (/lm) %particles< 5 /lm 
AMB-DOC 1.38 83.2 
L-AMB 2.43 86.6 
ABLC 0.90 91.2 
ABCD 2.29 86.7 
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Table 2. Deposition of AMB in lungs (~g'g) directly after (0 h) and 6 weeks after aerosol 
administration (60 minutes) of 4 different AMB formulations 
AMB cone (mg'ml) AMB in lungs AMB in lungs 
in nebuliser (~g'g) at 0 h (~g'g) at 6 wk 
AMB-DOC 2 26.9 (8.5)' 11.4 (1.3) 
L-AMB 4 46.7 (15.5) ll.l (2.9) 
ABLC 4 24.9 (11.4) 7.7 (0.4) 
ABCD 4 30.9 (5.1) 14.8 (2.5) 
-values are mean (SDJ, n=3 
significant difference in the deposited AMB between the 4 formulations. With all 
4 products, AMB was still detected in lungs at 6 weeks after nebulisation, which 
indicates a very slow clearance of AMB from the lungs. The amount of AMB in 
blood was below the limit of detection in all samples. 
Effect oi nebulised AMB-DOC. L-AMB, ABLC and ABCD on survival of rats 
The effect of aerosol treatment on survival is shown in Figure 1. In this model of 
IPA, control rats die between day 4 and day 9 after fungal inoculation. Empirical 
treatment started at 16 h afterfungal inoculation, the time at which hypha I out-
growth begins. This treatment resulted in a significantly prolonged survival as 
compared to controls for all 4 regimens (P < 0.05) (Fig. la), with no difference 
between the 4 AMB-formulations. Prophylactic treatment was started at 1 week, 
2 weeks or 6 weeks before fungal inoculation. Treatment started at 1 week before 
inoculation resulted in a significantly prolonged survival as compared to controls 
for all4 regimens (P < 0.05) (Fig. lb), again with no difference between the 
4 AMB formulations. Treatment started at 2 weeks before fungal inoculation 
resulted in a significantly prolonged survival for AMB-DOC and L-AMB (P < 0.05), 
whereas ABLC showed borderline significance (P = 0.06). Treatment with ABCD 
did not result in a significantly prolonged survival (P = 0. 77). Only for L-AMB did 
treatment at 6 weeks before inoculation result in a significantly prolonged survival 
as compared to controls (P < 0.05). 
Figure 1. Effect of a single dose of aerosolized AMB-DOC (e), L-AMB (o), ABLC (v) 
and ABCD (T) on survival of persistently leukopenic rats with pulmonary aspergillo-
sis (Kaplan-Meier plot). Treatment was started at 16 hours after (a) or 1 week (b), 
2 weeks (c) or 6 weeks (d) before fungal inoculation. Nebuliserreservoir AMB con-
centrations were 4 mg/ml, exceptfor AMB-DOC, where the nebuliser reservoir con-
centration was 2 mg/ml. Each group of 15 animals was exposed for 60 minutes. 
Control animals received nebulised 5% glucose(---). *P < 0.05 versus controls. 
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Table 3. Mean minimal surface tension (ym,) of surfactant (1 mgtmL) together 
with saline, AMB, desoxycholate, AMB-DOC, L-AMB, ABLC and ABCD 
Concentration (mglmll Minimal surface tension (mN/m)' 
AMB DOC 
Saline 1.97 ± 1.23 
AMB 2 2.70 ± 0.53 
Desoxycholate 2.1 23.13± 1.16' 
AMB-DOC' 2 1.6 47.53± 0.89' 
L-AMB 2 1.42 ± 0.83 
ABLC 2 1.45 ± 0.39 
ABCD 2 3.33 ± 0.39 
•each value represents the mean ± sd of three individual experiments 
~In AMB-O DC, 54% (gfg) isAMB, 46% is DOC, corresponding with 2 mgfml AM Band 1.6 mgfml DOC 
'p<0.05 as compared to saline 
Influence of AM B products on surfactant function 
Table 3 shows the mean minimal surface tensions (ymin) of surfactant alone or in 
combination with AMB alone, desoxycholate, AMB-DOC, L-AMB, ABLC and ABCD. 
The natural surfactant was highly surface active at the examined concentrations 
(ym" 1.97 ± 1.23). Minimal surface tensions after mixing of surfactant with AMB 
alone, L-AMB, ABLC or ABCD yielded similar low values. Addition of AMB-DOC 
to natural surfactant resulted in significantly increased minimal surface tensions, 
indicating a loss of surface activity of the mixtures. An increase in minimal surface 
tension of natural surfactant was also seen with addition of desoxycholate alone. 
Discussion 
IPA is a serious opportunistic disease in patients with immunosuppression. A diffi-
cult diagnosis, which is often confirmed late in the course of the infection, hampers 
an adequate treatment of IPA. In order to treat IPA effectively, multiple high doses of 
intravenous AMB-DOC are needed, but these can usually not be given due to 
nephrotoxicity of AMB. Using aerosol administration of AMB formulations, the drug 
is directly deposited at the intended site of action, which could be highly attractive 
both in terms of avoidance of toxicity as in terms of efficacy. In the present study, 
we have examined the value of aerosol administration of 4 commercially available 
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AMB formulations in a model of IPA in persistently leukopenic rats. 
The amount of deposition of an aerosol in the respiratory tract is mainly determined 
by the particle size distribution of the aerosol droplets. Large particles with a diame-
ter of> 5 mm are deposited in the upper airways and will not be distributed to the 
peripheral regions of the lungs. Particles with a diameter of< 0.5 ~mare exhaled 
[16]. Inhaled Aspergillus fumigatus spores, with an average particle size of 1-2 ~m. 
are deposited in the peripheral [alveolar) region ofthe lungs and invasive disease 
develops from thereon. It is suggested that the optimal range of particle sizes for 
peripheral deposition for AMB aerosols is between 1 and 5 ~m. We have shown 
before that AMB-DOC and L-AMB aerosols are characterised by an adequate parti-
cle size [15]. Although the 4 tested AMB formulations have distinct different physi-
co-chemical properties, all formulations were efficiently nebulised by the nebuliser 
used in the present study. Although the mass median diameter is different for the 
4 formulations, this is probably not relevant for their peripheral deposition. The 
median particle size of all 4 AMB formulations is between 1 and 5 ~m. and >80% 
of generated particles are below 5 ~m. A substantial peripheral deposition of AMB 
can therefore be expected for all formulations. 
We previously described pulmonary kinetics of aerosolised AMB-DOC and L-AMB 
[17]. In this work, we showed the favourable AMB deposition and retention in the 
lungs of rats after nebulisation of AMB-DOC or L-AMB. In the present study, we 
show that for all 4 AMB formulations, the pulmonary concentrations of AMB 
directly after nebulisation are substantial and exceed the MIC for Aspergillus fumi-
gatus, which is 0.4-0.8 mg/L for non-lipid associated AMB. The deposition data 
of the different formulations directly after nebulisation were not in discrepancy 
with the differences in aerosol particle sizes. The pulmonary deposition seemed 
not to differ significantly between the different products. Furthermore, we show 
that AMB can still be detected in pulmonary tissue at 6 weeks after nebulisation of 
all4 formulations. No AMB was detected in blood at all times. This indicates that 
aerosol administration leads to very low systemic exposure of AMB. The substan-
tial deposition as well as the extensive pulmonary retention and low systemic 
exposure of AMB renders the aerosol delivery of either product very suitable for 
empirical as well as prophylactic treatment of pulmonary aspergillosis. 
Few clinical data are available on the nebulisation of AMB formulations in patients 
with pulmonary fungal infections [18-20]. Until now, the exact value ofthis 
approach still has to be determined. In models of aspergillosis in mice and rats 
with corticosteroid induced immunosuppression, prophylaxis or treatment of IPA 
with nebulised AMB-DOC or L-AMB was evaluated [9,10]. In these studies, 
the nebulised formulations were effective in decreasing the number of viable 
Aspergillus fumigatus counts in the lungs and in increasing survival of animals. 
L-AMB was more effective than AMB-DOC [9]. In rats with corticosteroid induced 
immunosuppression, prophylactically nebulised ABLC resulted in improved sur-
vival of IPA [11]. These studies were all focused on the prophylaxis of IPA, and 
temporary or mild immunosuppression was applied in the experimental model. 
In the clinical situation however, patients with severe IPA are generally persistently 
leukopenic. An important feature of the experimental set-up of the present study is 
therefore the persistently immunosuppressed state. In this model, we have previ-
ously described the therapeutic efficacy of nebulised AMB-DOC versus L-AMB, 
with the start of treatment at 30 h after fungal inoculation [12]. In that study we 
showed that nebulised AMB-DOC as well as nebulised L-AMB resulted in a statis-
tically significant prolonged survival in rats with established IPA. In the present 
study start of treatment was at 16 h after and at different times before inoculation. 
Histopathological examination confirms that at 16 h after fungal inoculation 
hypha I outgrowth begins. We have seen that aerosol treatment started at 16 h 
with all 4 formulations resulted in a significantly prolonged survival as com-
pared to control rats. However, we showed before that aerosol administration of 
AMB formulations does not prevent dissemination ofthe infection. [12] We 
concluded therefore, that aerosol administration of AMB will be of limited value 
as treatment of I PA. 
The deposition data show that long term protection could be expected from the 
nebulised AMB products, since at 6 weeks after a single dose of nebulised AMB-
DOC, L-AMB, ABLC or ABCD, AMB is still present in lung tissue. The measured 
AMB concentrations exceeded the MIC value of Aspergillus fumigatus strain for 
AMB. Whether this AMB is indeed biologically active, remains to be proven by the 
efficacy data. We showed prophylactic efficacy for all 4 formulations when 
aerosols were given at 1 week before fungal inoculation. The efficacy seemed not 
to differ between the 4 products. When aerosol treatment was g·1ven at 2 weeks 
before fungal inoculation, we see that nebulised AMB-DOC and L-AMB still 
showed prophylactic efficacy, whereas nebulised ABCD did not and ABLC did not 
conclusively. When given at 6 weeks before only nebulised L-AMB showed prophy-
lactic efficacy. The differences between the 4 formulations in the efficacy experi-
ments are not reflected by the aerosol particle size or the deposition data. We can 
therefore only speculate about the reason for the observed discrepancy between 
the chemical presence and the biological activity of AMB. It is known that AMB 
tightly binds to cell membranes and sterol receptors which may render AMB 
inactive over time, however, still extractable with organic solvents as we did. 
It is tempting to suggest that the liposomal formulation acts as a slow release 
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pool, which results in long term efficacy as is shown in the survival data. 
The toxicity of aerosolised AMB formulations was evaluated in an in-vitro experi-
ment in which their influence on surfactant function was determined. It appeared 
that AMB-DOC, and not the lipid formulations, had a detrimental effect on surfac-
tant. This was due to the detrimental effects of desoxycholate on surfactant func-
tion, since this agent alone showed high influence on surface activity of natural 
surfactant as opposed to AMB without desoxycholate. The detrimental effect of 
deoxycholate ·,s probably caused by its deterging capacities. The lip'1d formulations 
showed no detrimental effects, which was as expected because the lipid formula-
tions consist in a large part of phospholipids, which are the surface active compo-
nents of pulmonary surfactant. Therefore, it is assumed that the lipid formulations 
will be more safe to administer to the respiratory tract and that administration of 
aerosols of AMB-DOC is more likely to lead to local toxic effects. 
In summary, we have described the nebulisation of 4 commercially available AMB 
formulations. All formulations were nebulised efficiently in terms of aerosol particle 
size and deposition in the lungs. Nebulisation of all4 AMB formulations did not 
lead to systemic AMB exposure and therefore side effects which are frequently relat-
ed to intravenous administration of AMB formulations are expected to be minimal. 
Local toxicity on the lungs is expected to be minimal with the lipid formulations. All 
nebulised formulations showed promising efficacy when administered prophylacti-
cally. However, L-AMB is superior as it is effective for a relatively long period of time 
compared to the other formulations. The presented work provides support for more 
effective strategies to prevent the threat of Aspergillus infections during periods of 
prolonged immunosuppression. These positive results from the presented work 
have instigated a clinical trial with nebulised L-AMB in our institution. 
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The aim of the work described in this thesis was to evaluate the merits of inhala-
tional amphotericin B formulations in the prevention and treatment of experimen-
tal invasive pulmonary aspergillosis. In this last chapter, the sum of results of the 
in vitro experiments and the preclinical studies, described in the previous chap-
ters, are discussed and put in perspective. 
Background 
The incidence of invasive pulmonary aspergillosis has increased in the last 
decades and is still increasing in patients with impaired immunity such as patients 
who are treated with aggressive chemotherapeutic agents, transplant recipients 
and HIV patients. Although potent antifungal agents are available, morbidity 
and mortality from invasive pulmonary aspergillosis remains unacceptably high. 
The golden standard fungicidal drug, amphotericin B (AMB), has been formulated 
in lipid carriers to allow more flexible, higher dosing of this toxic agent. However, 
due to the delay in diagnosis of invasive pulmonary aspergillosis, treatment is 
often started too late in the course of the infection. Therefore, we are still faced 
with the severe life-threatening features of invasive pulmonary aspergillosis. 
Several strategies are under investigation to reduce the incidence of invasive 
aspergillosis or to enhance therapeutic outcome of an established infection: 
As long as simple and adequate treatment is not available, prevention of inva-
sive aspergillosis, for patients who are at particular risk, would be the strategy 
of choice for decreasing aspergillosis related mortality and morbidity. HEPA-
filtration of air in rooms of patients who are at risk does reduce the incidence 
of invasive fungal disease. However, HEPA-filtration of room air does not 
completely eliminate the incidence of invasive aspergillosis in these settings. 
Another option is to prevent disease by prophylaxis with antifungal agents. 
Results of studies that have been performed with prophylactic systemic itra-
conazole or (liposomal) AMB, are controversial and this strategy is currently 
not recommended or practised. 
Under development are better diagnostic techniques that would allow us to 
better select patients who have early stages of invasive pulmonary aspergillo-
sis and to start antifungal treatment earlier in the course of infection. These 
new techniques include the detection of circulating galactomannan in serum 
or broncho-alveolar lavage fluid, the use of high resolution CT scans and the 
use of amplification methods to detect fungal DNA in patient samples. These 
techniques have shown to be of value in the detection of invasive aspergillosis. 
Their value in terms of reduction of mortality and morbidity as a result of earli-
er indication offungal infection still has to be determined. 
Many research efforts are focused at new antifungal entities and new treat-
ment strategies with existing antifungal agents to achieve better therapeutic 
outcome. Chapter 2 ofthis thesis describes the chemical entities that have 
proven in vitro or in vivo activity against Aspergillus spp. Some of these 
agents, including new azoles such as voriconazole and peptides such as 
echinocandins and pneumocandins, are currently entering the market. Their 
value as promising new antifungals will become clear in the coming years. 
The lipid formulations of AMB, liposomal AMB (L-AMB, AmBisome~), 
AMB lipid complex (ABLC, Abelcet') and AMB colloidal dispersion (ABCD, 
Amphocii(Jil, Amphotec('l), clearly have an improved therapeutic index as com-
pared to AMB-DDC (AMB desoxycholate, AMB-DOC, Fungizone'). Because of 
this improved therapeutic index, these lipid formulations can be administered 
·m a higher dose. For liposomal amphotericin B, this higher dosing has result-
ed in a better efficacy in clinical trials than AMB-DOC. As yet, this has not 
been shown for the two other lipid-formulations. Future clinical practice will 
elucidate the differential value of these lipid formulaf1ons as compared to 
AMB-DOC as well as compared to each other. 
Administration of (lipid-associated) AMB via the inhalational route, either as pro-
phylactic measure or as treatment of invasive pulmonary aspergillosis is an attrac-
tive approach for the following reasons, 
Development of invasive pulmonary aspergillosis starts with the inhalation of 
Aspergillus spores and subsequent deposition of these spores in the bronchial 
tree. Inhalation of an aerosol of (lipid associated) AMB targets the drug to the 
bronchial tree, to the site where the infection originates. 
Systemic toxicity, which can be a dose-limiting consequence of intravenously 
adm-Inistered AMB formulations, is m·lnimised with aerosol admin-Istration. 
In Chapter 3 to 8 of this thesis, the inhalational route has been studied as an alter-
native administration route of AMB formulations. This work presents an evaluation 
of the aerosol-characteristics, pharmacokinetics, toxicity and prophylactic and 
therapeutic efficacy of aerosolised AMB formulations in an experimental 
aspergillosis model in immunocompromised rats. 
The feasibility of aerosol administration of AMB 
Aerosol characteristics 
Before the efficacy of nebulised AMB or either of the lipid formulations can be 
evaluated, the aerosol procedure must first be validated. In chapter 3 we describe 
the characteristics of aerosols of AMB-DOC and of liposomal amphotericin B. It 
was shown in this work that AMB-DOC as well as the liposomal formulation can 
be efficiently nebulised with the experimental nebuliser system such that adequate 
AM B concentrations are deposited in the respiratory tract of rats. A large portion of 
inhaled AMB is deposited elsewhere than in the respiratory tract. Measurement of 
radiolabelled aerosol deposition shows that the largest part of the aerosol is 
deposited in the oral cavity and in the gastro-intestinal tract. Since AMB is poorly 
absorbed after oral administration, this amount of extrapulmonary AMB does not 
lead to systemic concentrations, and thus not to systemic toxicity or antifungal 
activity additive to activity from pulmonary deposited AMB. This finding is an obvi-
ous distinction from intravenous administration, where the severe side effects due 
to the systemic distribution limit the use of AMB. 
Pulmonary kinetics 
Pharmacokinetic evaluation of nebulised AMB-DOC and L-AMB (Chapter 4) 
revealed that the amount of AMB deposited in infected lungs of rats, apparently 
supersedes the MIC values of susceptible Aspergillus strains, to be fungicidal to 
conidia or hyphae that are present at that site. With regard to the correlation of 
measured AMB tissue concentrations with Aspergillus M!C the following com-
ments are of importance: 
AMB was quantified with a chemical analysis, preceded by a vigorous extrac-
tion procedure. This quantification method does not allow to equate the chem-
ically measured AMB with actually bioactive AMB. We have tried to determine 
bioactive AMB with a diffusion-agar plate assay. However, this method 
appeared erratic, since this assay was not reproducible and not of use for 
quantitative determination of AMB. Efficacy experiments aimed at biological 
activity are needed to provide the proof whether these chemical data correlate 
with in vivo bioactive AMB. 
Total lunglobes (lungtissue, alveoli and bronchioles) were excised and 
analysed for AMB. Consequently, there is no understanding on where the 
aerosol was exactly deposited inside the respiratory tract. The aerosol droplet 
size, which has been measured for all formulations, ensures that the largest 
part is deposited in the peripheral regions of the lungs, that is in the terminal 
bronchioli and the alveolar sacs and ducts. Furthermore, the results of the 
experiments with nebulised gold-labelled liposomes (Chapter 4) indicate that 
the liposomes are indeed deposited in the alveoli and at the site of the infec-
tion. It ·,s therefore plausible that the nebulisation of AMB products leads to 
presence of AMB at the site of intended action. 
The absence of detectable AMB in blood or other organs than the lungs (Chapter 4) 
indicates that no systemic toxicity is expected from this mode of administration. 
This is very interesting, since the side effects of AMB, especially on the kidneys, 
limit the intravenous use of this agent. 
After a single dose of aerosol of either AMB formulation, AMB was retained in the 
lungs for up to 6 weeks. Assuming that deposition is associated with bioactivity, 
this implies that a single dose will be effective for weeks. The strikingly long reten-
tion time would, therefore, allow infrequent administration schedules, which are 
wellcome to patients and their caretakers. 
Treatment of confirmed invasive pulmonary 
aspergillosis with nebulised conventional and 
liposomal AMB: Effective and safe? 
The treatment of an established infection of I PA is correlated with high failure rates. 
This failure rate is the result of a combination of the troublesome diagnosis of inva-
sive pulmonary aspergillosis resulting in diagnostic delay and the limited efficacy of 
intravenous antifungal regimens. To determine whether nebulised AMB-DOC and 
L-AMB were effective in the treatment of IPA, an animal model of invasive pulmonary 
aspergillosis was used. In this model, which was developed in our laboratory, the 
fungal infection was induced in deeply leukopen·lc rats. Leukopenia was induced by 
cyclophosphamide in order to mimic the chemotherapy-induced neutropenia in 
haematological oncology patients. This model is a severe infection model with all 
untreated rats dying between day 4 and day 9 after inoculation with the fungal 
spores of Aspergillus tumigatus. Prolonged survival of treated animals as compared 
to controls was chosen as primary endpoint of efficacy of antifungal regimens. 
When a single aerosol dose of conventional and L-AMB was administered to rats 
with an established infection of invasive pulmonary aspergillosis, i.e. with hypha! 
outgrowth of Aspergillus conidia in the lungs, both products yielded a prolonged 
survival as compared to non-treated control rats (Chapter 5). When compared to 
controls of intravenous treatment with conventional or L-AMB in the same rat 
model, there was no difference in efficacy between the intravenous or the aerosol 
treatment. Aerosol treatment did not however, prevent dissemination of the infec-
tion to the liver. 
The use of inhalation treatment of AMB formulations is not presumed to lead to 
systemic toxicity. However, local toxicity on the lung epithelium must be taken into 
account The toxicity of aerosolised AMB formulations was evaluated in an in vitro 
experiment in which their influence on the surfactant function was determined. 
It appeared that AMB-DOC, and not the lipid formulations, had a detrimental 
effect on surfactant Therefore, it was assumed that the lipid formulations are 
more safe to administer to the respiratory tract than AMB-DOC, which is likely to 
lead to local toxic effects. 
In conclusion, aerosol administration of lipid formulations of AMB is safe and has an 
effect in the treatment of an established experimental infection. Aerosolised AMB-
ODC might lead to local side effects, but is as effective as the lipid-preparations. 
Nevertheless, all regimens did not prevent spreading of the infection from the lungs to 
other organs. Therefore, the therapeutic value of this application is probably limited. 
Efficacy of standard intravenous treatment can 
be improved when a single dose of nebulised 
L-AMB is added 
Treatment of invasive pulmonary aspergillosis with only a single dose of 
aerosolised AMB, conventional or liposomal, shows a limited efficacy. Combining 
aerosol treatment with a regimen that does prevent dissemination, (intravenous 
treatment with AMB), could enhance outcome of treatment of confirmed invasive 
pulmonary aspergillosis. 
In chapter 7 we describe the combination of intravenous and aerosol therapy in the 
treatment of an established infection. It was shown, that this regimen was much 
more effective than mono-therapy with either intravenous or aerosol therapy. 
Furthermore, this combination therapy prevented dissemination of the infection. 
This shows that systemic AMB concentrations resulting from intravenous adminis-
tration, are crucial to prevent bloodstream dissemination of Aspergillus fumigatus. 
The efficacy in this combination therapy is remarkable when the results were com-
pared to that of other treatment regimens studied by us. These results encourage 
the use of aerosol AMB as additive therapy to currently used intravenous AMB treat-
ment in the management of invasive pulmonary aspergillosis. 
Prophylaxis of invasive pulmonary aspergillosis 
with nebulised AMB: Long term protection 
Given the troublesome diagnosis in combination with the high refractory rate of 
·Invasive pulmonary aspergillosis to systemic ant"ifungals, the best way to over-
come aspergillosis related mortality and morbidity is to prevent the infection. 
HEPA filtration of air in rooms of patients does reduce the incidence of invasive 
pulmonary aspergillosis, but patients can be colonised with Aspergillus before 
hospital admission, which emphasises an additional need for chemoprophylaxis. 
At present, there is not an intravenous antifungal regimen which has been shown 
to be effective in preventing invasive pulmonary aspergillosis. 
Prophylaxis of invasive pulmonary aspergillosis with aerosolised AMB has some 
appeal'lng aspects. Inhalation of AMB (either conventional or lipid-associated) 
targets the drug to the lungs where spores may already reside and/or where 
spores may be acquired during hospitalisation when inhaled. After deposition in 
the lungs, we have shown that the drug will be present in the pulmonary tissue 
for weeks. This allows infrequent aerosol administration. Furthermore, we have 
shown that aerosolised AMB (lipid-associated or conventional) does not lead to 
systemic toxicity. 
The hypothesis that aerosolised AMB formulations can have prophylactic efficacy 
in invasive pulmonary asperg-Illosis, was tested in the same rat model which was 
used for the experiments to study established invasive pulmonary aspergillosis. 
Commercially available AMB formulations were evaluated (Chapter 7 & 8). It was 
investigated whether a single dose, given at different times before the rats were 
infected, could prevent, completely or in part, mortality that resulted from the 
subsequent infection. All formulations showed prophylactic eff1cacy, they pro-
longed survival of treated rats as compared to controls. The effect was present 
even when the aerosol was administered at 2 weeks before fungal infection was 
applied. The activity of the liposomal formulation existed even for 6 weeks. This 
finding demonstrates that the AMB concentrations measured in the deposition 
experiments (Chapter 4) had a therapeutic significance and were indicative for 
antifungal activity. More interesting even, was the fact that these results convinc-
ingly show the usefulness of aerosolised AMB formulations in the prophylaxis of 
invasive pulmonary aspergillosis. 
Conclusions and final remarks 
Considering the aim of the work presented in these studies, we have shown the 
value of nebulised AMB formulations in the treatment or prevention of invasive 
pulmonary aspergillosis. We have shown thatthe commercially available AMB 
formulations can be nebulised and that a single aerosol dose leads to adequate, 
long-lasting concentrations of bioactive AMB in the lungs. 
Systemic toxicity after aerosol administration is unlikely, as AMB was undetectable 
in blood or other organs than the lungs. Local toxicity is probably absent for 
the lipid-associated products. AMB-DOC had detrimental effects in vitro on the 
pulmonary surfactant system. 
Administration of aerosolised AMB formulations had only a limited efficacy in the 
treatment of established invasive pulmonary aspergillosis, because spreading of 
the infection with this mode of administration is not prevented. Combining 
aerosolised AMB formulations with intravenous AMB was more efficacious than 
either aerosolised or intravenous treatment alone, with no dissemination of 
the infection. Since current intravenous treatment regimens still lack sufficient 
efficacy, further clinical investigation of this approach of combination therapy is 
warranted. The long retention of AMB after aerosol administration of either 
formulation resulted in a long-lasting prophylactic efficacy after single dose aerosol 
treatments. We propose therefore that this elegant concept is also investigated in 
the clinical situation. 
In conclusion, we have shown the potential of inhalational AMB when adminis-
tered both in a therapeutic and prophylactic setting with regard to invasive 
pulmonary aspergillosis. Our results provide a strong case for further studies in a 
clinical setting. Up to now, treatment outcome of invasive pulmonary aspergillosis 
is often disappointing, both due to limitations in diagnosis and in therapy. Our 
studies provide evidence that can change this scene. lnhalational AMB may 
enhance therapeutic efficacy of treatment of established invasive pulmonary 
aspergillosis. Moreover, the favourable retention behaviour and low toxicity of 
inhaled L-AMB make prophylaxis feasible and therefore the preferred approach. 
Samenvatting voor niet-ingewijden 
In dit proefschrift worden de resultaten weergegeven van proefdieronderzoek dat 
gedaan is naar de verbeteringvan de behandelingvan de schimmelinfectie lnvasieve 
Pulmonale Aspergillose. lnvasieve Pulmonale Aspergillose is een infectie in de Iangen 
die wordtveroorzaakt door de schimmelsoortAspergillus. !nvasieve Pulmonale 
Aspergillose komt vrijwel uitsluitend voor bij mensen die een ernstigverzwakte 
afweertegen infecties hebben. Dit zijn bijvoorbeeld patienten die behandeld worden 
met langdurige en intensieve chemokuren tegen kanker of patienten die een been-
merg- of orgaantransplantatie hebben ondergaan en ten gevolge daarvan geneesm"ld-
delen krijgen toegediend die afstotingvan het transplantaattegengaan. Deze mensen 
hebben een verzwakte afweer, waardoor ze meervatbaar zijn voor infecties met aller-
lei micro-organismen, waaronder de schimmel Aspergillus. 
AspergWus is een schimmel die normaal in onze omgeving vee I voorkomt. De 
schimmel groeit in de vorm van schimmeldraden, waarbij aan het uiteinde schim-
melsporen {conidia) ontstaan. Door hun kleine diameter kunnen deze sporen zich 
gemakkelijk verspreiden door de Iucht. Daardoor kunnen ze vervolgens door mens en 
dier worden ingeademd. Bij gezonde person en is het afweersysteem voldoende om 
deze sporen op te ruimen, echter mensen met een verzwakte afweer zijn daartoe 
slecht in staat, waardoor de schimmel zich kan gaan nestelen, uitgroeien en vervol-
gens kan leiden tot een infectie. 
De diagnose van lnvasieve Pulmonale Aspergillose is gecompliceerd, omdat de aan-
doeningweinigspecifieke verschijnselen heett. Daardoor is het moeilijk onderscheid 
te maken tussen lnvasieve Pulmonale Aspergillose en andere infecties. Het moment 
dat de diagnose met zekerheid kan worden gesteld laat hierdoor vaak lang op zich 
wachten, metals gevolg dat de schimmel de kans krijgt om uit te groeien in de Ian-
gen en vervolgens naar andere delen van het lichaam. De late diagnose bemoeilijkt 
dan ook een adequate behandeling met het huidige arsenaal aan anti-schimmelmid-
delen metals gevolg een hoge sterfte ten gevolge van lnvasieve Pulmonale 
Aspergillose. Omdat de slaagkans van de behandeling teleurstellend klein is, is 
preventie van lnvasieve Pulmonale Aspergillose de beste strategie. 
De standaardbehandelingvan mensen met een (vermoedelijke) lnvasieve Pulmonale 
Aspergillose bestaat uit hetgeven van anti-schimmelmiddelen via de bloedbaan 
(intraveneus). Hierbij heett men de keuze uittwee geneesmiddelen met een werking, 
tegen Aspergillus: itraconazol of amfotericine B. Vanwege de krachtige werking 
wordt amfotericine 8 het meest gebruikt. Amfotericine 8 wordt rla inname via de 
mond niet opgenomen het bloed, waardoor het noodzakelijk is het mid del intra-
veneus te geven als een infectie in het lichaam moet worden voorkomen of behan-
deld. Het gebruik van intraveneus amfotericine B is echter wei beperktvanwege de 
ernstige bijwerkingen, het is met name schadelijk voor de nieren. Terverbetering van 
de behandeling zijn er in de laatste jaren nieuwe formuleringen van amfotericine 8 
ontwikkeld. Deze nieuweformuleringen hebben gemeenschappelijk dat amfotericine 
B is gekoppeld aan bepaalde vetmoleculen, fosfolipiden, waardoor de bijwerkingen 
van amfotericine B verminderd zijn. Er is een drietal van deze amfotericine B lipide-
formuleringen op de markt, amfotericine 8/iposomen (vetbolletjes), amfotericine 8 
J;p;den-complex en amfoter;c;ne 8 co/Jo;dale d;spers;e. 
Hoewel deze nieuwe, minder schadelijke amfotericine B lipide-formuleringen, 
waarmee hager gedoseerd kan worden ten opzichtevan het conventionele (niet lip·l-
de-gebonden) amfotericine B, op de marktzijn gekomen en inmiddels bij patienten 
worden toegepast, zien we nag steeds een hoge sterfte bij patienten met lnvasieve 
Pulmonale Aspergillose. Daarom is men nag steeds naarstig opzoek naar mogelijk-
heden om lnvasieve Pulmonale Aspergillose te voork6men of de slaagkans van de 
behandeling van de infectie te verbeteren. 
Een van de aantrekkelijke alternatieven voor de huidige intraveneuze behandelingen 
zou zijn de toepassingvan de antischimmelmiddelen via de luchtwegen ofwel via 
inhalatie ervan. Dit heeft een aantal voordeleno de medicatie komt direct op de plek 
waar de schimmelsporen zijn neergestreken (de sporen komen immers oak b"mnen 
via inhalatie). De rest van het lichaam hoeft niet belastte worden met het 
geneesmiddel metals gevolg minder bijwerkingen. Daarnaast wordt aan mensen 
niet meer een infuus gegeven, maar inhaleren ze, wat mogelijk een meer 
patientvriendelijke toe passing is. Bovendien blijkt uit de literatuur van andere 
onderzoekers dat het inhaleren van lipiden zoals die van de amfotericine B-lipide 
formuleringen, goed verdragen wordt en bovendien resulteert in een langdurig 
verblijf in de Iangen, metals gevolg een langdurig effect. 
Het doe I van het onderzoek dat beschreven wordt in dit proefschrift was 
inzicht te verkrijgen in de haalbaarheid en de waarde van inhalatie 
van amfotericine B formuleringen voor de preventie of behandeling 
van invasieve pulmonale aspergillose. Het onderzoek werd uitgevoerd 
in een diermodel. 
De inleiding op het onderzoek is beschreven in Hoofdstu k l. Hoofdstuk 2 is 
een beschrijving van aile bestaande antischimmel-middelen, en middelen die in de 
pijplijn zitten, die gebruikt kunnen gaan worden bij de preventie of behandeling 
van lnvasieve Pulmonale Aspergillose. Dit hoofdstuk schetst hoe het landschap er 
nu uit ziet, welke middelen we nu hebben, en water in de toekomst mogelijk a an 
extra middelen ter beschikking komt. Vanwege de ernst van lnvasieve Pulmonale 
Aspergillose en de teleurstellende resultaten van behandeling met het huidige 
arsenaal aan anti-schimmelmiddelen, is men zoals gezegd wereldwijd naarstig op 
zoek naar betere alternatieven. Dit heeft geleid tot de ontwikkelingvan een aantal 
potentieel bruikbare nieuwe stoffen rnet werking tegen Aspergillus. Een aantal van 
de nieuw ontwikkelde stoffen hebben geheel andere werkingsmechanismen dan 
amfotericine B of itraconazol. Hierdoor kunnen we mogelijk van deze stoffen een 
meer potente werking, minder (of andere) bijwerkingen ten opzichte van de huidige 
middelen verwachten. Sommige middelen zoals voriconazol of caspofungin zijn al 
in een ver gevorderd stadium van ontwikkeling en hebben hun activiteit bij patien-
ten reeds bewezen. Deze middelen zijn binnenkort op de Nederlandse marktte 
verwachten. De exacte plaats van de nieuwe middelen ten opzichte van de stan-
daardbehandelingen is nag niet vastgesteld, maar zeker is wei dat we in de 
toekomst een aantal waardevolle alternatieve anti-schimmelmiddelen erbij krijgen. 
Om de waarde van inhalatie van amfotericine B formuleringen bij de preventie of 
behandelingvan lnvasieve Pulmonale Aspergillosete kunnen beoordelen, is hetvan 
belang om eerstte onderzoeken hoe hetvernevelen van amfotericine B formulerin-
gen in zijn werk gaat en of het wei mogelijk is via inhalatie het amfotericine Bin 
adequate hoeveelheden in de Iangen te krijgen. Daarom wordt in Hoofdstuk 3 de 
verneveling beschreven van amfotericine B formuleringen bij ratten. Vemevelen is het 
proces waarbij een vloeistof wordt omgevormd in een mist (aerosol), die kan worden 
ingeademd. In dit hoofdstuk wordt de vernevelprocedure beschreven die wordt 
gebruikt in de rest van het onderzoek. De grootte van de neveldruppels is gemeten. 
Het bleek dat de neveldruppels klein genoeg waren om diep in de Iangen te pene-
treren. Bovendien bleek dat de neveldruppels ongeveer dezelfde grootte hebben als de 
sporen van Aspergillus. Dit is gunstig aangezien dan de neveldnuppels vermoedelijk 
op dezelfde plek terecht komen als de geinhaleerde schimmelsporen. Daarnaast is er 
gemeten hoeveel AMBer in de Iangen van de ratten, maar oak in andere del en van het 
lichaam van de rat, na vernevelingterecht was gekomen. De gerneten hoeveelheid 
amfotericine B die in de Iangen terecht komtzou in theorie voldoende moeten zijn om 
de sch.lmmel te dod en en dus lijkt de gevolgde procedure de ju·1ste. Verder bleek dater 
veel neveldnuppels terecht komen in de mondkeelholte en in het maagdarmkanaal. 
Dit is te verwachten omdat de neveldruppels een lange weg van het vernevelvaatje 
naar de Iangen moeten afleggen en de kans dat ze ergens 'uit de bocht vliegen' groat 
is. Het amfotericine B dat in de mond-keelholte of het maagdarmkanaal terecht komt 
wordt niet in het bloed opgenomen, maar verdwijnt via het spijsverteringskanaal weer 
uit het lichaam en Ievert geen bijdrage aan de effectiviteit of bijwerkingen. 
In Hooidstuk 4 wordt meer uitgebreid beschreven water met de neveldruppels en 
amfotericine B gebeurt na inhaleren. Hier bleek dat de hoeveelheid amfotericine B 
die na vern eve len in de Iangen terecht komt na eenmalige vemeveling niet aileen 
hoog genoeg is (in theorie) om de schimmel te doden, maar oak dat het amfotericine 
B gedurende zeer lange tijd, nl enkele weken, in de longen aanwezig bleef. 
Amfotericine B word! blijkbaar erg langzaam uit de longen verwijderd. Dit gold ook 
voor ratten die met opzet waren ge'infecteerd met Aspergillus. Foto's van het long-
weefsel van behandelde ratten bevestigden dat amfotericine B liposomen daad-
werkelijk op de plek in de longen waar de schimmelsporen zich bevinden terecht 
komen. In het bloed en organen anders dan de Iangen werd geen amfotericine B 
gemeten waaruit bleek dat ervanuit de Iangen geen of onmeetbaarweinig, amfo-
tericine B terecht komt in het bleed. Drt betekent dat de b.1jwerkingen die gezien 
worden bij intraveneuze behandeling met amfotericine 8 producten, zeer 
waarschijnlijk nietzullen optreden bij de inhalatietoepassing van amfotericine B. 
Concluderend uit de voorgaande twee hoofdstukken kunnen we zeggen dat hetver-
nevelen van amfotericine B formuleringen voor inhalatietoepassing, zeer wei bruik-
baar is voor zowel preventie als behandeling van lnvasieve Pulmonale Aspergillose. 
Het eerste onderzoek naar de etfectiviteit van verneveld AMB staat beschreven in 
Hoofdstuk 5. In dit hoofdstuk hebben we onderzocht ofverneveling van AMB in 
de conventionele vorm of in de vorm van liposomen een gunstig effect heeft op het 
verloop van een kunstmatlg aangebrachte lnvasieve Pulmonale Asperg"lllose. We 
hebben daarvoor een diermodel gebruikt waarbij de ratten eerst een sterk vermin-
derde afweer hebben, analoog aan mensen die met chemotherapie zijn behandeld. 
Vervolgens werd aan de ratten een bepaalde hoeveelheid Aspergi//us-sporen toege-
diend in de luchtwegen. Zo ontstond er een infectie als gevolg waarvan de dieren, 
net als patienten, ernstig ziek werden en uiteindelijk overleden ten gevolge van de 
infectie. Dit ziekteproces verlooptvergelijkbaar als bij de mens. Getest kan worden 
of een experimentele behandeling effectief is door te bezien of behandelde dieren 
Ianger Ieven dan dieren die niet met een anti-schimmelmiddel worden behandeld. 
Wanneer we dieren die lnvasieve Pulmonale Aspergillose hebben verneveld conven-
tioneel amfotericine B of amfotericine B liposomen gaven, zagen we dat ze statis-
tisch significant Ianger leefden. Met andere woorden, de behandeling had een 
gunstig effect. Het maakte niet uit of het conventionele amfotericine B werd 
gebruikt of amfotericine B liposomen, beide formuleringen vertoonden dezelfde 
effectiviteit. In hetzelfde onderzoek is nagegaan of er een schadelijk effect optrad 
in de luchtwegen. Dit hebben we gedaan doorte onderzoeken of de amfotericine B 
formuleringen een schadelijke uitwerking hadden op het pulmonaal surfactant. 
Pulmonaal surfactant is het laagje vloeistof dat de Iangen bekleedt en zorgt dat de 
longen voldoende elasticiteit hebben bij het in- en uitademen. Het bleek dat het 
conventionele amfotericine B schadelijk was voor dit surfactantterwijl de lipide 
formuleringen niet schadelijk bleken te zijn. Vervolgens is onderzocht wat de 
waarde is van toevoeging van vernevelde amfotericine 8 liposomen aan de 
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intraveneuze behandeling met ofwel conventioneel amfotericine B ofwel amfo-
tericine B liposomen (Hoofdstuk 6). Het bleek dat de effecten dan zeer gunstig 
uitvallen: het effect van de combinatie van verneveld en intraveneus amfotericine 
B is beter dan een van de behandelstrategieen aileen. Hieruit kan men concluderen 
dat het zeer zinvol lijkt de huidige behandelingvan lnvasieve Pulmonale 
Aspergillose, nl de intraveneuze behandeling met ofwel conventioneel amfotericine 
B, ofwel met amfotericine B liposomen, te combineren met een eenmalige behan-
deling met verneveld amfotericine B liposomen. Prevent1e van lnvas·leve 
Pulmonale Aspergillose is nog altijd beter dan de behandeling ervan vanwege 
de geringe slaagkans van behandeling. In Hoofdstuk 7 en Hoofdstuk 8 wordt 
de mogelijkheid van preventieve behandeling metver-nevelde amfotericine B 
formuleringen beschreven. In deze hoofdstukken worden het conventionele 
amfotericine Ben de drie bestaande lipide-formuleringen met elkaar vergeleken. 
Aile formuleringen lieten zien dat de overleving van behandelde dieren statistisch 
significant Ianger was dan die van controle dieren indien de verneveling eenmalig 
voorafgaande a an het aanbrengen van de infectie werd uitgevoerd. Aile vier de 
formuleringen lieten dit gunstig effect zien, oak wanneer de vernevelingtwee 
we ken voor de infectie geschiedde. Behandeling met amfotericine B liposomen 
was zelfs nag effectief wanneer dit 6 weken voor het aanbrengen van de infectie 
wordt gegeven. 
Terugkomend op het doel van het onderzoek zoals dat staat beschreven a an het 
begin van deze samenvatting, kunnen we concluderen dat we de technische haal-
baarheid en de therapeutische waarde van de toepassing van inhalatie van amfo-
tericine B formuleringen hebben aangetoond. De resultaten zijn zeer bemoedigend 
en vragen erom deze manier van toedienen van amfotericine B te onderzoeken in 
de klinische situatie. Tot nu toe is het resultaat van de behandeling van rnvasieve 
Pulmonale Aspergillose vaak teleurstellend, door een complexe diagnose die vaak 
veel tijd kost en een tekortschietende behandeling. Ons onderzoek laat zien dat 
dit mogelijk kan veranderen. lnhalatie van amfotesicine B formuleri~gen gecombi-
neerd met standaard intraveneuze behandeling verhoogt de slaagkans van de 
behandeling. Daarnaast lijkt de inhalatie van amfotericine B formuleringen zeer 
zinvol om toe te passen ter preventie van lnvasieve Pulmonale P-spergillose. 
Het klinisch patientenonderzoek naar dit laatste is in voile gang en het is spannend 
om af te wachten of de veelbelovende resultaten behaald bij proefdieren net zo uit 
zullen pakken bij de patienten. lndien dat het geval is, hebben we niet aileen vee I 
geleerd van de, in dit onderzoek uitgevoerde, experimenten, maar hebben ze oak 
betekenis voor de kwaliteit van de behandeling van patienten. 
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DSPG 
ymin 
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HPLC 
HSPC 
i.p. 
IPA 
i.v. 
L-AMB 
MFC 
MIC 
MMD 
PEG 
spp. 
amphotericin B colloidal dispersion 
amphotericin B lipid complex 
amphotericin B 
amphotericin B desoxycholate 
broncho-alveolar lavage fluid 
bone marrow transplant 
colony forming units 
concentration at time zero 
cholesterol 
counts per minute 
computed tomography 
desoxycholate 
dimyristoyl phosphatidylcholine 
dimyristoyl phosphatidylglycerol 
distearoyl phosphatidylcholine 
distearoyl phosphatidylethanolamine 
distearoyl phosphatidylglycerol 
minimal surface tension 
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geometric standard deviation 
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intraperitoneal 
invasive pulmonary aspergillosis 
intravenous 
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minimal fungicidal concentration 
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